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Abstract
The HIV epidemic continues to spread at a rate of over 6000 new infections per
day. A better understanding of HIV pathogenesis and the mechanisms underlying
HIV-1 related disease in specific tissues such as the brain is still a high priority in
tracking the medical impact of the pandemic. This project was aimed to investigate
the cellular localisation of HIV-1, cytopathology and viral phenotype variation in
various organs throughout the course of HIV-1 infection. The cellular localisation of
HIV-1 infection was demonstrated by immunohistochemistry, and the virus
distribution, genotypes and inferred phenotype and virion diversity were determined
by nucleotide sequencing.
Immunohistochemistry applied in serial tissue sections or combining the
double-labelling technique with various cell markers was employed to examine the
variety of HIV-1 infected cell populations. During the clinically latent stage, HIV-1
p24 signal was detected primarily within lymphoid organs and occasionally within
lung tissue. However, in the symptomatic stage, the p24 signal was detected within a
wider range of organs, including lymph node, spleen, lung, ileum, colon, liver,
kidney and central nervous system. Among the lymphoid organs, p24 antigen was
localised to follicle centres and intimately colocalised with CD21-positive follicular
dendritic cells. In lung and intestine, detection of p24 antigen was confined to
secondary lymphoid tissue, primarily associated with CD21-positive cells and
occasionally with tissue macrophages and T-cells. In brain tissue, the HIV-1 p24
positive cells were identified as microglia and were a defining feature of HIV-
encephalitis.
The distribution of the HIV-1 co-receptors CXCR4 and CCR5 was also
examined by immunohistochemical techniques in these organs. The staining patterns
of CXCR4 and CCR5 positivity showed overlap. Commonly, CXCR4 and CCR5
expression was detected on neurones, epithelium cells, blood vessel endothelium
cells, tissue macrophages and occasionally lymphocytes. Interestingly, in the
lymphoid aggregates or lymphoid follicles where p24 antigen was generally detected,
neither CXCR4 nor CCR5 expression was detected.
xviii
The in vitro phenotype was predicted according to the amino acid sequences in
V3 region obtained from direct isolates. Most of the variants isolated from various
organs were CCR5-dependent (non-syncytium inducing) strains. CXCR4-dependent
(syncytium inducing) variants were found preferentially in individuals with low
CD4-positive cell counts at death, and in the male homosexual risk group.
Phylogenetic analysis of nucleotide sequences from the V3 and pl7gag regions
revealed a variety of relationships between variants recovered from different tissues.
HIV-1 proviral DNA was detected in all lymph node and lung samples. Variants
from each tissue were invariably interspersed suggesting a shared population
between these tissues and target cell type. The detection of proviral DNA in brain
was strongly associated with HIV-encephalitis. Variants detected in the brain had a
predicted CCR5-dependent phenotype and were phylogenetically distinct from the
variants from lymph nodes. Sequence relationships between variants in the colon
were more complex. Colon variants from two study subjects showed sequences
interspersed with lymph node and lung isolates. However variants from the colon of
three other individuals were genetically distinct from those in lung and lymph node,
and more similar to those found in the brain.
Discordant phylogenetic relationships between pl7gag and V3 regions of HIV-1
genome were observed in some samples. For example, separate grouping of pl7gag
region sequences from lymph node and colon were observed in two study subjects
while sequences in V3 from these tissues were interspersed. Similarly in another
individual, pl7gag sequences from the brain were extremely diverse and polyphyletic,
while V3 sequences clustered into two discrete clades. These observations suggest
genetic recombination between different evolutionary lineages ofHIV.
Together these results suggested that there may be at least two mechanisms of
spread of HIV-1 into non-lymphoid tissues. For tissues such as the lung and the
gastrointestinal tract, combined immunohistochemical and genetic observations
suggest that infection of these tissues arose directly from infiltration by lymphocytes
and other lymphoid cells. A different mechanism seems likely for HIV-1 variants
detected in the brain, which were found predominantly in microglial cells, and these
xix
formed genetically distinct populations from those in lymphoid tissues. In three of
the study subjects, in whom HIV-1 proviral sequences were detected in the colon,
there was also evidence for tissue specificity, consistent with infection of cells
distinct from those in lymphoid tissue, although p24 immunostaining failed to
identify the infected cell type.
In the future, in-situ PCR for HIV proviral sequences combined with
immunostaining for cell surface markers might be employed to investigate the cell
types which are latently or non-productively infected and therefore provide a more
complete description of the cellular targets of HIV-1 in vivo. Phenotypic
characterisation of HIV-1 variants infecting different cell types would also be of
value in understanding the mechanism of the observed genetic compartmentalisation
between tissues, and the extent to which sequence differences represent adaptation
for replication in different cell types.
xx
Chapter 1: General Introduction
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1.1 Background
1.1.1 Acquired Immunodeficiency Syndrome
Acquired immunodeficiency syndrome (AIDS), which was until very recently
an almost inevitably fatal disease in the modern world, is caused by infection with
the human immunodeficiency virus (HIV), and is characterised by a long latent
period prior to the development of symptomatic diseases.
The disease first came to public notice in the summer of 1981. A rare type of
pneumonia, Pneumocystis carinii pneumonia (PCP), was reported by the U.S.
Centers for Disease Control (CDC) in previously healthy gay men (Gottlieb et ai,
1981; CDC, 1981). Later that year, an unusual vascular cancer, Kaposi' s sarcoma
(KS), and other opportunistic infections were also reported in previously healthy
homosexual groups (Durack, 1981; Thomsen et al., 1981; Friedmankien et al., 1982;
Gottlieb & Ackerman, 1982). This was taken as signaling a new acquired cellular
immunodeficiency since PCP and KS were varieties of opportunistic infection
commonly associated with immune-compromised patients who received
immunosuppressive drug therapy, but now affecting homosexuals who did not
display an obvious reason for being immunosuppressed. Subsequently, faced with a
rapidly growing number of cases not only among homosexuals, but also in
intravenous drug users and haemophiliacs (CDC, 1982), U.S. health officials utilised
the term acquired immunodeficiency syndrome (AIDS) for this new disease.
1.1.2 Discovery of The AIDS Virus
Clinical findings suggested that the course of the disease was characteristically
that of an immune disorder, developing during a long term latent period, and finally
ending with severe illnesses such as opportunistic infections, neurological disorders,
and neoplastic complications. Epidemiological studies suggested that the infectious
agent of AIDS could be transmitted during sexual intercourse, through intravenous
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drug abuse, or by therapies utilising contaminated blood and blood products (CDC,
1982; Marmor et al., 1982; Jaffe et al., 1983; Cowan et al., 1984). Because infection
with the prototype members of the lentivirus genus are commonly associated with a
variety of neurological and immunological diseases such as autoimmunity,
pneumonitis, brain and joint disorders (Haase, 1986; Coffin, 1996; Levy, 1998), as
AIDS researchers looked for a pathogen which would first cause an immune disorder
in humans, and later developed neurological, neoplastic complications and
opportunistic infections, a human lentivirus was an obvious suspect.
In 1983, a French group which led by Dr. Barre-Sinoussi in the Pasteur Institute
recovered a virus containing reverse transcriptase (RT) from an enlarged lymph node
of a gay man with persistent multiple lymphadenopathy syndrome (LAS) (Barre-
Sinoussi et al., 1983). This was the first evidence that AIDS might be caused by a
retrovirus, since the virally encoded RT is known to be the major character of
retroviruses, and the LAS was confirmed as an AIDS-related syndrome (Barre-
Sinoussi et al., 1983). This virus was similar to the human T-lymphotropic virus
(HTLV) in infecting CD4+ lymphocytes. However, it grew to substantial titer in
CD4+ lymphocytes and killed them, instead of establishing the cells in culture as
does HTLV (Montagnier et al., 1984). This virus was later named
lymphadenopathy-associated virus (LAV) by Montagnier and coworkers
(Montagnier et al., 1984).
Later, Gallo and associates isolated a virus from the peripheral blood
mononuclear cells (PBMCs) of adult and paediatric AIDS patients (Gallo et al., 1983;
Gallo et al., 1984; Popovic et al., 1984). This virus was lymphotropic, and reported
to cross-react with some viral proteins ofHTLV-I and HTLV-II, particularly the core
p24 protein (Gallo et al., 1984). Thus, this virus was named HTLV-III. They
believed that it merited inclusion in the HTVL group, even though the newly isolated
virus was cytolyic and did not induce an established cell line from infected
lymphocytes.
1-3
At the same time, Levy and coworkers also recovered viruses from AIDS
patients from different known risk groups (Levy et al., 1984a; Levy et al., 1984b;
Levy et al., 1985). Their viruses, which were named AIDS-associated retroviruses
(ARV) showed some cross-reactivity with the French LAV strain. It was also
observed that ARV grew substantially in PBMCs, killed CD4+ lymphocytes, and did
not immortalise them (Levy et al., 1984a).
Subsequently, the three prototype viruses, LAV, HTLV-III and ARV were
recognised as members of the same group of retroviruses, and their properties
identified them as members of the lentivirus genus of the family Retroviridae. These
AIDS viruses had many properties distinguishing the from HTLV, in 1986 the
International Committee on Taxonomy of Viruses (ICTV) recommended giving the
AIDS viruses a separate name, human immunodeficiency virus (HIV) (Coffin et al.,
1986). Soon after the recognisation ofHIV, a unique lentivirus discovered by Clavel
and coworkers has also been linked to AIDS in West Africa (Clavel et al., 1986;
Clavel et al., 1987). Therefore, HIV-1 refers to the genetically related viruses found
in several regions of Africa, Asia, Europe and both North and South America, and
HIV-2 is the distinct virus prevalent in certain West African countries (Hirsch &
Curran, 1996; Luciw, 1996).
1.1.3 Classification of Human Immunodeficiency Viruses
It has been confirmed that HIV is a member of Lentivirina, one of the seven
genera in the Retroviridae family of RNA viruses.
Retroviridae was named because they possess reverse transcriptase (RT). Based
on their pathogenicity, the Retroviridae family were originally classified into three
subfamilies: Oncovirinae, Lentivirinae, and Spumavirinae. Oncoviruses are the only
genus of retroviruses that can transform target cells, and are associated with cancers
and neurological disease. Lentiviruses are responsible for a variety of neurological
and immunological diseases, but are not directly implicated in any malignancies.
Spumaviruses appear to cause a vacuolated "foamy" cytopathological effect but not
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effect but not clinical disease (reviewed in Coffin, 1996). Subsequently, in the late
1980s, as nucleotide sequence relationship and genome structure were introduced as
criteria for virus classification, the ITCV then redefined the taxonomy of the
Retrovirida. According to virion structure, utilisation of particular cell receptors,
lifestyle, presence or absence of an oncogene, and other pathogenic properties,
viruses were classified into seven distinct genera, including Avian-leukosis-sarcoma,
Mammalian C-type, B-type viruses, D-type viruses, HTLV-BLV group, Spumavirus






















Figure 1. 1. Relationships and example isolates of retrovirus groups. The
relationships are based on amino acid sequence similarities in the RT protein of
the group shown. HSRV: Human spumaretrovirus; MLV: Murine leukemia viruses;
HERV-C: Human endogenous retrovirus type C; HIV-1& HIV-2: Human immunodeficiency
virus type 1 and type 2; Visna: Visna.maedi virus; EIAV: Equine infectious anemia virus;
SMRV: Squirrel monkey retrovirus; MMTV: Mouse mammary tumor virus; IAP:
intracisternal A particle; RSV: Rous sarcoma virus; BLV: Bovine leukemia virus; HTLV-1 &
HTLV-2: Human lymphotropic virus type 1 and 2. (Modified from Fields Virology, 1996).
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Lentiviruse genus includes complex exogenous viruses responsible for a variety
of neurological and immunological diseases. The prototype members of this family
were the "slow" viruses visna, equine infectious anemia virus, and caprine arthritis-
encephalitis virus. More recent isolates include HIV and simian immunodeficiency
viruses (SIV), and the more distantly related feline and bovine immunodeficiency
viruses (FIV and BIV). Characters and phylogenetic relationships of these viruses
are described in Table 1. 1 & Figure 1. 2.
Table 1. 1. Clinical disorder and host range of lentiviruses.





Equine infectious anaemia virus Horse
Cyclical infection in the first year; Autoimmune;
Haemolytic anaemia; sometimes
Encephalopathy
Visna / maedi virus Sheep Encephalopathy / Pneumonia
Caprine arthritis-encephalitis virus Goat Immune deficiency; Arthritis; Encephalopathy
Bovine immune deficiency virus Cow Lymphadenopathy; Lymphocytosis;Central nervous system disease
Feline immunodeficiency virus Cat Immune deficiency
Simian immunodeficiency virus Primate Immune deficiency and Encephalopathy
Human immunodeficiency virus Human Immune deficiency and Encephalopathy
According to the distinctly serologic properties, and the differences observed in
sequence analysis, HIV has been grouped into two types, HIV-1 and HIV-2 (Clavel
et al., 1986; Coffin et al., 1986). Both HIV-1 and HIV-2 are a cause of AIDS, and the
modes of transmission are similar (Markovitz, 1993). However, some investigators
have reported that the transmissibility and pathogenic potential of HIV-2 strains are
lower than HIV-1 strains. It has been found also, individuals infected with HIV-2
appears to have a longer pre-symptomatic period and a lower cytopathogenicity than














Figure 1. 2. Phylogenetic relationships of lentiviruses. Representative
lentiviruses are compared usingpol gene nucieotide sequences for establishing
phylogenetic relationships. Five groups of primate lentiviruses are shown:
HIV-1, HIV-2, SIV from sooty mangabey monkey (SIVSMM), Svkes monkey
(SIVSYK), chimpanzee (SIVCPZ), African green monkey (SIVACM) and mandrill
(SIVMND). Nonprimate lentiviruses are Visna / maedi virus (VMV), Caprine
arthritis-encephalitis virus (CAEV), Equine infectious anaemia virus (EIAV),
Bovine immune deficiency virus (BIV), and Feline immunodeficiency virus
(FIV). The scale indicates percentage difference in nucleotide sequences in the
pol gene. (Copied from Fields Virology, 1996.)
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HIV-2 was first recovered in Portugal from AIDS patients from West Africa
(Clavel et al., 1986). After cloning and sequence analysis, it was found that this virus
differed by more than 55% from the HIV-1 strains, and appeared to be antigenically
distinct (Clavel et al., 1986). Also, the genome ofHIV-2 presents a unique accessory
gene, vpx, which does not exist in HIV-1 genome. In contrast, the genome of HIV-1
presents the vpu, which is absent in HIV-2 genome (Figure 1. 3). The major serologic
difference between HIV-1 and HIV-2 resides in the envelope glycoproteins. Using
immunoblot analyses, antibodies to HIV-2 would generally cross-react with the Gag
and Pol proteins of HIV-1, but might not detect HIV-1 envelope proteins and vice
versa (Clavel et al., 1987; Levy, 1998). In fact, the envelope glycoproteins of HIV-
2 appear to cross-react serologically with envelope proteins from strains of simian
immunodeficiency virus (SIV), a complex group of primate Antiviruses. Most
commonly with wild sooty mangabeys SIV (SIVsm) (Clavel et al., 1987; Chen et al.,
1997).
Both HIV-1 and HIV-2 could further divided into several groups. According to
the extraordinary sequence diversity in the env gene, HIV-1 is currently divided into
three groups, M, O and N. "M" accounting for the major group, which comprises ten
worldwide distributed genetically distinct subtypes (A through J). "O" refers to the
outlier group, which consists of a pool of highly divergent, genetically related strains
with no defined clade. The distribution of the "O" group is localised in Cameroon.
Gabon, and Equatorial Guina (Quinn, 1996). Group N is recently identified in 1998
from three people in Cameroon by French and African scientists (Simon et al., 1998).
This highly divergent HIV-1 isolate is phylogenetically situated between group M of
HIV-1 and chimpanzee simian immunodeficiency virus (SIV ), but far from group
O. The letter "N" is then designated to signify this divergent strain as "non M-non O"
group. As for HIV-2, at least five subtypes (A through E) are identified, and most of
the HIV-2 strains are localised in Africa, especially in the western regions (Quinn,
1996).
The focus of studies described in this thesis is HIV-1. Therefore, HIV-2 will not
be described further.
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1.2 The HIV-1 Virion
1.2.1 Genomic Organisation
HIV-1 is an RNA virus, which belongs to the genus of lentiviruses of the
Retroviridae family. The size of the HIV-1 genome is about 9-10 kb, which is
bounded by the non-coding long terminal repeat regions (LTR) at both 3' and 5' end,
with several open reading frames coding for viral proteins. Similar with other
lentiviruses, the HIV-1 genome contains three principal structural genes, gag, pol
and env, which encode essential constructing precursor proteins for the virion
(Figure 1. 3).
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Figure 1. 3. Genome organisation of HIV-1 and HIV-2. In general, the genome
ofHIV-1 and HIV-2 is known to have nine genes, including three principal
structural genes (gag, pol and env), and six accessory genes (vif vpr, rev, tat,
nefand vpu (HIV-1) or vpx (HIV-2)), which is bounded by the LTR at both 3'
and 5' end. The relative positions of the known accessory genes (not drawn to
scale) are shown in relationship to the gag, pol and env genes. Note the unique
presence of vpu in HIV-1 and vpx in HIV-2. (Modified from Fields Virology,
1996).
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The gag gene (group-specific antigens) is located immediately at downstream
of 5'-LTR gene, and encodes a 55 kDa precursor protein (Pr55gag). This gag
precursor protein is then proteolytically cleaved into smaller proteins, including Gag
p24 capsid protein (CA), matrix pi7 protein (MA), nucleocapsid p9 and p7 proteins
(NC). Located between gag and env genes, HIV-1 pol gene encodes three virus
enzymes, reverse transcriptase, integrase, and protease. Initially, all these gag and
pol products are presented as a 160 kDa Gag-Pol precursor protein (Prl60gag"po1). The
viral protease is then employed to cleave Prl60pol"8ag and Pr55gag into individual
proteins. The env gene encodes envelope 160 kDa precursor glycoprotein, gpl60.
This precursor gpl60 is then cleaved by cellular protease to generate an external
envelope glycoprotein, gpl20, and an anchoring transmembrane glycoprotein, gp41
(reviewed in Luciw, 1996).
Apart from these essential structural genes, the HIV-1 genome also contains six
regulatory genes, including tat, rev, vif vpu, vpr, and nef Tat and rev encode small
non-structural viral proteins, which are required for viral replication. Vif, vpu,
vpr, and nefbelong to non-essential genes, also named as "accessory" or "auxiliary"
genes, which work as the regulators for virus replication.
1.2.2 Virion Structure
The HIV-1 virion has a spherical shape, and is about 110 nm in diameter. It
consists of a lipid bilayer envelope, which surrounds the cone-shaped virus capsid.
The cone-shaped virus capsid is about 100 nm in the long dimension with one 40 to
60 nm wide end, and another 20 nm narrow end. It is the main part of the HIV-1
virion and composed of the viral Gag p24 capsid protein (Gelderblom et al., 1989;
reviewed in Luciw, 1996). Inside this capsid, there are two identical single-stranded
RNAs, with which the viral reverse transcriptase (p51 and p66), protease (pi 1), and
integrase (p32) are closely associated with the nucleocapsid proteins (p7 and p9).
Surrounding the viral capsid, there is a matrix protein, pi7, which is located
underneath the viral envelope.
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Figure 1. 4. Processing of viral proteins and virion structure. The top portion of
the figure shows the processing ofHIV-1 viral proteins. Precursor polyproteins
Gag-Pol (Prl60gag"po1), Gag (Pr55gag), and Env (gpl60) are enzymatically
processed to yield mature virion proteins. The Prl60gag"po1 and Pr55gag are
processed by the viral aspartic protease into several smaller proteins, which
include matrix (MA, pi7), capsid (CA, P24), Nucleic acid binding (NC, P9),
proline-rich (P6), transcriptase (RT, p51 and p66), protease (PR, pi 1), and
integrase (IN, p32). The Env gpl60 is processed by a cellular protease into the
surface glycoprotein (SU, gpl20) and transmembrane protein (TM, gp41). Of
the accessory proteins encoded by HIV-1, only Vpr is found to assemble into
virions, but the precise location in virus particles has not been determined.
Neither the other accessory proteins (Vif, Vpu and Nef) nor the regulatory
proteins (Tat and Rev) have been detected in virion particles. Symbols
representing the various virion proteins are indicated. (M: myristoylated).
























On the surface of the lipid bilayer envelope, there stand approximately 72
spikes. Each spike is about 8 to lOnm long and contains three or four heterodimers.
Each heterodimer consists of two envelope glycoproteins that present an ovoid distal
end, and a stem, which links the ovoid end to the lipid envelope. The ovoid distal end
is composed of the external surface envelope glycoprotein, gpl20, and the stem is
composed of the transmembrane envelope glycoprotein, gp41. These two subunits
are non-covalently linked together (reviewed in Luciw, 1996). The schematic model
ofmature HIV-1 virion is shown in Figure 1. 4.
1.2.3 The Functions of Viral Proteins
1.2.3.1 Core Proteins
Matrix pi7 (MA), capsid p24 (CA) and nucleocapsid p7 and p9 (NC) proteins
are the main components of the HIV core region which are employed for virion
morphogenesis. They function to package genomic viral RNA into the virion and are
possibly involved in the early steps of the viral replication cycle (reviewed in Luciw,
1996).
Gag p24 Capsidprotein tCAl
Capsid protein is the major subunit of the virus capsid, which is released from
the central portion of the Pr55sag by two cleavages mediated by viral protease (PR),
and displays a high degree ofhydrophobicity. The mature form ofCA contains about
240 amino acids, and presents a molecular weight of 24 to 27 kDa (reviewed in
Luciw, 1996). The actual functions of CA are not clear yet. Evidence from genetic
studies suggests that one domain locating in the C-terminal portion of CA might
govern nucleocapsid assembly (Dorfman et al., 1994a). Other studies, based on in
vitro systems, indicate that specific interactions of CA with the viral RNA genome
and other Gag proteins may play a role during capsid assembly, however this needs
further exploration (reviewed in Luciw, 1996).
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NucleoCapsid protein (NC)
NC is a hydrophilic protein, which is cleaved from the C-terminus of Pr55gag by
viral protease (PR), and links genomic viral RNA to the capsid shell. The mature
form ofNC protein contains about 70 amino acids, and shows a molecular weight of
7 to 9 kDa. Two copies of a special cysteine-histidine motif (Cys-X2-Cys-X4-His-
Cys) are found incorporated in the NC protein. The second cysteine-histidine motif
might be functionless; however, genetic studies with site-specific mutations in the
viral genome have demonstrated that the first cysteine-histidine motif is important
for nucleocapsid assembly. Further evidence from in vitro binding studies indicate
that the first cysteine-histidine motif is also essential for the efficient and specific
interaction with the major packing site on genomic viral RNA. This interaction is
responsible for the formation and stability of the dimeric form of viral RNA in
virions (reviewed in Luciw, 1996).
Matrix p!7 protein (MA):
MA provides a matrix for the viral structure and is essential for the virion
integrity. It is cleaved from the N-terminus of Pr55gag by viral protease, contains 130
amino acids, and its molecular weight is about 17 to 18 kDa. MA is required for the
viral assembly (Hunter, 1994). Mutagenesis studies have demonstrated that deletions
in the first two-thirds of HIV-1 MA will cause a failure in the incorporation of
envelope glycoproteins into the mature virion, although the processing of the gag
proteolysis or virion assembly and release might not be affected (Dorfman et al.,
1994b). In addition, noninfectious virions are produced when cultured cells are
transfected with HIV-1 containing small deletion mutations at the C-terminus ofMA.
This result suggests that MA is also important for the early stages of viral infection
(reviewed in Luciw, 1996).
1.2.3.2 Viral Enzymes
Protease (PR), integrase (IN), reverse transcriptase (RT) are the three viral
enzymes of HIV-1, which are the products of pol gene. All of them are very
important and indispensable for the replication ofHIV-1.
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Protease tPRt
Protease contains 99 amino acids and its molecular weight is about 10 kDa
(Katz & Skalka, 1994). During post-translated processing of viral proteins, the
mature HIV-1 protease dimer is first released from the Prl6CF8"po1 by an autocatalytic
cleavage. HIV-1 protease is required for viral replication. The fully active viral
protease targets specific proteolytic sites in Prl60gag~po1 and Pr558ag, proteolyses these
precursor proteins, and finally produces RT, IN, MA, CA, and NC (Katz & Skalka,
1994, Luciw, 1996). Studies in the site-specific mutagenesis have demonstrated that
noninfectious particles, containing uncleaved Prl608a8"po1 and Pr55sas polyproteins,
are produced if this enzyme is inactivated by mutation (Luciw, 1996).
Because HIV-1 protease is indispensable for viral replication, many efforts have
been made to inhibit its enzymatic in the development of antiviral therapies (Deeks et
al., 1997). Currently, four protease inhibitors are used clinically either alone or in
combination with RT inhibitors or other PR inhibitors, which are introduced at
section 1.7 .
Reverse Transcriptase (RT1
Reverse transcriptase was first discovered in retroviruses. It is an RNA-
dependent DNA polymerase, which allows HIV-1 itself to synthesize double-
stranded DNA (cDNA) using viral RNA as the template. HIV-1 RT is a heterodimer
composed of p51 and p66. It contains the activity of RNase H, which functions in
reverse transcription by degrading the RNA moiety of RNA/DNA hybrids and
thereby uncovering the template for viral DNA synthesis (reviewed in Luciw, 1996).
RT is processed in two steps from Prl608ag"po1 precursor by viral encoded PR.
Initially, protein p66, which consists of an N-terminus polymerase domain and a C-
terminus RNase H domain, is cleaved from the central portion of Prl60ga8"po1 and
forms a homodimer. Subsequently, a portion of the C-terminus is cleaved from one
p66 subunit to produce a heterodimer of p66/p51. The N-termini of p51 and p66 are
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identical, however, only subunit p66 retains the RNase H domain (reviewed in
Luciw, 1996). The predicted structure ofp66 has been compared to that of a clenched
right hand, specific subdomains are designated as palm, thumb, and finger. A short
connection sub-domain joins the p66 and p51. The viral RNA template and the tRNA
primer are positioned within the palm position (reviewed in Coffin, 1996). Both
domains ofRT are indispensable for viral replication. Inhibitors of RT were the first
prescription used in antiretroviral therapy. Although treatments with RT inhibitors
are commonly associated with severe side effects and the emergence of resistant viral
strains, RT inhibitors are still used for HIV-1 therapy because of their clinical value
in combination with protease inhibitors.
Integrase (INI
IN is about 32 kDa, and is proteolytically cleaved by PR from the C-terminus of
Prl60gas"po1 polyprotein. Genetic studies of viral mutants have shown that this viral
enzyme is also essential for viral replication. The two principle functions of HIV-1
integrase are DNA cleavage and joining activities. After viral DNA has been
generated by RT, IN assists in joining this double-stranded DNA covalently to the
host DNA to form the provirus (reviewed in coffin, 1996).
1.2.3.3 Envelope Glycoproteins
HIV-1 envelope glycoproteins, including gpl20 and gp41, are the products of
highly variant env gene. They are expressed in the late stages of viral replication, and
their expression is altered by the viral rev gene. The primary product of env gene is
the envelope precursor gpl60 glycoprotein that contains 850 amino acids. It is then
cleaved by intracellular protease to yield an N-terminal gpl20 subunit and a C-
terminal gp41 subunit. Gpl20 is designated the SU (surface glycoprotein) domain,
which locates on the external surface of the virion envelope. Gp41 is designated the
TM (transmembrane glycoprotein) domain, which traverses the virion envelope and
severs as an anchor for gpl20 (Veronese et al., 1985). This envelope heterodimer is
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shaped in a knob-and-socket-like formation (Figure 1. 4 & Figure 1. 5), and mainly
functions for virus attachment and infection. These viral glycoproteins are
responsible for the induction of syncytia in tissue culture cells. In addition, they serve
as the major targets for the antiviral immune response of the infected host (Luciw,
1996; Levy, 1998).
Transmembrane glycoprotein: gp41
Gp41, the transmembrane (TM) subunit of envelope glycoprotein, is about 350
amino acids in length, contains 3 cysteine residues and four potential glycosylation
sites, including fusion peptide, leucine zipper motif, transmembrane domain, and
cytoplasmic peptide (Figure 1.5). The first 20 amino acids at the N-terminus of gp41
are hydrophobic and define the fusion peptide. It is the intracellular portion of gp41,
and required for the fusion of virion membrane with cell plasma membrane during
the entry steps in viral replication (Luciw, 1996; Chang et al., 1999). A second
hydrophobic domain is the transmembrane domain of gp41, which spans the virion
or cell membranes, serving as a bridge to link the cytoplasmic portion and
intracellular portion of gp41. The region between fusion peptide and transmembrane
domain is external to the membrane, and contains a highly conserved sequence
predicated to be similar to the leucine zipper motif. Investigators have demonstrated
that mutations in this region of gp41 block viral infectivity and cell fusion (Kliger et
al., 1997). Two a-helical regions, LLP-1 (for Arg826 to Leu854) and LLP-2 (for
Tyr768 to Arg788) are predicted in the cytoplasmic domain of gp41. Synthetic
peptides representing these two regions have shown the ability to induce the
formation of pores in plasma membranes of tissue culture cells and cause cell lysis;




Figure 1. 5. Predicted folding pattern of HIV-1 envelople glycoprotein. Nine
disulfide bonds have been identified within gpl20 subunint, which are indicated by
short connecting lines in the figure. Hypervariable domains are designated V1
through V5 and are drawn as broken lines. The predicted folding pattern and
membrane association of the gp41 subunite are also shown. Regions labelled in the
gp41 subunit are: F, fusion peptide (large arrow at N-terminus); Z, leucine
zipperlike region (shown as a helix); TM, transmembrane domain (cross-hatched
box); LLP-1 and LLP-2, lentivirus lytic peptides 1 and 2 (shown as WW). Amino
and carboxyl termini are labeled N and C, respectively, for both subunits. (Copied
from Fields Virology, 1996)
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Surface glycoprotein: gp!20
Gpl20 contains about 550 amino acids, involving 18 highly conserved cysteine
residues. As an external surface subunit of HIV-1, the principal function of gpl20 is
interaction with cellular receptors, especially with CD4 receptor. This has been
proved by previous studies, which employed antibodies to gpl20 which successfully
blocked CD4 binding (Moore & Ho, 1993; Levy, 1998).
Based on the biochemical analysis, a predicted model for the gpl20 shows that
about nine intra-chain disulfide bonds are formed between these cysteine residues
(Luciw, 1996). The formation of these disulfide bonds delineates gpl20 into five
hypervariable regions (V1-V5) and five conserved regions (C1-C5) (Figure 1. 5).
The actual function of each region is not yet entirely understood; however analyses
of genetic mutations and molecular structure both provide evidence that each region
of gpl20 plays a role in the interaction with the cellular receptor (reviewed in Levy,
1998).
Investigations of the neutralizing antibody activity in HIV-1 infected hosts
further confirmed that the majority of this neutralizing activity is specific for the V3
loop in gpl20 (La-Rosa et al., 1990; Robert-Guroff et al., 1994; Levy, 1998). In in
vitro studies, synthesized V3 peptides are capable of eliciting the virus neutralizing
antibodies. Thus, the V3 region is designated as a principal neutralizing determinant
(PND) of HIV-1 and believed to playing an important role in the early stage of
infection (Luciw, 1996; Levy, 1998).
The V3 domain is the third hypervariable region of the gpl20. It contains 35
amino acids arranged in a disulfide loop involving two cysteine residues, Cys301 and
Cys336 (Figure 1. 6) (Milich et al., 1993; Luciw, 1996). The nucleotide sequence of
the V3 region shows great variability, however there are some relatively conserved
sequences located either at the top of V3 loop (Gly317-Pro318-Gly319-Arg320-
Ala312-Phe222) or near the Cys301 and Cys336 at the bottom of the loop (reviewed
in Luciw, 1996).
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Figure 1. 6. V3 loop of HIV-1 envelope gpl20. The one-letter amino acid code is
used to identify residues in the consensus sequence for the V3 loop ofHIV-1.
The motif, G15-P16-G17-R18-A19-F20 at the crown of the loop is relatively
conserved between HIV-1 isolates. T-tropic SI viruses generally have a basic
amino acid at least one of the positions at 11 and 25 and M-tropic NSI strains
have an acidic amino acid or alanine at positions 11 or 25. (Modified from
Fields Virology, 1996).
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Mutagenetic studies demonstrated that point mutations within these conserved
residues of the V3 loop might influence several properties of HIV-1. For example,
some HIV-1 strains with mutations in Gly317-Pro318-Gly319 are not infectious and
do not induce syncytium formation (de Jong et al., 1992). Also, it has been found that
mutations in the V3 sequence affect stabilisation of the association between gpl20
and gp41 (Willey et al., 1994; Luciw, 1996). Moreover, mutation of the conserved
Cys3 3 6 at the base of the V3 loop precludes the cleavage of gp 160 and binding to the
CD4 receptor. Seemingly, this point mutation alters the overall tertiary loop structure
of envelope glycoprotein and changes the conformation of the binding site for the
CD4 receptor (Willey et al., 1994). Apart from modulating affinity with the CD4
receptor, virus infectivity, and stability between gpl20 and gp41, the V3 sequence
has also been proved to hold the determinants for viral syncytium formation and cell
tropism (Chesbro et al., 1991; Milich et al., 1993; Willey et al., 1994; reviewed in
Luciw, 1996). Single or multiple point mutations in amino acid Ser306, Ala321,
Phe322, Gln328 of the V3 loop correlate with a slowly replicating non syncytium-
inducing phenotype (NSI), whereas the original amino acids in these positions confer
a rapidly replicating syncytium-inducing phenotype (SI) (Chesebro et al., 1992; de
Jong et al., 1992; Fouchier et al., 1992; Milich et al., 1993). It is also documented
that T-cell line-tropic viruses generally have a nonacidic amino acid at position
Gln328, whereas macrophage-tropic viruses have an acidic amino acid at this
position (de Jong et al., 1992; Fouchier et al., 1992; Milich et al., 1993; Luciw,
1996).
1.2.3.4 Other Viral Genes and Their Products
As described previously, HIV genome contains six regulatory genes, including
tat, rev, vif vpu, vpr and nef, which encode Tat, Rev, Vif, Vpu Vpr and Nef viral
proteins respectively. Tat and Rev are essentially regulatory proteins for RNA
binding. Tat protein works for transcriptional initiation and elongation of viral RNA
at the transcriptional level. Rev protein regulates splicing and transport of viral RNA
from the nucleus to the cytoplasm at the post-transcriptional level (Cullen & Greene,
1990). Both Tat and Rev are very important for viral gene expression. They are
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synthesised at both early and late stages of the life cycle ofHIV-1, but are not packed
into the virion (Cullen & Greene, 1990; Luciw, 1996). Vpu, Vif, Vpr and Nef are the
accessory proteins of HIV-1. Only Vpr is found to be assembled into virions, others
are not detected perhaps due to the small amounts in virus particles. Functions of
these accessory proteins are not yet clear. Early studies of viral replication, based on
tissue culture systems, showed that these gene products could be dispensed within
certain HIV strains. Recently, more comprehensive studies performed in vivo
suggested that Nef, Vif, Vpu and Vpr of HIV-1 play important roles in viral
replication and HIV pathogenesis (reviewed in Miller & Sarver, 1997).
Transcription activator ITatl
Tat is a product of the transcriptional transactivator (tat) gene, and about 14 kDa
in molecular weight. It is encoded by two exons, the first coding exon is located in
the central region of the viral genome between vpr and env\ the second coding exon
overlaps the translation frame for both rev and the gp41 domain in env (refer to
Figure 1. 3). Tat is the major protein involved in up-regulating HIV transcription,
and functions by interaction with a Tat-responsive element (TAR). TAR is an RNA
loop structure formed in the 3' repeat R portion of the viral long terminal repeat
(LTR). The interaction between Tat and nascent TAR RNA facilitates formation of
an initiation complex for viral transcription and stabilization of the elongation
complex. Genetic studies have demonstrated that when Tat is absent, initiation of
viral transcription is low and transcriptional elongation is inefficient (reviewed in
Luciw, 1996).
Recently, Tat has been found to be toxic to neurons and to induce cytokine
production by glial cells in vitro (Jones et al., 1998). They demonstrated that even a
transient exposure of the brain tissue to Tat protein could result in profound and
progressive neuropathological changes including an influx of inflammatory cells,
gliosis, ventricular enlargement, and eventually lead to cellular loss and functional
derangement of central nervous system (Jones et al., 1998).
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Regulator of Viral Expression (Rev)
Similar to the tat gene, the regulator of viral expression (rev) gene is also
composed of two exons. The first coding exon is located in the central region of the
viral genome between vpr and env; the second coding exon overlaps the translation
frame for both tat and the gp41 domain in env regions (refer to Figure 1. 3). The rev
gene encodes Rev protein, which has a molecular weight of 19 kDa and functions to
regulate splicing and transport of viral RNA from the nucleus to the cytoplasm
(Malim et al., 1988; Luciw, 1996). For function, Rev requires a complex stem-
looped mRNA, Rev-responsive element (RRE), which is located within the env gene
immediately 3' of sequences encoding the junction of the gpl20 and gp41 subunits
(Malim et al., 1992; reviewed in Luciw, 1996). The interaction between Rev and
RRE functions to export unspliced or single spliced mRNA from nucleus to
cytoplasm, which then act as templates for the translation of gag-pol or envelope
precursor proteins. In the absence of Rev, no structural proteins can be made (Malim
et al., 1991; Luciw, 1996).
Viral Infectivitv Factor (Vif)
The vif protein of HIV-1 is encoded by vifgene, which is located immediately
downstream of the pol gene (refer to Figure 1. 3). Vif contains 193 amino acids, has a
molecular weight of 23 to 27 kDa, and presumably influences the infectivity of
cell-free virions. It is produced in the late stage of viral replication cycle, and is
observed to accumulate in the cytosol and cytoplasmic membrane fractions of
infected cells (reviewed in Luciw, 1996).
The HIV-1 Vif protein is hypothesised to play a role in the early events in viral
replication. Liu et al. demonstrated that abundant Vif molecules were present in
intact virus particles (Liu et al., 1995). It was observed that these Vif proteins were
associated with intermediate filaments in the cellular cytoskeleton which directly
connect the plasma membrane with the nuclear membrane. The association and
interaction between Vifproteins and intermediate filaments are thought to provide an
additional mechanism for transporting incoming virions to the nucleus (Karczewski
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and Strebel, 1996). Also, Vif was observed to stabilise newly synthesised virion
DNA intermediates during virion formation in the virus-producing cells (Fouchier et
al., 1996; Simon and Malim, 1996). However, all these observation need further
investigations.
Viral Protein R IVpr)
Vpr is a 14kDa virion-associated protein and so far, it is the only accessory viral
protein found to assemble into HIV-1 virions. It is encoded by vpr gene, which
locates between the end of vif gene and the beginning of the first exon of tat gene
(refer to Figure 1. 3).
Two principle functions ofVif have been identified recently, both related to the
presence of Vpr in the intact virion. The first, Vpr has been observed to assist in
targeting of the viral preintegration complex (PIC) to the nucleus (Heinzinger et al.,
1994; Yao et al., 1995). Entry of the PIC into the nucleus is an essential step in
retrovirus replication and is required for subsequent integration of the proviral
genome into host DNA. Unlike other retroviruses, HIV has developed specific
mechanisms for the PIC nuclear import, which are mediated by Vpr and MA
independently via distinct nuclear localisation signal sequences (NLS) (Heinzinger
et al., 1994; Yao et al., 1995). Cultured cells infected with viral particles with double
mutations in the NLS of both MA and Vpr showed in a reduction of viral replication
(Miller and Sarver, 1997).
The second function ofVpr is the arrest of dividing cells in G2 phase of the cell
cycle. Generally, the cell cycle involves four major phases, G1 (first gap), S (DNA
synthesis), G2 (second gap) and M (mitosis) sequentially. In in vitro culture system,
it was found that the cytostatic function of Vpr caused cells to stay in the G2 phase
(DiMarzio et al., 1995; Jowett et al., 1995; Bartz et al., 1996). Experiments
estimated that HIV-1 infected cells arrested in G2 phase spend an average of 20
hours producing virus whereas cells progressing normally through the cell cycle
spend only three hours in optimal virus production, thus arrested cells displayed an
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increase of virion production (Miller and Sarver, 1997). Moreover, with the presence
of Vpr, some cells that arrest in G2 phase returned to S phase instead of progressing
to M phase, and thus the virus production is further enhanced (Bartz et al., 1996).
Viral Protein U IVpul
The Vpu protein is encoded by vpu gene. This reading frame is unique to HIV-
1, which is located from the 3' end of first tat and rev exon to the 5' end of env gene
(refer to Figure 1. 3). HIV-1 Vpu protein is about 9.2 kDa in molecular weight, and is
a multifunctional phosphoprotein composed of two distinct protein domains, which
are the N-terminal hydrophobic domain and the C-terminal hydrophilic cytoplasmic
domain. Immunolocalisation studies revealed that Vpu is usually present in the
perinuclear membranes ofHIV-infected cells, including endoplasmic reticulum (ER)
and Golgi-bodies (Strebel et al., 1989; reviewed in Miller and Sarver, 1997).
Two biological functions of Vpu have been identified recently. The first is the
degradation of the CD4/gpl60 complexes. This CD4/gpl60 complex is formed in
the ER system during the course ofHIV infection. Vpu appears to recognise specific
sequences in the cytoplasmic domain of CD4 and bind to the CD4/gpl60 complex.
The interaction between Vpu and CD4 then triggers the degradation of CD4 and
releases gpl60. Once released from the complex, gpl60 is processed to gp41 and
gpl20, which construct the virion envelope. It has been found that the
phosphorylation of the cytoplasmic domain of Vpu is absolutely essential for this
degrading pathway (Paul et al., 1998). The other function of Vpu is to enhance the
release of HIV-1 particles from the surface of infected cells (Paul et al., 1998). It has
been observed that vpw-deficient virions are released poorly from infected cells in
vitro. Although the actual molecular mechanism is not conclusive yet, it is believed
that Vpu is critical in virus release (Paul et al., 1998).
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Negative Factor (Neft
HIV-1 Nef protein is encoded by nef gene (refer to Figure 1. 3), and its
molecular weight is about 27 kDa. During the early stage of virus replication, Nef is
abundantly synthesised in the cytoplasm, becomes myristoylated and then associated
with the plasma membrane of infected cells. The name, negative factor, was given
when Nefwas thought to be a down-regulator ofviral gene expression. Subsequently,
according to the discoveries that infection with nef-defective virus is usually
associated with low levels of viral replication and absence of clinical disease in
animal models (Kestler et al., 1991), and the Nef-defective HIV-1 strain was
identified in a naturally occurring human cohort of long-term non-progressors
(Deacon et al., 1995), Nef protein is now known to play a prominent role in HIV
replication (Vicenzi et al., 1997), and pathogenesis (Mangasarian & Trono, 1997;
reviewed in Miller and Sarver, 1997).
Recently, Nef has been observed to downregulate the expression of CD4 from
the surface of infected cells in cell culture systems. Also, it has been found that Nef
protein might enhance the infectivity of cell-free virus (Guatelli, 1997). However the
relevance of these findings to HIV pathogenesis in vivo requires further
investigation.
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1.3 Life Cycle of HIV-1 Replication
The replication cycle of HIV-1 can be simply divided into an early and a late
phase. The early phase begins with attachment of a virion to a cell surface receptor
and continues to the formation of a provirus integrated into the host cell genome. The
late phase begins with transcription and processing of viral RNA from the integrated
proviral template and ends with release of progeny virions from the infected cell.
1.3.1 Virion Attachment and Entry
At least two cell surface receptors are now known to be involved in HIV-1 entry
to cells. They are the CD4 and chemokine receptors.
1.3.1.1 Interaction with the CD4 Receptor
The discovery of the CD4 molecule as the major cellular receptor of HIV-1 was
an early and important step in the understanding of HIV-1 infection. CD4 is a
member of the immunoglobulin superfamily and functions primarily as a coreceptor
in antigen-MHC II dependent interactions. The structure of the N-terminal
extracellular portion of CD4 appears to be a rod-like monomer consisting of four
immunoglobulin-like domains (D1 to D4). This extracellular portion is anchored to
the cell surface by a transmembrane region followed by a short cytoplasmic tail at the
C-terminus (Janeway & Travers, 1996). Studies in electron microscopy and X-ray
crystallography reveal that direct fusion of the viral and cell plasma membranes
should be the principle pathway for virion entry, which is initiated by virion
attachment (Wang et al., 1990; Ryu et al., 1990; Luciw, 1996).
The CD4 molecule is identified as the major receptor responsible for HIV-1
attachment through an interaction with gpl20. By means of biochemical and genetic
analyses, the first immunoglobulin-like domain (Dl) of the CD4 molecule has been
recognized as the major binding site for the viral surface envelope protein gpl20
(Broder et al., 1993; Brand et al., 1995; Sullivan et al., 1996). The CD4 binding
region on gpl20 appears to be a complex folded structure with discontinuous sites
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from several regions coming in contact with CD4 molecule (Moore & Ho, 1993).
This interaction is observed to involve primarily two hydrophobic domains in the
conserved C2 and C4 regions ofgpl20, and probably other unspecified regions. Both
conformations of CD4 and gpl20 are very important for virus binding, and will
affect virus entry (Moore & Ho, 1993).
The high affinity binding of the HIV-1 Env proteins to the CD4 molecule
appears to induce conformational changes in CD4-gpl20-gp41 complex (Figure 1.
7). The actual mechanism is not yet clear. In a prevalent model, it is believed that
interaction ofCD4 and other surface receptors, such as CCR5 or CXCR4 with HIV-1
gpl20 promotes dissociation of the gpl20 subunit from the gp41 subunit in virion
membranes (Moore & Ho, 1993; Luciw, 1996; Levy, 1998; Doranz et al., 1999).
This dissociation results in exposure of the hydrophobic fusion peptide at the N-
terminal of gp41 (Figure 1. 7). After exposure, this fusion peptide integrates into the
lipid bilayer of the cell plasma membranes. Subsequently, the viral and cell
membranes fusion are fused. The entry process then continues with formation of the
fusion pore and transfer of the viral nucleocapsid complex into the cell interior thus
initiating the infection cycle (Luciw, 1996; Kliger et al., 1997; Levy, 1998; Chang et
al., 1999; Doranz et al., 1999).
Though CD4 was found to be the major receptor of HIV-1, further studies have
shown that the CD4 receptor is not sufficient on its own for virus entry. There is
evidence from the studies of Kikukawa et al. that several human cells expressing
high levels of CD4 molecule cannot always be infected by HIV-1 (Kikukawa et al.,
1986). Also, Tersmetta et al. demonstrated that in some animal models, although
human CD4 molecules were successfully expressed on the cell surface, these cells
remained resistant to HIV-1 infection (Tersmette et al., 1989a). Moreover, Rey et al.
found that productive infection ofCD4+ cells by certain HIV strains was not blocked
by anti-CD4 antibodies (Rey et al., 1991). Taken together these findings suggest that
other cell surface factors are involved in HIV-1 entry.
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1.3.1.2 Alternative Factors
The discovery of chemokine receptors was another important step in
understanding the pathogenesis of HIV-1 infection. In searching for accessory
receptors for HIV infection, a human cDNA clone that expressed a protein, fusin,
was found capable mediating fusion in the mouse-human CD4+ cell model. When
introduced into HIV-resistant mouse cells expressing human CD4 molecules, this
fusion-inducing molecule, fusin, rendered those HIV-resistant cells susceptible to
HIV infection (Feng et al., 1996). This molecule, now termed CXCR-4, has been
proved to act as a coreceptor for T-cell-line tropic HIV-1 strains, which plays a
critical role in T-tropic virus fusion and entry into permissive cells (Feng et al., 1996;
Berger, 1997; Berger et al., 1999).
CXCR4 is a 46 kDa integral membrane glycoprotein and a member of the a-
chemokine receptor family within the superfamily of G-protein-coupled seven-
transmembrane-domain receptors (Feng et al., 1996). The natural ligand for CXCR4
is stromal cell-derived factor 1 (SDF-1). SDF-1 is a member of a family of low-
molecular-weight cytokines called CXC-chemokines that mediate inflammation by
recruiting immune cells to the site of injury (Bleul et al., 1996; Feng et al., 1996;
Oberlin et al., 1996). CXCR4 has been shown to act as a coreceptor for T-tropic, but
not for macrophage-tropic HIV-1 strains.
Some investigators also found that the presence of certain (3-chemokines
including RANTES (regulated-upon-activation normal T expressed) and
macrophage inflammatory protein-la (MlP-la), and MIP-ip in the cell culture
supernatant inhibit cell: virus membrane fusion and the entry ofmacrophage-tropic or
NSI HIV-1 strains, however these P-chemokines are insensitive to T-cell-line-tropic
or SI strains (Deng et al., 1996; Dragic et al., 1996). More chemokine receptors,
mainly CCR3 and CCR5, were subsequently identified as the coreceptors
responsible for the entry of macrophage-tropic, NSI HIV-1 strains (Alkhatib et al.,
1996; Choe et al., 1996; Berger, 1997).
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(A)
Figure 1. 7. Model for virion attachment and entry.
(A) HIV entry begins when the gpl20 subunit of Env contacts CD4 on the surface of
a cell (far left). CD4 binding induces a rapid and reversible conformational
change in gpl20 that exposes a binding site for coreceptor. Binding to a
coreceptor brings the virus in close proximity to the cellular membrane and
induces a conformational change in the gp41 subunit of Env. The change in gp41
exposes the fusion peptide ofEnv gp41 (far right). (Modiefied from Doranz et al.,
1999).
(B) Subsequently, the exposed fusion peptide inserts into, and destabilizes, both the
target and viral membranes primarily as a helix. Insertion of the fusion peptide
facilitates mergence of these two membranes. (Modified from Chang et al.,
1999).
(C) After target and viral membranes merge, several units of gp41 fusion peptide
assemble to form the fusion pore to allow the flow of nucleocapsid of the virus.
(Modified from Chang et al., 1999).
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Further evidence that CCR5 could be an essential co-receptor for HIV-1
infection was shown in studies of cells with defective CCR5 receptors. Several
individuals who remained free from infection with HIV despite repeated exposure
through sexual intercourse with HIV-positive partners were reported by Paxton et al.
(Paxton et al., 1996). Subsequently, a mutant allele of CCR5 gene that contains a
homozygous 32-base-pair deletion was identified from the exposed but uninfected
individuals. This deletion inhibits the expression of CCR5 receptor on the cell
surface, and presumably results in resistance to HIV-1 infection (Liu et al., 1996;
Samson et al., 1996; Quillent et al., 1998). Similar to a-chemokine receptors, the
P-chemokine receptor also belongs to the G-protein-coupled seven-transmembrane-
domain family. Without these receptors, the env-mediated membrane fusion at the
early binding steps might be inhibited and result in blocking HIV-1 infection,
however this do not appear to inhibit virus production in chronically infected cells
(Oravecz et al., 1996; Levy, 1998). Although the details remain to be resolved, the
sequence of the V3 loop is an important determinant ofwhich receptors are used for
viral entry (Cocchi et al., 1996; Wu et al., 1996; Moore, 1997; Farzane/a/., 1998).
Other co-receptors have also been discovered, including CCR-2b,
Bonzo/STRL33, BOB/GPR15, but how they interact with virus infection requires
further investigation (Deng et al., 1997; Frade et al., 1997; Liao et al., 1997).
1.3.2 Integration of Viral DNA
A pre-integration complex is produced due to virion capsid rearrangement soon
after the HIV-1 nucleocapsid gains entry into the cytoplasm of the host cells (Farnet
& Haseltine, 1991). Subsequently, the synthesis of proviral DNA is activated by
reverse transcriptase (RT). The newly synthesized complementary viral DNA is then
incorporated into the host genome with the help of viral integrase (IN), and the
HIV-1 life cycle goes into the provirus stage.
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1.3.2.1 Mechanism of Reverse Transcriptase
For the purpose of incorporation of the viral genome into the host cell genome,
single-strand viral RNA requires first to be transcribed into complementary double-
strand DNA. This transcription is generated by the virally encoded RT enzyme.
At both the 3' and 5' ends of HIV-1 RNA genome, there exist a short repeated
RNA sequences (R), which belongs to LTR region. Initially, RT activates the
synthesis of the first DNA strand (minus strand). The procedure starts from a tRNAlys
primer hydrogen-bonded to the primer-binding site (PBS), which located near the
5' end of the viral RNA genomic template. A short DNA copy is first made
consisting ofR and U5 regions lying between PBS and the 5' end of the viral genome.
This fragment is designated as the strong-stop DNA of the minus strand (Figure 1. 8).
Once the strong-stop DNA is produced, the RNase H of p51/p66 RT heterodimer is
activated and degrades RNA in the DNA/RNA hybrid. The degradation results in
exposing the newly synthesized R' region of the strong-stop DNA which is
complementary to the short repeated R region at the 5' end of the viral RNA genome.
This strong-stop DNA then jumps to the 3' end of viral genome, and the exposed R'
region hybridizes to complementary sequences in the R region at the 3' end of the
viral RNA genome. After the strong-stop DNA primes, the minus strand DNA is
extended completely by RT to the 5' end of PBS, since R and U5 have been removed
at the beginning. As the minus strand DNA elongates, the RNA template is gradually
degraded by the RNase H of RT. Therefore, the synthesized minus strand DNA can
serve as the template for synthesis of plus strand DNA (reviewed in Coffin, 1996,
and Luciew, 1996).
The synthesis of plus strand DNA utilises two primers, poly-purine track (PPT)
that borders the U3 region and central PPT (cPPT) that nears the pol gene of the
minus strand DNA template. The elongation of plus strand DNA is started in parallel
from PPT and cPPT primers. One elongation generated by the PPT primer is
extended toward the end of the minus strand DNA template to produce strong-stop
DNA of the plus strand DNA, which functions the same as minus strand strong-stop
DNA. Once produced, this strong-stop DNA will then jump and hybridize to
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complementary sequences in the PBS region at 3' end of the minus strand DNA
template, and continues to elongate the plus strand DNA to the central termination
signal (CTS) that nears cPPT site (Wainberg & Gu, 1995; Luciw, 1996). At the same
time, another DNA elongation initiating at the cPPT site is completed by RT to the
end of the minus strand DNA template. These synthesized fragments are then linked
together to yield the completed double-stranded linear DNA which contains the LTR
(U3-R-U5) at each end.
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Figure 1. 8. Mechanism of reverse transcriptase. The viral RNA genome is shown as a
thin solid line, designated (+)■ The poly-A tail on viral RNA is labelled A(n). The first strand of
DNA is shown as a heavy solid line, designated (-), which is primed by a tRNAlys. Synthesis of
the second DNA is primed by a short viral RNA fragment generated by RNase H activity at the
PPT that borders U3 and cPPT. The second DNA strand is represented as thick solid line.
Details were described in text. (Copied from Fields Virology, 1996).
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1.3.2.2 Integration of Proviral DNA
Following viral DNA synthesis, the pre-integration complexes containing linear
synthesised DNA, IN and other viral proteins are formed and translocated into the
nucleus of the host cell. The entry of this pro-integration complex initiates viral
integration. During the process of translocation, two bases at the either 3'end of viral
DNA are cleaved by IN, leaving a 3'OH end. The ends thus have the sequence
5 AATG CA-OH3'
3 HO-AC GTAA5
This modified viral DNA joins into the host DNA by a strand transfer reaction.
The strand transfer reaction simultaneously joins the 3'ends of viral DNA to host
genomic DNA through a direct attack on a phosphate group by hydroxyl group of the
3' end of viral DNA; however the unaltered 5'ends of the viral DNA remains
unjoined. A cellular DNA repair system fills in the resulting gap in the molecule,
displacing two mismatched bases at the 5'end of the viral DNA and ligating the
remaining ends. Thus, viral DNA successfully integrates into the host genome and
initiates the provirus stage. Subsequently, proviral DNA may replicate and survive as
long as the host cell is alive. At this stage, the viruses stay latent or co-exist with the
host genome in a non-productive stage until unknown factors trigger off a productive
stage. When a provirus goes into a productive stage, proviral DNA starts to express
and produce the viral components. After viral assembly is completed, the host cell
will be destroyed and progeny viruses will be released (reviewed in Coffin, 1996,
and Luciw, 1996).
1.3.3 Expression of Viral Products
Viral RNA synthesis occurs in the cell nucleus and uses the integrated provirus
DNA as the template. This process is complicated, and involves several cellular
proteins and viral regulators. HIV-1 proviral DNA contains two identical LTRs at 3'
and 5' end, but they function differently. 5' LTR works for the initiation of viral
RNA synthesis, whereas 3' LTR works for ending transcription (Luciw, 1996). The
U3 domain ofHIV-1 5' LTR contains basal promoter elements, including a TATAA
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box for initiation by host cell RNA polymerase II, and sites for binding the cellular
transcription factor SP1. Initiation of viral RNA synthesis occurs at the U3/R border
of the 5' LTR. First of all, an initiation complex for full-length viral RNA
transcription is formed through interaction between HIV-1 Tat and nascent TAR
RNA. Subsequently, an R-U5 segment is transcripted and serves as the leader
sequence for RNA elongation. The 5'ends of the transcripts are post-
transcriptionally capped with 7-methylguanosine by cellular enzymes soon after
elongation initiates. HIV-1 RNA is synthesised by cellular RNA polymerase II and
the 3' end of the viral transcript is terminated at the border of R/U5 in the 3' LTR.
Signals in U3 region are recognised by cellular enzymes that add poly-A tails at the
3' ends of viral transcript (Barre-Sinoussi, 1996; Luciw, 1996). After transport to the
cytoplasm, a fraction of these full-length RNA copies is reserved as the genomic
RNA that is eventually assembled into progeny virions. The others serve as
precursors for alternatively spliced mRNAs that are translated in the cytoplasm to
produce viral proteins (Barre-Sinoussi, 1996). In general, this gene expression is
regulated by tat and rev genes (refer to section 1.2.3.4).
1.3.4 Virion Assembly
The first event in virion assembly is presumed to be the production of an
assembly of intermediate nucleoprotein complexes, which are composed of gag-pol
precursor polyprotein (Prl60gag'po1), Pr55gag and genomic viral RNA. Subsequently, as
described previously, viral protease is activated to generate the proteolytic
processing of Gag, Gag-Pol and Env precursor polyproteins. Cleavage of these
polyproteins produces a mature nucleocapsid composed of fully processed gag (MA,
CA, NC, p6, pi and p2) andpol gene products (PR, IN, RT) as well as two molecules
of the viral single-stranded RNA genome. This mature nucleocapsid then migrates to
a budding site in the plasma membrane. Finally, oligomers of Env glycoproteins are
also inserted into the budding site in the plasma membrane. Under the interaction
between the cytoplasmic tail of the gp41 subunit in these oligomers and the MA
domain of Pr55gag in the newly formed viral nucleocapsid, viral particles are extruded,
or budded through the plasma membrane. The life of the host cell ends with release





















Figure 1. 9. Overall life cycle of HIV-1. (From Furtado et al., 1999).
Early stage: HIV virions enter host cells after binding to the cellular receptors (refer to Figure 1. 7).
The HIV-1 RNA genome then enters the cytoplasm as part of a nucleoprotein complex. The
viral RNA genome is reverse-transcribed into a collinear DNA duplex, which has terminal
duplications (LTRs). Soon as the viral DNA synthesised, the linear viral DNA molecule is
incorporated into a preintegration complex that targets to the nucleus. In the nucleus, most of the
viral DNAs are integrated into the host genome, although some remain unintegrated.
Late stage: Production of new virus particles is initiated by the transcription of new viral RNAs. Both
full-length unspliced viral mRNA and spliced viral mRNA are synthesised. A fraction of the
unspliced viral RNAs are translated into the viral structural precursor proteins, and others are
reserved as the viral genomic RNA. The spliced mRNAs are translated into the viral
accessory/regulatory proteins. All the viral transcripts are exported into the cytoplasm, where
translation and assembly and processing of the retroviral particle take place.
This cycle is completed by the release of infectious retroviral particles from the host cell.
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1.4 Genetic Diversity of HIV-1
A major problem for HIV-1 researchers has been the extraordinary ability of
HIV-1 to undergo genetic variation. HIV-1 has been cloned and sequenced by a
number of independent groups and a large number of nucleotide differences were
detected. These studies have reported that a high degree of genomic heterogeneity in
HIV-1 was present between and even within patients (reviewed in Barre-Sinoussi,
1996). This observation led to the term "quasispecies" to describe a group of closely
related but genetically distinct viral variants (Goodenow et al., 1989). It has been
postulated that mutation and perhaps genomic recombination are the major factors
responsible for this viral variation (Luciw, 1996).
Genetic variability is determined by the mutation rate per replication cycle, the
number of replication cycles within a fixed time, and the selective advantage or
disadvantage of a particular variant. The life cycle ofHIV-1 involves several enzyme
systems during replication, which is complex and thus provides many opportunities
for mutation. Among these enzyme systems, reverse transcriptase that facilitates
proviral DNA synthesis involving two strand-transfer or strand-jump steps is
believed to play an important role in genomic mutation (Coffin, 1996; Luciw, 1996).
The fidelity of HIV-1 RT is low. It has been reported that the error rate of HIV RT
was 1/1700 (Roberts et al., 1988) to 1/4000 (Preston et al., 1988), equal to 5 to 10
errors per genome per round of replication. In addition, frame shifts, deletions,
insertions and recombination events might also increase the infidelity of RT (Katz &
Skalka et al., 1990; Coffin, 1995; Temin, 1993). Also, some investigations
demonstrated that viral RNA polymerase II might cause errors to be incorporated in
genomic RNA during synthesis. Mansky et al. estimated recently that the mutation
rate ofHIV-1 was 3.4 x 10"5 mutations per base pair per replication cycle (Mansky &
Temin, 1995). Thus, a high mutation rate combined with the extremely high turnover
rate of HIV-1, which is estimated in the order of 109 virions produced per day,
provides the basis for the continual emergence ofnew virus variants (Barre-Sinoussi,
1996).
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Further evidence suggests that the high sequence variability of HIV-1 may be
also due to selection by the host immune system. It has been known for some time
that individual HIV-1 genes differ in their variability. Generally the env gene is much
more diverse than gag or pol genes. Within the env gene, V1/V2 and V3 domains
show much higher variability than other regions. These super-variable domains
function as the targets for neutralizing antibodies. In order to escape from antibody
neutralization or cytotoxic T cell elimination, the outstanding diversity of these
surface domains is very advantageous (Barre-Sinoussi, 1996).
At a functional level, these various selective forces imposed by the host immune
response may generate HIV-1 variants, which differ in their tropism for cells of
different lineage. While the CD4 molecule is ordinarily required for efficient entry of
most HIV-1 variants, some strains are able to infect macrophages and others show a
preferential tropism for T cell lines. Macrophage-tropic viruses are more effective at
invasion across a mucosal barrier, however subsequent in vivo evolution may lead to
the emergence of more T-cell tropic variants. This suggests that diversity of HIV-1
may facilitate infection of different cell types (reviewed in Barre-Sinoussi, 1996).
Recombination between HIV-1 genomes has been reported, and this may also
attribute to genomic diversity (Robertson et al., 1995). The process of recombination
could lead to new viruses being produced with different biologic and pathogenic
properties. Moreover, it could introduce new strains into the population thereby
challenging vaccine approaches. Between HIV-1 strains, recombination appears to
occur most often within the gag and env regions (Cornelissen et al., 1996; Kampinga
et al., 1997). The extent of recombination between strains is not yet clear, but it is
believed that the natural frequency may be very high (Robertson et al., 1995).
1-38
1.5 Clinical Aspects of HIV-1 Infection
1.5.1 Natural History of HIV-1 Infection
Generally, infection with HIV-1 will initiate an acute phase characterised by a
transiently high viral load. The symptoms in the acute phase are minor, and many
infected individuals do not even know that they have been infected. In some cases, a
flu-like seroconversion illness might also occur within 1 to 4 weeks. The symptoms
of primary infection, including headache, retro-orbital pain, muscle aches, sore
throat, low-grade or high-grade fever and swollen lymph nodes normally last for 1 to
3 weeks, though lymphadenopathy, lethargy and malaise can persist for many
months. Antibodies against the core or envelope viral proteins can be detected,
usually six to eight weeks after initial infection (reviewed in Feinberg, 1996; Levy,
1998).
Following acute phase, a sharp reduction of free virus in the blood will then
ensue, and HIV-1 infections go into an "asymptomatic" period. This asymptomatic
phase can last from several months to more than 10 years. During this phase,
physical examination might show no obvious abnormality, but about one-third of
patients have persistent generalised lymphadenopathy (PGL) (reviewed in Feinbery,
1996; Levy, 1998).
As the disease progresses, the amount of infectious virus and the number of
infected cells gradually increase, but the number of CD4+ lymphocytes declines.
Later in infection, patients develop symptoms and abnormalities consequent on the
low level of CD4+ T cells. This is known as the symptomatic phase or acquired
immune deficiency syndrome (AIDS) commonly associated with immune
abnormalities, opportunistic infections, neurological disorders, and unusual forms of
cancer (Schulz et al., 1996).
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1.5.2 Diagnostic Techniques
HIV infection is commonly diagnosed by detecting antibodies specific to the
virus or by detecting the virus itself (Table 1.2).
Table 1. 2. Criteria for HIV infection for persons aged more than 13 years
(From MMWR, CDC, 1992)
• Repeatedly reactive screening tests for HIV antibody (e.g., enzyme
immunoassay) with specific antibody identified by the use of supplemental tests
(e.g., Western blot, and immunofluorescence assay).
• Direct identification of virus in host tissues by virus isolation
• HIV antigen detection
• A positive result on any other highly specific licensed test for HIV
1.5.2.1 Immunoassays
Antibodies to HIV are undetectable in the first six to eight weeks after infection.
This period is known as the diagnostic window or serologic latency. Subsequent to
serologic latency, antibodies to HIV-1 viral envelope glycoproteins, IN, RT, and gag
gene products are produced (Gurtler, 1996).
To detect viral antibodies, enzyme-linked immunosorbent assay (ELISA) and
agglutination assays are usually used. Routinely, ELISA assays are employed for
screening, follow by a confirmatory assay. Usually, the immunoblot assay (Western
Blot) is employed for confirmation, and has become the gold standard for
investigating reactive results of ELISA screening (Gurtler, 1996). A double-antigen
ELISA assay is frequently used in the early phase of seroconversion, because it is
more sensitive and more specific than any other assay (Constantine et al., 1993).
However, the higher specificity of this assay may cause a poor ability to capture
various antibodies against variant HIV strains. The possibilities of false-negative
results need to be taken into consideration (Schable et al., 1994).
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1.5.2.2 Nucleic Acid Based Assays
Nucleic-acid-based assays, such as the Polymerase Chain Reaction (PCR) are
employed to achieve genomic level testing for HIV. These assays are extremely
sensitive and specific; moreover, they may detect free RNA virus particles by
reverse- transcript PCR (RT-PCR) method. These tests are likely to be particularly
useful in the serological diagnostic window period (Giirtler, 1996).
Usually, nucleic-acid-based assays are more expensive and not as convenient as
the methods described above. They are not always necessary in the primary
diagnostic procedure. Nevertheless they are of considerable use in more detailed
investigations, for example, to determine the infection status of newborn babies of
infected mothers, to subtype HIV variants and to identify various HIV strains for
forensic reasons. They are also used to sequence viral enzymes, such as reverse
transcriptase or protease genome fragments, for monitoring drug resistance and
therapeutic efficacy (Giirtler, 1996).
1.5.3 Classification System for HIV Infection
After the discovery of the infectious agent ofAIDS, numerous terms were used
to describe the symptoms, signs, and laboratory findings of HIV infection. It is
important to have a universal classification system for HIV infection and AIDS.
Categorising the clinical conditions and stages of HIV infection makes it easier to
compare directly reports from different centres and countries on clinical trials and
other research projects. Therefore, in 1986, the Centers of Disease Control in the
USA proposed a classification system on the basis of clinical disease criteria (CDC,
1986). Aetiological studies later confirmed that the primary target ofHIV was CD4+
T-lymphocytes. Also, studies in the natural history ofHIV infection discovered that
the loss of CD4+ T-lymphocytes was strongly associated with the progression of
illness. The more CD4+ T lymphocytes decline, the higher the risk that severe illness
was observed (CDC, 1992). In the early '90s, measures of CD4+ T-lymphocytes
were widely used as a determinant of clinical and therapeutic management in United
States. In order to reflect the importance of CD4+ T-lymphocyte count in medical
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care, and systematize more accurately the HIV-related morbidity, the CDC in the
USA decided to revise the HIV infected classification system in 1993 (CDC, 1992).
Based on the clinical conditions associated with HIV infection and CD4+ T-
lymphocyte counts, this revised classification system for HIV-infected adolescents
and adults divided disease progression into nine categories (Table 1. 3). Three ranges
of CD4+ T-lymphocyte counts and three clinical categories are defined in this
revision.
Table 1. 3. 1993 Revised Classification System for HIV infection and Expanded






CD4+ T-Lymphocyte Acute not (A) nor (C) indicator
Categories (primary) HIV or PGL conditions Conditions
1 : ^ 500 cells/pl Aj gj
2:200 - 499 cells/pl A2 g2 C2
3 : < 200 cells/ptl A3 B3 C3
"Shaded area: Patients with AIDS indicator conditions (category C) and CD4+ T-Iymphocyte counts
<200 cells/pl (category A3 and B3) were reportable as AIDS in the United States and territories
effective January 1, 1993.
a PGL, persistent generalized lymphadenopathy.
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CD4 positive T-Lvmphocyte Categories:
Three categories correspond to CD4+ T-lymphocyte counts per microliter of blood
and guide clinical and therapeutic actions in the management of HIV-infected
adolescents and adults. It also allows the using of the percentage of CD4 positive
T-cells
• Category 1: greater than or equal to 500 cells/pl (greater than or equal to 29%)
• Category 2: 200-499 cells/pl ( 14-28% )
• Category 3: less than 200 cells/pl (less than 14%)
Clinical Categories:
Category A - consists of one or more of the conditions listed below in an adolescent
or adult (greater than or equal to 13 years) with documented HIV infection.
Conditions listed in Categories B and C must not have occurred.
• Asymptomatic HIV infection
• Persistent generalized lymphadenopathy (PGL)
• Acute (primary) HIV infection with accompanying illness or history of acute
HIV infection
Category B - consists of symptomatic conditions in an HIV-infected adolescent or
adult that are not included among conditions listed in clinical category C and that
meet at least one of the following criteria: (i) the conditions are attributed to HIV
infection or are indicative of a defect in cell-mediated immunity, or (ii) the
conditions are considered by physicians to have a clinical course or to require
management that is complicated by HIV infection.
Category C - includes the clinical conditions listed in the AIDS surveillance case
definition. For classification purposes, once a category C condition has occurred,
the person will remain in category C.
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1.5.4 Modes of Transmission
A high virus load is observed in blood and body fluids during the phase of acute
HIV infection and during the symptomatic period. Any contact with contaminated or
infected blood, blood products and body fluids, especially in the acute and
symptomatic phases might be expected to present the greatest risk of HIV
transmission (reviewed in Levy, 1998). There are three principal modes - sexual,
parenteral, and perinatal, which permit the transmission of HIV-1 (Quinn, 1996).
Among these three modes, sexual transmission, which includes homosexual and
heterosexual transmission, is more important than other two. About 75% of all HIV
infections worldwide are acquired in this way (UNAIDS/WHO, 1998).
At the beginning of the HIV pandemic, homosexual transmission was the
primary mode in developed countries. However, epidemiological statistics show
recently that heterosexual transmission has gradually replaced homosexual as the
majority of HIV infections worldwide and was probably already in the majority in
some parts of the world. Because of this change, from typical male-to-male sexual
transmission to male-to-female transmission, female HIV infections are increasing
very quickly, from 25% in 1990 to 45% by 1997 (UNAIDS/WHO, 1998). And, these
female HIV infections create another transmitted problem - perinatal transmission
Perinatal transmission might occur by intrauterine infection of fetus, during
delivery, exposure of the newborn to maternal blood or postnatally via breast-feeding.
The transmission rate from mother to child is about 11 to 60%, which is regionally
dependent (Peckham and Gibb, 1995). Perinatal transmission is also influenced by a
variety of factors. Generally, the level of infectious virus in the mother at the time of
delivery is a critical factor (Scarlatti, 1996).
Parenteral transmission may occur during transfusion with infected blood
products, and exposure to infected blood through re-use of needles or syringes
among intravenous drug users, or in health care facilities where sterilization of
instruments is inadequate (Quinn, 1996). Transmission among IDUs is a serious
problem in developed countries, Southeast Asia, and some countries in Latin
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America. Recently, the use of sterile injecting equipment has been proved to reduce
the rates ofHIV-1 transmission among intravenous drug users. This gives some hope
for reducing the transmission through IDU (d'Cruz-Grote, 1996; Coates et al., 1996a;
Coates et al., 1996b).
Furthermore, to eliminate the transmission through blood transfusion and blood
products such as factor VIII and factor IX, a heating procedure is now applied before
or after lyophilisation. This has prevented transmission of HIV-1 to haemophiliacs
and other users of blood products (reviewed in Levy, 1998).
1.5.5 AIDS Epidemic
AIDS has now risen to the level of global pandemic proportions and the number
ofHIV infections is growing frighteningly fast, especially in Africa and South East
Asia. Statistics from the annual report of the Global HIV/AIDS Joint Programme
indicates that over 32.4 million adult and 1.2 million children are living with
HIV/AIDS at the end of 1999, and that about 16 million people around the world had
already died with AIDS (UNAIDS/WHO, 1999). An estimated 5.6 million adult and
570,000 children were newly infected in 1999.
1.5.5.1 Regional Epidemics
According to various factors, such as the time that the epidemic started, the
density and number of population, and cultural effects, the HIV epidemics in
different geographic regions possess their own dynamics. UNAIDS and WHO
reporters divide the global HIV infected populations into 8 groups: Market
Economies, Caribbean, Latin America, North Africa and Middle East, sub-Saharan
Africa, Eastern Europe and Central Asia, East Asia and Pacific, South and South-
East Asia. The regional statistics and features are summarized in (Table 1. 5).
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Table 1. 4. Global summary of the HIV/AIDS epidemic, December 1999
(Modified from the Report on the global HIV/AIDS epidemic update: December 1999)
Number of people living with HIV/AIDS Total 33.6 million
Adults 32.4 million
Women 14.8 million
Children < 15 yrs 1.2 million
People newly infected with HIV in 1998 Total
Adults
Women





AIDS death in 1998 Total
Adults
Women





Total number of AIDS deaths since the Total 16.3 million
beginning of the epidemic Adults 12.7 million
Women 6.2 million
Children < 15 yrs 3.6 million
Total number of AIDS orphans* since the beginning of the 8.2 million
epidemic
*Defined as children who lost their mother or both parents to AIDS when they were under the age of 15.
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Sub-Saharan Africa
The biggest HIV-infected population is located south of the Saharan desert.
Around 21 million adults and children were living with HIV/AIDS in this area by the
end of 1997, which is equal to two-thirds of the HIV global infected population. The
mode of transmission in this region is usually by heterosexual intercourse. In
comparison with other areas in which the major transmission route is by means of
male-with-male sexual activity or by blood contamination in intravenous drug
injection, 80% of the global HIV-positive female population live in sub-Saharan
Africa indicating their high risk of infection in this area. Moreover, African women
have more children on average than do other women worldwide. Infected mothers
may pass the virus on to their children during pregnancy or during childbirth or
through breast-feeding. Therefore, 87% of the global population of HIV-positive
children are also in Africa. Though zidovudine (AZT) and some of the newer
antiretroviral drugs can reduce this vertical transmission, the high price of these
drugs means that they are less available in these indigent countries so that the
prevalence of HIV in this area is accordingly likely to rise even faster than before
(reviewed in UNAIDS/WHI, 1998; UNAIDS/WHO, 1999).
Asia
The HIV pandemic started relatively later in Asia than in the rest of the world.
However, the prevalence increased sharply from the early '90s. By the end of 1997,
an estimated 6 million people were living with HIV/AIDS in South East Asia, and
1.3 million were newly infected during 1997 (UNAIDS/WHO, 1998).
HIV was first introduced among drug injectors around the "Golden Triangle"
area. Subsequently, female sex workers were found to have been infected following
commercial sex with these drug injectors. Although highly variable by region, HIV
then spread rapidly through commercial heterosexual intercourse, especially in
Vietnam, Thailand and India. For the more developed countries such as Japan, South
Korea, Taiwan, Singapore and Hong Kong, the HIV epidemics have not grown as
rapidly as in South East Asia, but it is believed that the number of HIV infected
subjects is increasing slowly and steadily (Kaldor et at., 1994).
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Established Market Economies. Latin America. Caribbean
HIV epidemics commenced at the beginning of the '80s in Latin America, the
Caribbean and in industrial countries, including Western Europe, North America,
Australia and New Zealand. Up to 1997, there were about 3 million infected
individuals living in these regions. The epidemic was initially distributed among
homosexual/bisexual men, and drug injectors. Infections among women increased
after 1995, due to heterosexual contact with partners who were in high-risk groups.
Fortunately, because of good education and the use of antiretroviral drugs, the
infection rate in these areas is falling slightly (d'Cruz-Grote, 1996; UNAIDS/WHO,
1998).
North Africa. Eastern Europe. Middle East
The epidemiological data is not well established in these regions. However it is
unlikely that these areas will escape the pandemic of HIV/AIDS. An estimated
360,000 people were infected with HIV by the end of 1997 in these regions, and the
rate of infection has increased sharply since 1995, especially among big cities.
The pattern of HIV/AIDS spread and pathogenicity is clearer in a variety of
fields than before. However, there are still around 16,000 new HIV infections
worldwide every day. To have a clear understanding ofHIV/AIDS pathogenicity is a
priority, so that the rate of spread of the infection is slowed down and so that more
practical treatment may be developed (UNAIDS/WHO, 1998).
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1.6 Cytopathic Properties of HIV-1
1.6.1 General Immune Response
During acute HIV infection, very high levels of infectious virus can be detected
in the peripheral blood. Large numbers of cells, mainly CD4+ cells, are infected at
this stage. Generally, within weeks after acute infection, viremia is markedly reduced,
the number ofCD4+ cells is decreased, and in contrast, the number of CD8+ cells is
increased in blood (Pantaleo et al., 1994; Feinberg, 1996; Levy, 1998).
A few months after primary virus infection, virus replication is observed to stay
at a low level, although still continuing. The disease at this stage is asymptomatic.
The CD4+ cell numbers at this stage usually rise to near-normal levels, followed by a
steadily decline until the symptomatic stage, and the number of CD8+ cells remains
slightly raised (Levy, 1998).
When the individual develops symptoms, the number ofCD4+ cells has usually
dropped below 200 cells/pl. The virus in the blood and lymphoid tissues rises again
to high levels, and the response of antiviral CD8+ cells is also decreased. Eventually
in the absence of treatment the whole immune response fails. Interestingly,
investigators have found that most T cells that die during HIV infection do not
appear to be infected with HIV (Thompson, 1993). This dramatic depletion ofCD4+
and CD8+ cells is thought to be responsible for the severe immunosuppresssion and
the development of opportunistic infections and neoplasms (Pantaleo et al., 1993b).
Although the exact mechanisms of the loss of immune cells remain unclear at present,
the possible factors involved might be direct cell destruction by HIV-1, or by viral
proteins, or as the result of secondary effects of the immune system disorder
(reviewed in Levy, 1998).
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1.6.2 Mechanisms of Cytotoxicity
1.6.2.1 Syncytium Formation
The first sign of HIV-1 infection of PBMCs in culture is the formation of
multinucleated cells, also known as syncytium formation. This kind of cell-to-cell
fusion results when uninfected CD4+ cells fuse with HIV-1-infected cells (Lifson,
1993; reviewed in Levy, 1998). It is temperature dependent, and does not require
cellular DNA, RNA or protein synthesis (Frey et al., 1995). Although the mechanism
of syncytium formation is still a mystery, the HIV-1 envelope glycoproteins and cell
surface CD4 molecule are believed to be involved in this process (Frey et al., 1995;
Dragic et al., 1995). It is known that HIV-1 gpl20 has a high affinity for the cell
surface CD4 molecule. During virion assembly, these envelope proteins are inserted
into the host cell membrane, which then have an opportunity to bind to the CD4
molecules on the surface of uninfected cells, hence leading to syncytium formation
(Dragic et al., 1995). These fused cells died in culture shortly after they were formed
(Lifson, 1993). This observation suggests that cell-to-cell fusion leads to viral
cytopathicity and that cell death may be one mechanism to account for the depletion
of CD4+ cells (Levy, 1998). Moreover, this cell-to-cell fusion provides an even more
effective route for HIV-1 diffusion. It has been estimated that cell-to-cell
transmission might be 100 times more efficient than infection by free virus particles
(Sato et al., 1992).
According to their ability to induce cell fusion in established T-cell lines,
isolates of HIV-1 have been divided into two major groups, syncytium-inducing (SI)
strains that replicate rapidly and cause syncytium formation, and non-syncitium-
inducing (NSI) strains that replicate slowly and do not form syncytia (Fenyo et al.,
1988). The cellular target of viruses with the SI phenotype is lymphocytes, and
isolates of SI strains are commonly associated with patients who have advanced
disease. The cellular target of NSI phenotypic viruses is preferentially monocyte -
derived macrophages, and NSI species are generally isolated from patients who are
asymptomatic (reviewed in Levy, 1998).
1.6.2.2 Toxicity ofHIV-1 and Viral Proteins
Excessive budding of virus particles from infected cells could also lead to cell
death. When high levels ofHIV-1 virions are produced, consistent budding from the
cell surface could weaken the integrity of the cell membrane resulting in membrane
discontinuities and pores. Voss et al. suggested that cells are unable to control the
influx of monocovalent and divalent cations while virus production is in progress
(Voss et al., 1996). The loss in control of the intracellular ionic strength would
change the electrical potential of the cell, leading to the impairment of cellular
functions and eventual lysis of the cells (Voss et al., 1996).
Accumulation of viral cDNA in the cytoplasm of infected cells in culture is also
likely to lead to cell death (Levy, 1998). In the study of Pang et al., neurologic
damage has been found to be associated with large amounts of unintegrated HIV-1
DNA in the brain cells of AIDS dementia patients (Pang et al., 1990). Tang et al.
further confirmed that the persistent production of unintegrated cDNA in HIV-1-
infected T cells appeared to block cell replication leading to cell death (Tang et al.,
1992). These observations suggest that high levels of intracellular DNA could be
toxic to the cell and could contribute to the initial cell killing observed in the early
stages of infection (Levy, 1998).
Other investigations have demonstrated that several HIV-1 viral proteins are
cytotoxic for CD4+ cells. For example, HIV-1 envelope gpl20 and gp41 proteins
were reported to be toxic to cells, most probably through altering the membrane
permeability (Miller et al., 1993). Also, gpl20 and gp41 presumably played
important roles in cell fusion that accompanied cell death. Lamb & Pinto showed that
the auxiliary viral proteins Vpu and Vpr could affect cell viability through their ion
channel activities (Lamb & Pinto, 1997). Moreover, the presence of excessive Nef
and Tat proteins in culture systems is found to cause the death of neuronal cells
(Jones et al., 1998).
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1.6.2.3 Effects of Host Immune Responses
The host immune system plays a vital role in arresting or eliminating the
infectious agent. Since in HIV infection, it is cells of the immune system which are
infected, the destruction of virus-infected cells either by cell-mediated cytotoxicity
or humoral immunity is thought to be the major mechanism leading to loss of
immune cells, and resulting in diseases.
Cell-Mediated Cvtotoxicitiv
The most appropriate immunologic defense against certain viral infections is
cell-mediated cytotoxicity, which is primarily generated by cytotoxic T lymphocytes
(CTLs). This response is major histocompatibility complex (MHC) class-I-restricted,
antigen specific, and requires cell-to-cell contact. CTLs, also known as CD8+
lymphocytes, function to recognise viral antigen processed endogenously in infected
cells and presented on their surface as a binary complex of a peptide fragment and the
human leukocyte antigen (HLA), an human equivalent of the MHC molecule.
Following recognition, CTLs are activated and finally kill the infected cells. Besides
this specific CTL activity, other studies demonstrated that cytotoxic CD8+ cells
recovered from the blood of HIV-infected individuals may mistakenly kill
uninfected CD4+ cells that were coated with soluble gpl20 produced elsewhere,
causing the lysis of these CD4+ cells (Wilson et al., 1997).
Although HIV-induced CTL activity is thought to be one of the mechanisms
leading the depletion of immune cells, other studies have proposed a protective role
for CTLs in HIV-1 infection (Kazi et al., 1996; Wolinsky et al., 1996). Wolinsky et
al. demonstrated that there was an inverse relationship between progression to
disease and the humoral or CTL immune response (Wolinsky et al., 1996). They
found an increased CTL activity in those individuals showing a slower rate of disease
progression, thus suggesting that CTL activity may protect the host (Wolinsky et al.,
1996). Moreover, the anti-HIV activity of these CD8+ lymphocytes might present
clinically as a diffuse infiltrative lymphocytosis syndrome (Kazi et al., 1996). This
syndrome is characterised by a CD8+ cell infiltration, which is primarily found in
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salivary glands, lungs, gastrointestinal tract, and kidney. Patients with this syndrome
usually have a delay in CD4+ T-cell loss and a longer survival period (Kazi et al.,
1996).
Other than CD8+ cells, some CD4+ cells are also capable of CTL activity
directed either at infected or uninfected CD4+ cells, or at cells expressing HIV
peptides in association with the MHC class II molecule (Miskovsky et al., 1994).
Similar to cytotoxic CD8+ cells, these CD4+ lymphocytes with CTL activity may
help to eliminate HIV-1 through cell-mediated responses, but could also have a
detrimental effect on uninfected cells (Miskovsky et al, 1994). The rapid lysis
observed between CD4+ cells and infected target cells in culture appears to be a
result of CTL activity (Miskovsky et al., 1994), and may be related to cell-to-cell
contact and syncytium formation (Heinkelein et al., 1995). However, no HLA-
class-II restricted CTLs (CD4) has been detected in fresh tissues of infected patients,
and this CD4 CTL activity has been detected only following repeated stimulation in
vitro. Thus, their role in the HIV-1 immune response requires further investigation.
Humoral Immune Rresponse
Antibody-dependent cellular cytotoxicity (ADCC) responses, which are
mediated by the antibodies to HIV-1 envelope proteins, may also contribute to the
depletion of immune cells (Skowron et al., 1997). Generally, the antibody-antigen-
coated cells are recognised by NK cells or by monocytes or macrophages bearing Fc
receptors, and then killed by a cytolytic mechanism (reviewed in Levy, 1998).
However Weinhold et al. demonstrated that uninfected cells might be destroyed by
non-specific ADCC responses in culture (Weinhold et al., 1989). The gpl20 is
presumed to be released from the budding virions or following the lysis of infected
cells. This freely circulating gpl20 could bind to the CD4 receptor on the surface of
uninfected CD4+ cells, result in an appearance of infection and therefore becoming a
target for lysis by ADCC responses (Tyler et al., 1989; Weinhold et al., 1989).
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Effects of Complement
Complement can play a role in the antiviral response by enhancing
complement-mediated lysis of virions or by destroying virus and virus-infected cells
through binding and activation by the classical or alternative pathway (Susal et al.,
1994). Moreover, complement could indirectly lyse the CD4+ cells carrying
envelope proteins, causing the loss of CD4+ cells (Marschang et al., 1997).
Apoptosis
Apoptosis, a kind of programmed cell death is a morphologically distinct form
of cell loss and occurs through the activation of a complex cell-intrinsic suicide
program. It plays a major role during development, homeostasis, and in many
diseases including cancer, AIDS, and neurodegenerative disorders (Steller, 1995)
and has been proposed as one of the mechanisms involved in CD4+ T cell loss during
HIV-1 infection (Pantaleo & Fauci, 1995; Tian et al., 1996). Apoptosis is usually
associated with the activation of a Ca~~-dependent endogenous endonuclease that
degrades the chromosomal DNA into very small nucleotide units that are then
membrane-bound, followed by rapid phagocytosis and digestion by macrophages or
neighboring cells (Steller, 1995; Sasaki et al., 1996).
There is no clear understanding as yet on how apoptosis is linked to HIV
pathogenesis. Some investigators have suggested HIV-1 viral proteins and
superantigens might contributed to the induction of apoptosis (Pantaleo & Fauci,
1995; Tian et al., 1996). Evidence has emerged that cross-linking of HIV gpl20
bound to CD4+ lymphocytes followed by T-cell activation has caused apoptosis of
these cells (Pantaleo & Fauci, 1995). Also, HIV-1 Vpr could cause apoptosis of
CD4+ cells by blocking virus replication at the G2 stage of the cell cycle
(Kolesnitchenko et al., 1995). Moreover, HIV-1 Tat protein has been shown to
induce apoptosis in normal, uninfected CD4+ cells through the activation of cyclin-
dependent kinases (Li et al., 1995).
Superantigens can play a role in up-regulating cell replication and inducing cell
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activation associated with apoptosis (reviewed in Levy, 1998). In general, antigens
must bind in the groove of the MHC class II molecule interacting with both the
variable elements of the a and (3 subunits (Va and Vp) of the T cell receptor (TCR).
Superantigens differ from typical antigens in that they are less specific and are
required only to bind to the Vpsubunit of the TCR. However they can stimulate and
activate a much larger proportion of T cells than conventional antigens. These
activated T cells may be deleted, rendered anergic or made more susceptible to viral
infection (Pantaleo et al., 1993b). It has been postulated that superantigens are
implicated in HIV-mediated immunosuppression. The actual mechanisms and
possible effects of superantigens involved in HIV-1 pathogenesis are still unknown.
Recently, a study found that a portion of HIV-1 gpl20 or immune complexes with
this glycoprotein could serve as superantigen inducing some of the B-cell responses
associated with HIV infection (Karray & Zouali, 1997). It is likely that superantigens
are not directly responsible for the loss of immune cells, but may be indirectly
involved by activation of large number of T cells, resulting in enhanced HIV-1
infection, replication and subsequent cytopathogenicity (Cossarizza et al., 1995).
1.6.3 General Pathology of Organ Infections
It is known that severe depletion of CD4 lymphocytes is followed by a severe
deficit in immunological responses. At the late stages of HIV infection, patients
become extremely sensitive to infectious agents and may also develop certain
neoplasms. Most of the infections associated with AIDS are caused by opportunistic
organisms including viruses, bacteria, fungi and protozoa. Evidence from clinical
observation confirm that HIV-1 is a systemic disease affecting multiple organs or
systems of the body. Neoplasms or opportunistic infections in organs or systems are
responsible for the death of untreated HIV-infected individuals (Feinberg, 1996).
The following sections summarize the general pathological findings and the
possible mechanisms of systemic disorders in lymphoid organs, central nervous
system, respiratory system, and gastrointestinal system. These four systems are the
major targets of HIV-1 infection.
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1.6.3.1 Lymphoid Organs
Lymphoid organs are the primary anatomic sites for HIV replication and
propagation following acute HIV-1 infection (Pantaleo et al., 1993c; Pantaleo et ah,
1994). At the early stage of HIV-1 infection, some patients are unaware of any
constitutional changes and show no symptoms, others might develop flu-like acute
illnesses and probably a syndrome of persistent generalized lymphadenopathy (PGL)
(Spira et al., 1989). PGL is an early and relatively mild manifestation of HIV-1
infection and characterised by lymph nodes of one-centimeter or more in diameter in
two or more non-contiguous extrainguinal sites that cannot be explained by any other
infection or condition. The nodes are symmetrical, mobile and non-tender and
generally occur in cervical and axillary sites (Pantaleo et al., 1994).
Initially, these reactive lymph nodes show hyperplasia and high levels of virus
replication (Pantaleo et al., 1994). These nodes enlarge, with particular increase in
the secondary germinal centers (or follicles) filled with activated polyconal B cells
(Burke et al., 1994). Moreover, the paracortical areas increase in size with the
expanding number of CD8+ lymphocytes that might reflect the enhanced production
of (3-chemokines by resident macrophages (Tedla et al., 1996). Also, many infected
CD4+ cells are detected in the follicular mantle and paracortical regions in this acute
period (Tedla et al., 1996).
Subsequently in the asymptomatic period, large numbers of virus-infected
CD4+ cells are observed to reside in lymph nodes, particularly in the mantle regions.
Interestingly, most of these CD4+ cells are infected latently (Embretson et al., 1993b;
Rosok et al., 1997). Moreover, histologic and electron microscopic examinations
have indicated that viral particles can be visualized in the villous processes of
follicular dendritic cells (FDC) at this stage (Pantaleo et al., 1993a). FDCs are
localised in the germinal centres and thought to be the largest reservoir of virus in
lymphoid tissue during this transient period (Pantaleo et al., 1993c; Haase et al.,
1996).
With advancement to symptomatic disease, the lymph nodes atrophy and
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gradually lose their normal architecture owing to the slow but persistent destruction
of CD4+ cells, deterioration of the stromal elements and release of virus from
intercellular trappings in the FDCs or from infected lymphoid cells producing virus.
As the FDC network undergoes as destruction, immune function falters, with
consequent return to high levels of virus replication in peripheral blood and
lymphoid tissues (Pantaleo et al., 1994). In the end stages of disease or AIDS, the
viral load in lymph nodes is decreased and the viral expression in the peripheral
blood is increased to a high level. The findings suggest a breakdown in the FDC
network and release of virus into the blood. Eventually, Lymph nodes show typical
atrophy, with marked depletion of CD4+ cells and severe destruction of FDCs
(Pantaleo et al., 1994). The loss of these cells may be due to the toxicity of virus and
its proteins, the production of cytokines by cells in responding to increase virus
replication, or cytotoxic activity of active CTLs (Nuovo et al., 1994; Pantaleo et al.,
1995). Finally, these immune organs are destroyed and lose their function.
Through the AIDS stage of HIV-1 infection, neoplasms and opportunistic
infections may occur in lymphoid organs. Neoplasms such as malignant lymphomas
and Kaposi's sarcoma (KS) arising in AIDS resemble those complicating non-AIDS
immunosuppressive disorders in frequency and behaviour and they appear to occur
in unusual sites (Schulz et al., 1996; Goedert et al., 1998). Malignant lymphomas
occur in patients with AIDS as they do in the general population, but with a
significantly increased incidence (Knowles et al., 1988). High-grade non-Hodgkin's
lymphoma (NHL) is a neoplasm frequently associated with AIDS, and is most often
of B-cell type (Knowles et al., 1988). Up to 90% ofAIDS associated NHL occurs in
atypical extranodal locations including the lymphoid tissues associated with bone
marrow, gastointestinal tract and liver. Kaposi's sarcoma is a vascular tumor, which
is the most common neoplasm in patients with AIDS (Beral et al., 1991). Originally,
KS was considered a rare, slowly progressive tumour of elderly Mediterranean men.
In the early 1980s, KS was observed in AIDS patients and more commonly
associated with HIV-1 infection in homosexual or bisexual men than in other risk
groups (Beral et al., 1992). This variant, unlike the classic KS, is aggressive and
progresses rapidly. This AIDS-associated KS disseminates widely and includes the
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viscera and lymph nodes as well as skin (Beral et al., 1992), but does not generally
involve the central nervous system.
Lymph nodes are commonly sites for opportunistic infections in AIDS, usually
resulting in lymphadenopathy. Generally, the infections are multiple and are
sometimes found in association with neoplasms. Atypical mycobacterial infection
including those due to Mycobacteria avium-intracellulare (MAI) and other closely
related organisms, are frequently seen in AIDS patients (Schulz et al., 1996). With
MAI, the normal cortex and medulla structure of lymph nodes is almost completely
replaced by a diffuse and heavy infiltrate of macrophages containing numerous
bacteria (Levy, 1998).
The spleen is another lymphoid organ, and the HIV related changes reflect the
pathology elsewhere in the lymphoid system. With HIV-1 infection, it shows
profound atrophy of T- and B-cell zones, with total loss of germinal centres.
Lymphocyte depletion is the major abnormality seen in spleen with HIV-1-infected
individuals (Pantaleo et al., 1994; Levy, 1998).
1.6.3.2 Central Nervous System
Outwith the immune system, the other major target of HIV-1 is the CNS.
Approximately 80% of AIDS patients experience neurological or psychiatric
symptoms. The symptoms of HIV-1 CNS involvement may appear gradually and
become more severe with disease progression. Clinical manifestations of CNS
involvement in HIV-1 infection include headaches, confusion, memory loss,
impairment of movement, emotional/mood swing, and behavioural difficulties
eventually progressing to dementia in approximately 10 % of patients with AIDS
(Gray et al., 1996; Price, 1996; Bell, 1998). These symptoms together with a
progressive cognitive decline have collectively been termed AIDS related dementia
(ARD) and classified as an AIDS defining illness (Price et al., 1996). Common
problems occurring in the CNS include HIV-1 specific neuropathology,
opportunistic infections, and neoplasms (Gray et al., 1996; Price et al., 1996; Bell,
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1998). Approximately 10 % of untreated AIDS patient develop dementia.
HIV-encephalitis (HIVE) is a direct effect of HIV-1 infection of the CNS and
occurs in AIDS patients. Many patients with HIVE often suffer physiological and
psychological problems, and most will develop dementia. The definitive
characteristics of HIVE are the presence of multi-nucleated giant cells (MGCs)
and/or immunocytochemically detected HIV antigens in brain parenchymal cells.
MGCs are generally found in the central white matter and deep grey matter, and are
thought to be formed by fusing HIV-1 infected and possibly uninfected cells. The
presence of HIV-1 antigens or nucleic acid must be demonstrate by
immunohistochemistry staining or nucleic-acid-based detecting techniques before
HIV-1 encephalitis can be definitively diagnosed (reviewed in Bell, 1998).
Microglial nodules are focally concentrated collections of microglial cells,
macrophages and lymphocytes and they may be observed in both grey and white
matter (reivewed in Bell, 1998). MGCs may be absent in HIVE cases.
Another HIV-related abnormality in the CNS is HIV leucoencephalopathy
(HIVL), which is defined as white matter damage associated with diffuse myelin loss
and reactive astrocytosis, but with little or no inflammatory infiltrate. The diagnosis
between HIVE and HIVL is not entirely straight forward because they both present
MGCs and immunocytochemical evidence of the presence of HIV antigens
(reviewed in Bell, 1998). The histological findings should be carefully reviewed
since different pathogenic mechanisms may be involved.
Opportunistic infections occur frequently in immuno-compromised hosts when
their immune systems are failing. Most of the pathogens responsible for the
opportunistic infections are ubiquitous organisms to which commonly exposure
occurs. Cytomegalovirus (CMV) and Toxoplasma gondii are the pathogens that are
found commonly in the CNS in AIDS patients. Sometimes, progressive multifocal
leukoencephalopathy (PML) and fungal infectious also occur. They may affect the
CNS in isolation or associated with HIVE (reviewed in Bell, 1998).
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The most commonly found neoplasms in CNS ofAIDS patients are lymphomas,
especially the high grade B-cell, non-Hogdkin's lymphomas (Bell, 1998). Primary
CNS lymphoma is more common than secondary, and is most frequently found in the
periventricular deep grey matter, brain stem or cerebellum. Generally, neoplasms
occur during the late stages of illness and accompany other late effects of HIV-1
infection.
Other CNS pathology, including gliosis, astrocytosis, inflammatory infiltrates
and vascular abnormalities, is frequently present and may be accompanied by hepatic
encephalopathy in patients who co-infected with hepatitis B or C (Price et al., 1996;
Bell, 1998).
Although there is frequent involvement of the CNS in HIV-1 infection, the
mode and timing of viral entry and the neuropathogenic mechanisms of HIV-1 are
incompletely understood at present. The two most widely accepted theories are that
viral entry occurs early in infection with the virus remaining latent during pre-AIDS,
then becoming productive when systemic immunosuppression is evident (Saito et al.,
1994; Gray et al., 1996), or that major viral entry to the brain is a late event in HIV-
1 infection (Bell et al., 1993; Donaldson et al., 1994a). Using PCR analysis, some
studies have detected HIV-1 provirus DNA in the brains of some asymptomatic
HIV-positive patients (Sinclair et al., 1992; Sinclair et al., 1994). This gave support
to the idea that viral entry might occur early either during the acute seroconversion
reaction or at the time of subclinical infection (Nottet and Gendelman, 1995).
Several mechanisms have been proposed for the entry of HIV-1 to brain tissue.
The first is the "Trojan horse" hypothesis, which suggested that HIV-1 infected
monocytes act as a "Trojan horse" to carry virus across the tight interendothelial
junctions of the parenchyma blood brain barrier (Peluso et al., 1985). Later, Moses et
al. demonstrated that brain microvascular endothelial cells (BMVECs) are capable
of becoming infected with lymphotropic HIV-1 (Moses et al., 1993). This result
suggested that direct infection of the BMVECs might also be a route for the entry of
HIV-1. Recently, Falangola et al. and Bagasra et al. reported productive infection of
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the choroid plexus using immunohistochemistry and the in situ PCR technique
(Falangola et al., 1995; Bagasra et ah, 1996). The choroid plexus capillaries have
gap junctions and lie outside the brain blood barrier (BBB). It has been implicated as
the initial site of entry of infective agents due to its open capillary architecture
(Falangola et al., 1995). Many HIV-1 positive cells were identified as monocytes and
macrophages in the choroid plexus stroma (Falangola et al., 1995). It has been
hypothesised that HIV-1 infected cells in the choroid plexus could move from the
blood to the choroid plexus and into circulating CSF and possibly access brain
parenchyma, causing infection (Falangola et al., 1995; Bagasra et al., 1996). More
recently, Nottet et al. found that HIV-infected monocytes might induce the
expression of adhesion molecules on the BMVECs that allow binding and infiltration
of HIV-infected monocytes into brain (Nottet et al., 1995). Their investigation
demonstrated that active HIV-infected monocytes express the cytokines, TNF-a and
IL-1 (3, in a culture system. These cytokines in vivo could induce microvascular
endothelial expression of vascular cell adhesion molecule 1 (VCAM-1) and E-
selectin, which mediate transendothelial migration of HIV-infected cells, causing
infection of brain microglial cells (reivewed in Nottet & Gendelman, 1995).
Many cells have been proposed to harbour HIV-1 in CNS. Most of them belong
to the monocyte/macrophage lineage, such as brain macrophages, microglia and
MGCs. However infection of cells of neuroectodermal origin, including neurons,
astrocytes and oligodendrocytes is rarely reported (reviewed in Bell. 1998). although
astrocytes may support a form of non-productive HIV infection. Therefore HIV-1 is
likely to exert its damaging effect indirectly in tissue of the CNS (Epstein &
Gendleman, 1993). The most favoured theory is that infected cells release toxic
cellular factors leading to tissue damage and/or apoptosis. It is believed that after
infection with HIV-1 or exposure to viral envelope proteins, the microglial and brain
macrophages could be induced to produce certain cytokines, such as TNF-a, IL-1
and IL-6, which are toxic to the brain tissue (reviewed in Levy, 1998). IL-1 and IL-
6 have been reported to be cytotoxic, induce proliferation of astrocytes and cause
fever and inflammation (reviewed in Levy, 1998). TNF-a has also been reported to
contribute to neural damage by calcium influx (Soliven & Albert, 1992), stimulation
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of astrocytosis, induction of myelin damage and destruction of oligodendrocytes
(Nottet & Gendelman, 1995). Moreover, the interaction between envelope protein
gpl20 and glutamate via the N-methyl-D-aspartate (NMDA) receptor may mediate
excessive calcium influx into the neurons with subsequent neuron injury (Pittaluga et
al., 1996). The neuropathogenesis is complex, with the effects of cytokines, as well
as cytotoxic HIV-1 viral proteins thought to be responsible for neural dysfunction.
1.6.3.3 Respiratory System
Pulmonary complications appear in the late stage of HIV-1 infection. Over 60
percent of AIDS patients develop pneumonia. Generally, the respiratory failure is a
major cause of death of AIDS patients, manifested by severe refractory hypoxia
(Miller, 1996; Zuckerman et al., 1996).
Most of the cases with pneumonia are infected withPneumocystis carinii, which
presents as Pneumocystis carinii pneumonia (PCP), an AIDS defining illness
(Marchevsky et al., 1985; Huang & Stansell, 1996; Miller, 1996). Other respiratory
disorders including infections due to cytomegalovirus (CMV), mycobacterium, both
atypical and M. tuberculosis, pneumococci, cryptococci and other fungi may also be
present in AIDS patients. The biggest problem in treating these infections is that in
5-10 % of cases, pneumonia is mixed with coexisting infections by two or more of
these organisms. This often leads to treatment failures when only one of the
infectious agents has been identified. Other than infections, neoplasms, such as KS,
could also occur in respiratory system (reviewed in Miller, 1996).
Pneumocystis carinii is a unicellular, opportunistic organism responsible for
atypical pneumonia. PCP may occur in conditions other than AIDS in patients
suffering from malignant lymphomas and leukaemias as well as those on
imunosuppressive therapy or on long-term steroid or cytotoxic therapy. With the
appearance of AIDS the incidence of PCP increased dramatically (Masur et al.,
1989). Within the lung the pneumocysts are found primarily in the alveoli.
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Replicating pneumocysts appear to increase the permeability of the alveolar capillary
membrane leading to intra-alveolar oedema (Marchevsky et al., 1985; Harcourt-
Webster, 1993).
CMV peumonitis is the second most common respiratory infection in AIDS
(Harcourt-Webster, 1993; Miller, 1996). The characteristic feature ofCMV infection
is CMV inclusion bodies within the nucleus of the infected cells. The increased
protein synthesis leads to enlargement of the cell and the formation of viral particles.
Generally, CMV inclusion bodies may be observed in both alveolar and endothelial
cells in the lung. It is often a bystander infection rather than a tissure-damaging
pathogen in the respiratory system in AIDS patients (Millar, 1996).
MAI are the most common organisms in respiratory system in AIDS. Within
AIDS, it occurs more frequently in extra-pulmonary sites (Maguire et al., 1987).
HIV-1 can be isolated from the respiratory system even from occasional
asymptomatic individuals however none of the abnormalities occurring in lung are
directly linked to the infection of HIV-1 (Clarke et al., 1995). Studies have
demonstrated that the risk of developing respiratory disorders in HIV-1 infected
patients is much higher than in the general population (Masur et al., 1989;
Harcourt-Webster, 1993). Whether HIV-1 is involved in the pathogenesis of
respiratory system disorders, or these respiratory diseases happen only because of the
suppression of the host immune system requires further investigation.
1.6.3.4 Gastrointestinal System
The intestinal tract is both a digestive and an immunological organ. Bowel
symptoms have been reported in association with acute HIV-1 infection (Sharpstone
& Gazzard, 1996). The subsequent chronic malabsorption, malnutrition, and
diarrhoea occurring several years later have generally been attributed to
opportunistic infections in the bowel as a result of immune deficiency (DuPont &
Marshall, 1995; Sharpstone & Gazzard. 1996).
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Malnutrition is considered to be present in a patient with a loss of more than
10% of normal body weight and with greater protein loss than is observed in other
cases of starvation. Malnutrition in HIV-1 infection can result from anorexia or
nutrient malabsorption secondary to intestinal damage and inflammation (DuPont &
Marshall, 1995; Sharpstone & Gazzard, 1996).
Chronic diarrhoea and weight loss are the most common complications in the
gastrointestinal (GI) system associated with HIV-1 infection and AIDS. Weight loss
may occur with diarrhoea or in association with other HIV-associated infections and
disorders (DuPont & Marshall, 1995), such as CMV infection, Cryptosporidiosis,
MAI, and microsporidia infection. Usually, the gastrointestinal tract shows only
subtle histologic changes during HIV-1 infection unless opportunistic infections are
present (Harcourt-Webster, 1993).
CMV infection is commonly seen in AIDS patients with symptoms associated
with malabsorption or protein-losing enteropathy in GI system. Large number of
inclusion bodies may be found throughout the colon, and particular in the ascending
colon. Generally, CMV infection of the intestine occurs with minimal non-specific
chronic inflammation in the lamina propria; however when the infection becomes
severe and highly active, widespread inflammation accompanied by necrosis,
haemorrhage and bowel rupture may be seen (reviewed in Harcourt-Webster, 1993).
Infection with Cryptosporidiosis is rare in the immunocompetent, and manifests
as a self-limiting, non-toxic, mild watery diarrhoea, also known as "traveller's
diarrhoea" (DuPont & Marshall, 1995). However the incidence of this kind of
infection is greatly increased in HIV-positive patients. Cryptosporidiosis is a
coccidian protozoon prevalent in bovine animals but can be transmitted to human
through contaminated food or water. With immunosuppression, infection with
Cryptosporidiosis in the intestine may cause a diarrhoea that is severe, cholera-like,
non-bloody and very watery and accompanied by anorexia, vomiting, abdominal
pain and cramps with fever (DuPont & Marshall, 1995).
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Other opportunistic infections including MAI and microsporidia may occur
infrequently. KS and malignant lymphoma, especially non-Hodgkin's lymphoma,
may also involve the gastrointestinal tract. The small intestine is thought to be the
most frequent of all the extranodal sites for lymphoma (Harcourt-Webster, 1993).
It is known that the major protection in the intestinal system is generated by the
mucosal immune system (MIS) (DuPont & Marshall, 1995). The MIS consists of
focal aggregates of cells and tissue from the epithelium to the lamina propria and
includes T cells, B cells, mast cells, and macrophages. Among these cells, CD4+ T
cells and macrophages are susceptible to infection by HIV-1. Although no direct
correlation was found between HIV-1 infection and gastrointestinal symptoms,
studies investigating the cause of gastrointestinal disturbances have demonstrated
the presence ofHIV-1 in the bowel mucosa of HIV-1-positive patients with intestinal
disorders, including asymptomatic individuals (Kotler et al., 1991; Levy, 1998).
Moreover, in some cases, HIV-1 was the only pathogen identified in bowel
(reviewed in Levy, 1998). These unique bowel-derived HIV-1 strains, which are
often macrophage-tropic, can be distinguished from strains recovered from the blood
of the same individual (Barnett et al., 1991). Therefore, in these symptomatic
individuals in whom no other bowel pathogen was detected, direct infection of the
bowel mucosa by HIV-1 should be considered as pathogenic (Kotler et al., 1991).
Accordingly, the extensive diarrhoea and malabsorption observed in HIV-1-positive
individuals could be the effect of toxicity of virus itself or viral proteins that disturb
the intestinal cell membrane integrity, perhaps in the handling of sodium ions and
water (Levy, 1998).
Most researchers believe that AIDS associated gastrointestinal symptoms might
be an indirect effect of HIV-1 infection. There exist M-cells in the epithelium of
intestine. These special intestinal epithelial cells function to bind intraluminal
antigens, pass them to the macrophages of MIS and finally transport them to the
enteric lymphoid tissue (DuPont & Marshall, 1995). Since HIV-1 has been detected
in mononuclear leukocytes from the intestinal lamina propria of AIDS patients
(Barnett et al., 1991), it was hypothesized that HIV-1 may enter the MIS via M cells
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to infect macrophages in the lamina propria and transinfect the lymphocytes with
subsequent production of virus-specific IgA, the principal protective intestinal
immunoglobulin (DuPont & Marshall, 1995). These infected macrophages and T
cells could induce the production of cytokines that might be toxic for the bowel
mucosa (Levy, 1998).
With the progression of infection, an increased number ofCTLs has been found
in the small intestine of HIV-infected patients (Snijders et al., 1996). However the
number of CD4+ T cells and antigen-presenting cells (APC) in the bowel decline
with advancing infection (DuPont & Marshall, 1995; Veazey et al., 1998). Whether
the depletion of these cells is a cytotoxic effect of CTLs or other factors is not
conclusively decided yet. The dysfunction and destruction of APCs (e.g., activated
DC) and CD4+ T cells is believed to contribute to the dysfunction ofMIS (DuPont &
Marshall, 1995). As the disease advances, the number of CD8+ T cells also declines
as they do in the peripheral blood, and the MIS finally collapses. Following systemic
dysfunction of the immune system, the individual becomes more susceptible to
intracellular pathogens (DuPont & Marshall, 1995).
1.7 Prevention and Therapeutics
The ways to prevent further HIV spread, and to treat those who have been
infected, and thus to keep the HIV pandemic under control, include principally the
modification of human behaviour, the discovery and development of antiviral
therapies, and particularly the development of effective vaccines.
1.7.1 Modification of Human Behaviour
To alter human behaviour through education is a basic and effective method for
preventing further spread of the HIV epidemic. Programmes for preventing the
spread of HIV, led by the World Health Organisation (WHO), are divided into
mass-awareness campaigns for the general public and interventions combined with
supportive services targeted at specific groups (d'Cruz-Grote, 1996). Knowledge of
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HIV and how to avoid it are the most important items of information in which people
need to be educated. Also, correct and safe behaviours, such as a reduction in the
number of sexual partners, and the use of condoms, need to be established to protect
both at risk individuals and their partners. For high risk groups, such as homosexual
or bisexual men and drug injectors, some successes have been achieved through
providing cheap condoms, clean injection equipment, HIV testing and treatment;
creating the environment where safer sexual or drug-taking behaviour can be
discussed and acted upon; and arranging medical, social and mental health services
for HIV-infected people (Coates et al., 1996b; UNAIDS/WHO, 1998).
Although there is little firm evidence of impact on behavioural change, and the
strategies are not efficiently practiced, it is clear that prevention does work (d'Cruz-
Grote, 1996; UNAIDS/WHO, 1998). In some developing countries, behavioural
surveys have shown that the use of condoms is becoming prevalent, and that more
people are aware of the importance of having safer sex (UNAIDS/WHO, 1998). A
decrease in HIV prevalence is predicted as a result, but will take time.
1.7.2 Antiretroviral Treatment for HIV Infection
For those people who are now living with HIV/AIDS worldwide, altering their
risk behaviour or developing a vaccine is not a practical concept for them, and the
only way forward is the discovery and development of effective treatment to delay
the onset of disease or to prolong patients' survival time. The research efforts of
scientists leading to soundly based knowledge of the molecular mechanisms in the
HIV life cycle have provided an essential and useful basis for the design of antiviral
drugs. Several steps in the replication of HIV have received close attention in this
context (Table 1. 6). For the present, only the inhibitors of reverse transcriptase and
ofviral protein processing have been successfully applied in clinical therapy (Lipsky,
1996).
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Table 1. 6. Opportunities for antiviral action. (From: Lipsky, 1996)
1. Attachment of virus to the cell
2. Inhibition of reverse transcriptase, which creates DNA from viral RNA
3. Inhibition of RNase H, which degrades viral RNA after viral DNA has been
synthesised
4. Inhibition of viral integrase, which is used to integrate viral DNA into the cell's
DNA
5. Inhibition of expression of the HIV gene once it is integrated into the host-cell
DNA, including the processes of transcription ofmore viral RNA and the
translation of viral proteins
6. Inhibition of processing and post-translational modification of protein products
of the virus
1.7.2.1 Inhibition of Reverse Transcriptase
The first drug to be used in HIV infection was zidovudine (AZT), an inhibitor of
RT. It is a nucleoside analogue and works as a DNA chain terminator. The
replication of virus can be prevented since DNA synthesis is terminated, therefore
causing viral stasis (Levy, 1998).
Initially, AZT was shown to improve survival in patients with AIDS and
AIDS-related illnesses when large doses were taken (1500mg/day) without a break
for up to 6 months, but this regime was usually associated with severe side effects,
especially toxicity to the bone marrow (reviewed in Levy, 1998). Later, the
Concorde trial, a three year clinical trial which involved several cohorts in Europe,
showed that AZT was not effective in delaying the time of onset for AIDS or in
increasing survival significantly (Lipsky, 1996). However, AZT is good in reducing
maternal-infant transmission (Lipsky, 1996), and it shows great value in clinical
combination with other drugs (reviewed in Montaner et al, 1998a).
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With time, four more nucleoside analogues, didanosine (ddl), zalcitabine (ddC),
stavudine (d4T) and lamivudine (3TC), and three non-nucleoside RT inhibitors,
nevirapine, delavirdine, efavirenz, were introduced into clinical treatment for AIDS
and HIV infection. These drugs appear to be more effective and less toxic to bone
marrow than AZT. However, they soon lead to the emergence of resistant viral
strains and are also associated with unpleasant side effects such as neuropathy and
pancreatitis (reviewed in Levy, 1998).
1.7.2.2 Inhibition of HIV Protease
HIV protease functions to cleave viral precursor proteins to yield mature protein
products. This procedure is important for viral replication and any failure will lead to
the production of non-infectious virions (Refer to section 1.2.3.2). Thus, the
inhibition ofHIV protease provides another therapeutic category for AIDS and HIV
infection. At present, there are four protease inhibitors used clinically, including
saquinavir, ritonavir, indinavir, and nelfinavir.
When used alone or in combination with RT inhibitors, these drugs markedly
reduce the viral load and increased the number of CD4 cells, and also show
improvement in survival (reviewed in Deeks et al., 1997). Nevertheless, protease
inhibitors are found to cause clinical side effects. Most often, HIV patients who
received protease inhibitors develop hyperglycemia and diabetes. Also, these drugs
are able to interact with various analgesics, antibiotics, anticoagulants and other
antiretroviral drugs. Drug-resistant strains to these protease inhibitors usually
emerge very quickly, and the use of protease inhibitors requires to be carefully
regulated in an exacting therapeutic regime (Deeks et al., 1997; Levy, 1998 and in).
1.7.2.3 Highly Active Antiretrovial Therapy
Because of the limitations of individual drugs, a new therapeutic strategy,
highly active antiretroviral therapy (HAART) commenced in the summer of 1996.
This new strategy utilised two or three drugs in combination, and aimed to decrease
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the plasma viral load below the lower limit of detection.
Initially, two-drug therapy was used. Usually, two RT inhibitors were used
together to increase the efficiency of the treatment. This dual-nucleoside therapy was
abandoned because resistant strains quickly emerged and the persistent control of
virus replication was not achieved (reviewed in Levy, 1998).
The more recent regimen is triple-drug therapy, usually involving two
nucleoside analogues plus a protease inhibitor, or plus a non-nucleoside RT inhibitor.
This strategy has been confirmed as effective in decreasing AIDS-related morbidity
and mortality, and in achieving sustained and progressive immunological
reconstitution in both early and late HIV-1 infection into the second year ofHAART
(Li et al., 1998; reviewed in Montaner et al., 1998a;). Also, the risk of developing
resistance is reduced, because of the marked reduction of viral evolution during
treatment with the current therapeutic strategy.
Although triple-drug therapy dramatically decreased the plasma viral load and
effectively suppressed viral replication, the plasma concentration of HIV-1 proviral
DNA was found to decrease only slowly. This could provide a basis for continued
virus replication, and the rapid rebound of viral replication occurring after cessation
of drug therapy (Montaner et al., 1998b).
The safety of HAART is another cause for concern. More and more articles
report the potential long-term adverse effects of protease inhibitors, including
hypertriglyceridaemia, hypercholesterolaemia, hyperglycaemia, lipodystrophy (Carr
et al., 1998) and vascular complications (Henry et al., 1998). In addition, HAART is
expensive, and its cost is far out of reach for most HIV-infected people, especially
for people living in less developed countries, which can scarcely afford to provide
AZT. The fight against HIV still presents many challenges.
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1.7.3 HIV Vaccines
Apart from altering human behaviour, the development of HIV-1 vaccines is
thought to be the main hope of preventing further HIV-1 infection.
At the beginning of the HIV epidemic, much effort was devoted to searching for
an effective vaccine. However, little success was achieved because of poor
understanding of the interaction between protective immunity and HIV infection,
and of the amazing mutational ability ofHIV (Haynes, 1996).
Two recent studies show that neutralizing antibody against the HIV-1 envelope
glycoprotein can completely block HIV-1/SIV chimeric virus infections ofmacaque
monkeys (Igarashi et al., 1999; Shibata et al., 1999). In these two studies, macaques
were passively immunised with purified immunoglobulin (IgG) from chimpanzees
infected with several different HIV-1 isolates, then challenged intravenously with a
chimeric simian-human immunodeficiency virus (SHIV) bearing an envelope
glycoprotein derived from HIV-1DH12. Complete protection was achieved, but only if
a sufficient concentration of antibodies was infused. The ability of neutralising
antibodies to prevent HIV-1 infection is becoming clear. Therefore, to induce an
effective antibody response could be an important goal of those developing HIV-1
vaccines (Moore & Burton, 1999).
Although a wide variety of different vaccine strategies have been evaluated in
the animal model of macaques, including the use of recombinant poxviruses, DNA
vaccines, and whole inactivated virus, successes have not been claimed. Live
attenuated SIV vaccines have proven to be the most effective approach to induce
protection against challenge with pathogenic SIV, but the safety of this approach is
in question (Johnson, 1999). Baba and colleagues started their live attenuated
triple-deleted SIV vaccine studies in neonatal and adult macaques in 1995, and it
proved to offer good protection at the beginning (Babe et al., 1995). Unfortunately,
their macaques developed AIDS three years after immunization with defective virus
(Baba et al., 1999).
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The ideal vaccine should be the one that lacks toxicity, induces neutralizing
antibodies, and provides long-lasting immune responses at mucosal sites as well as in
the blood. Thus far, HIV-1 vaccine development is still in its early stages.
1.8 HIV-1 Infection in Edinburgh
The individuals observed in this study were from a cohort of predominantly
drug using HIV-1-infected patients identified in Edinburgh. Epidemiologic studies
have shown that these individuals were infected at approximately the same time
(Robertson et al., 1986), and detailed clinical follow up studies have been possible
due to the relative coherence of this group of individuals and despite their social
isolation (Bell et al., 1996a; Brettle et al., 1996; Goodwin et al., 1996). Serologic
analysis of stored serum samples indicated that HIV-1 was introduced into
Edinburgh and spread rapidly in late 1983 and early 1984 (Peutherer et al., 1985).
This rapid spread of the virus in Edinburgh may be explained by the high-risk
behaviour of the intravenous drug users (IDU) in Edinburgh, since at the time of this
rapid spread there was a very high frequency of needle sharing. In addition, an
extremely high level of HIV-1 encephalitis has previously been noted in IDU in the
Edinburgh cohort once they progressed to AIDS (Bell et al., 1996a).
The Edinburgh cohort provides an excellent opportunity to undertake
systematic investigations of the pathogenesis of HIV-1 infection, due to the
comprehensive clinical database and the availability ofmultiple tissue samples (Bell
et al., 1996b). Previously, studies have focused on the nervous system. In this thesis,
I investigated various organs from individuals in different stages of disease, and from
different risk groups. Both histological and virological examinations were
undertaken in order to understand the evolution of HIV-1 infection.
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1.9 Aims
For a better understanding of HIV-1 pathogenesis and the mechanisms
underlying HIV-1 related disease in specific tissues such as the brain, lung and
gastrointestinal system, this thesis was aimed to investigate the cellular localisation
ofHIV-1, cytopathology and viral phenotype variation in various organs throughout
the course ofHIV-1 infection. The studies included in this these are as follows:
A. To determine the cellular localisation ofHIV-1 in various organs obtained from
HIV-infected individuals at different stages of disease. Immunohistochemistry
was employed for detection ofHIV-1 viral proteins and identification of cellular
targets, and histology for visualisation of pathological abnormalities.
B. To investigate the genetic relationships of HIV-1 variants derived from various
organs within HIV-infected individuals. Nested PGR detecting HIV-1 proviral
DNA was employed for the investigation of the distribution of HIV-1.
Nucleotide sequencing followed by phylogenetic analysis was employed for the
investigation of HIV-1 quasispecies derived from various organs at different
stages of HIV-1 infection.
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Chapter 2: General Materials and Methods
2-1
2.1 Study Material
All autopsy samples used in this thesis were obtained from the Medical
Research Council Brain and Tissue Bank of Edinburgh (Western General Hospital,
Edinburgh). Tissues from various organs were obtained from fifty autopsies from the
cohort of HIV-1 positive individuals in Edinburgh. Twelve of the fifty patients died
of non-HIV related causes before developing AIDS. No HIV related changes were
observed on pathological examination of these cases, which were classified in the
pre-symptomatic stage (pre-AIDS). The other thirty-eight individuals died of
complications associated with HIV-infection, including opportunistic infections or
neoplasms. These patients were classified in the symptomatic stage (AIDS). Both
fresh frosen (-70°C) and formalin-fixed, paraffin-embedded tissues were available in
all cases.
Tissues from all of the study subjects were examined by immunohistological
staining with anti-p24 antibody and several cell markers. In addition, HIV-1 sequence
analysis was performed on nine autopsies, including six symptomatic and three
presymptomatic cases. Clinical information for each study subject is summarised in
the relevant chapters.
2.2 Autopsies
Autopsies were carried out within three days of death. At autopsy,
approximately 1-2 cm samples of various organs, including brain, lymph node,
intestine, lung, spleen, liver and kidney from each individual were removed and
stored at -70°C for polymerase chain reaction (PCR), sequence analysis and cryostat
studies. The remaining tissues were fixed in 10% formalin for later histological
examination. Approximately two weeks after fixation, tissues were processed
through a 41 hour program in the Vacuum Infiltration Processor (VIP) (Tissue Tek),
followed by paraffin wax embedding using a Tissue Tek embedding console. Fixed
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and processed tissues were thus rendered safe for study outside the Containment
Level 3 Lab.
2.3 Biological Risks ofWorking with HIV-1
Human immunodeficiency virus type 1 (HIV-1) has been classified as a
dangerous pathogen of the hazard group 3. All work with live HIV-1 must be carried
out within a specifically designed Containment Laboratory. It is recommended that
the growth and manipulation of HIV in research laboratories must be carried out in
Containment Level 3 facilities.
HIV-1 is a blood-borne virus. Transmission of HIV infection may occur via
contact with any body fluids of an infected individual which might contain virus
particles or infected cells, such as cerebrospinal fluid, peritoneal, pleural, pericardial
fluids, semen, vaginal secretions, breast milk and blood. Unfixed tissues, organs and
any other body parts from HIV positive patients are also included in this high-risk
categorization.
2.3.1 Safe Handling of HIV-1 Infected Tissues
Needle stick or scalpel blade injuries with contaminated items are the major
laboratory infection route in the laboratory. Any cut with a contaminated object can
result in the introduction of HIV into the blood or lymphatic systems with the
concomitant risk of infection, thus special care must be taken while dealing with
syringes, needles, scalpels and scissors. Appropriate safety measures should be
employed. These include wearing double gloves, a plastic apron over a dedicated coat,
and disposable plastic cuffs being worn at all times. Chain mail gloves between two
layers of rubber gloves should be worn when undertaking cutting of fresh tissues. A
face shield is also required to protect the eyes and mouth from splashes. All work
involving blood, body fluid, or tissues from HIV-1 positive individuals, must be
undertaken in a Containment Level 3 laboratory using a Class 1 microbiological
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safety cabinet. Unfixed high-risk specimens must not be exposed outside the Class 1
safety cabinet. All work surfaces must be disinfected regularly and all sources of
potential contamination eliminated as far as possible to ensure a safe working
environment for all staff.
2.3.2 Decontamination of HIV-1 Infected Tissues
HIV must be inactivated before any sample is removed from the Containment
Laboratory. There are several conventional methods that can be used to achieve this,
such as sterilisation by moist heat, dry heat or by chemicals.
2.3.2.1 Chemical Disinfection
Chemicals can be used to destroy HIV-1. Up to 107 fold decreases in infectious
ability can be achieved by the treatments listing in Table 2. 1 (Resnick et al., 1986).
Table 2. 1. Chemical disinfections.
Chemical Exposure Duration
0.5% (v/v) Nonidet P-40
0.5% (w/v) Sodium hypochlorite
70% (v/v) Ethanol
0.08% (w/v) Quaternary Ammonium chlorides






In general, chemical treatments provide a quick and convenient method of
disinfection, especially for the working surface or small equipment. However, the
major disadvantage of chemical disinfection is the incomplete penetration throughout
the contaminated sample. Chemical disinfection cannot therefore be relied upon to
work adequately with precipitates or blood clots in the sample. For this reason, heat
inactivation, such as autoclaving is always the method of choice for rendering
materials stage for disposal, ideally followed by incineration of the autoclaved waste.
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2.3.2.2 Autoclaving
HIV is very labile at high temperatures under wet conditions. Routinely used
conditions for the sterilisation of HIV-1 infected material is listed in Table 2. 2.
Autoclaving is used to decontaminate experimental waste, such as gloves, gowns,
tissue residues and small pieces of equipment. Fumigation is preferred for
decontaminating working space and large pieces of equipment, such as microtome.
Table 2. 2. Autoclaving Decontamination
Temperature (°C ) Times (Min)
2.3.2.3 Fumigation
Fumigation with formaldehyde, under moist conditions, is an effective method
of decontamination for rooms and for equipment, which is unsuitable for autoclaving.
Routinely, fumigating gas is produced by one portion of potassium chromate mixed
with one portion of formalin, which will then fill the whole space to be disinfected, if
left overnight. This method is commonly used to decontaminate the microbiological
safety cabinets after work. Since ingestion or inhalation of formaldehyde is extremely
toxic, it is necessary to have a safe method for venting the formaldehyde after use.
Also, it is important not only to use sufficient formaldehyde to achieve an effective
concentration for inactivation of HIV but also not too great an excess as the
formaldehyde will polymerize into paraformaldehyde on surfaces. This can result in
the partial obstruction of HEPA (high efficiency particulate absorption) filters, and
also a continuing slow release of formaldehyde back into the room due to







2.4 Preparation of Cryostat Samples
This work was carried out in the Containment Level 3 lab in the Department of
Pathology, University of Edinburgh under the supervision ofMs C-A McKenzie, and
Ms F. Brannan.
Protective clothing was worn as described in section 2.3.1 before entering the
lab. Frozen tissues from various organs were trimmed to appropriate sizes and
mounted on chucks with Tissue-Tek O.C.T. adhesive. This was carried out inside the
Class 1 safety cabinet, and samples were then transferred to the Bright's cryostat
freezing microtome (-20°C ). 5pm specimen sections were taken from each block
and transferred on to positively charged slides (Superfrost Plus glass slides, BDH
Laboratories companies). After fixation and disinfection with acetone for at least 10
minutes at room temperature, the slides were stored at -20°C for further investigation
in the routine laboratory. The used gloves, gowns and experimental waste were
decontaminated by autoclave. The used chucks and forceps were decontaminated by
immersion in detergent (Trigene) overnight. The cabinet and microtome were left for
fumigating overnight. All work surfaces were wiped with Disinfectant Wipes,
containing 70% alcohol.
2.5 Preparation of Paraffin Samples
All HIV infected tissues that are adequately fixed in formalin may be considered
decontaminated and therefore safe to handle in a routine laboratory. Formailin-fixed,
paraffin-embedded tissue blocks were cut at 3-5pm using a Reichert-Jung Biocut
2030 Rotary Microtome. Sections were then floated on to a water bath at 45°C, and
mounted on to appropriate glass slides, such as 0.1% w/v Poly-L-Lysine (Sigma)
coated slides or Superfrost Plus glass slides (BDH Laboratories companies), and then
incubated at 37°C for over 24 hours.
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2.6 Immunohistochemistry
2.6.1 Rehydration of Paraffin-Embedded Sections
Sections were de-waxed in xylene (Genta Medical) for 10 minutes, and then
rehydrated by passing through industrial methylated spirits (IMS) (Genta Medical)
for 5 minutes, 70% alcohol (Hayman) for 5 minutes, and de-formalinised with
saturated alcoholic picric acid buffer for 15 minutes. Finally, sections were placed in
tap water until clear.
2.6.2 Antigen Retrievals
Formalin fixation provides the best morphological preservation, however it is
believed that antigen identification in tissue sections is significantly limited by the
masking effect of fixatives because of the formation of formalin-induced cross-
linking proteins (Pileri et al., 1997). This is thought to be the reason why some
antibodies work well in paraffin sections, whilst others do not. One hypothesis,
modification-re-modification raised by Shi et al., suggested that the application of
antigen retrievals may lead to a re-modification of the protein structure that had
previously been modified when fixed with formalin, resulting in the reestablishment
of the three-dimensional structure of antigenic epitopes in their active condition, or
very close to that state (Shi et al., 1997).
Several antigen retrieval techniques, including detergent treatments, proteolytic
enzymes, and high temperature techniques were therefore developed since different
antigens might only be exposed under particular conditions. The antigen retrievals
described in the following sections were the ones most commonly used in this work.
All of the conditions had been optimised and were applied routinely in the
department ofNeuropathology and Pathology in the Western General Hospital.
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Antigen protein +Ab Negative or
+
^ Chemical ^ Masked Ag * weak
Formalin Fixation Modification IHC Pattern
Re-Modification
by Antigen Retrievals
* + Ab > Increased intensity
Unmasked Ag of IHC Pattern
Key: Ag = Antigen; Ab = Antibody; IHC = Immunohistochemistry
Figure 2. 1. Diagram of Modification-re-Modification Hypothesis. During
tissue fixation by formalin, the tertiary and quarter structure of cell surface
markers or antigens might be changed because of so-called antigen masking
effect. Such structural alternation will lead to an negative or weak IHC staining,
however, using properly retrieval techniques, it is believed that the three-
dimensional structure of these masked antigenic epitopes could be
reestablished in their active condition, or very close to that state, allowing
antibody detection, thus the intensity of staining could be increased. (Modified




• Trypsin (ICN Flow Laboratories)
• Calcium Choloride (Sigma)
• Protease (type XIV, 5 unit/mg, Sigma)
• 0.0125M TBS pH 7.8 — made up by 1 volume of 0.125M Tris-HCL pH 7.6 and
9 volume of 0.85% (v/v) Sodium Chloride, using IN HC1 adjust the pH value.
Protocol:
Two solutions are available for antigen retrieval: a. 0.1% (v/v) Trypsin & 0.1%
(v/v) Calcium Choloride solution, made up with 0.0125M TBS pH 7.8, or b. 0.5%
(v/v) Protease solution, made up with 0.0125M TBS pH 7.8. The use of solutions is
depended on the antibody (Table 2. 3).
Solutions for antigen retrieval were pre-warmed in a coplin jar, which was
placed in a water bath at 37°C. De-waxed slides were proteolysed in this pre-warmed
solution for 25-30 minutes at 37°C. The slides were then removed and rinsed in tap
water for at least 5 minutes, in order to remove the emzymatic solution completely.
2.6.2.2 Microwave Irradiation
Reagents and Equipment:
• Citric Acid (Sigma)
• EDTA (Sigma)
• Microwave (600W)
• Proper container suitable for microwave
Protocol:
Two solutions are availed for Microwave irradiation: a. 0.01M Citric Acid
buffer pH 6.0; b. ImM EDTA buffer pH 8.0. The use of solution is depended on the
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antibody (Table 2. 3).
De-waxed sections were placed in a microwave oven in a suitable container
filled with either citric acid buffer or EDTA buffer, which depended on the primary
antibody. The container was covered with cling film to prevent evaporation and
microwaved for 15 minutes (3X5 minutes) at full power (600W). After microwave,
the container was removed from the oven and left to cool at room temperature for 20
minutes. Sections were removed from the buffer and rinsed in tap water for at least 5
minutes to remove the microwave buffer thoroughly.
2.6.3 Blocking of Endogenous Biotin
Some tissues may non-specifically bind avidin, biotinylated horeseradish
peroxidase or other Biotin/Avidin system components without prior addition of
biotinylated antibody. This binding may be due to endogenous biotin or biotin-
binding proteins, lectins, or non-specific binding substances present in the section.
Vector Biotin blocking kit was required to block endogenous biotin, and these biotin-
binding proteins and lectins, and thus reduce background staining.
Reagent:
• Biotin blocking kit (SP-2001, Vector Laboratories), which consists of an Avidin
D solution and a Biotin solution.
Protocol:
After incubating with normal serum (SAPU), sections were then incubated with
the Avidin D blocking solution for 30 minutes at room temperature. Rinsed briefly
with washing buffer and then incubated with the Biotin blocking solution at room
temperature for another 30 minutes. Rinsed thoroughly again with washing buffer
prior to the addition of primary antibodies.
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2.6.4 Immunostaining Techniques
The staining techniques used in this study were ordinary Avidin-Biotin Complex
(ABC), immunofluorescence (IF), tyramide signal enhancement (TSA) and double-
immunolabelling techniques. Staining results were then observed using a microscope.
The imagines present in this thesis were taken using Leica Q5001W Analysis System
(Leica Microscopy Systems, GmbH), and edited using Adobe Photoshop computer
programming.
Reagents:
• Antibodies (summarised in Table 2. 3)
• TNB buffer — 1M Tris-HCl pH7.5, 0.15M NaCl, 0.5% bovin-serum albumin
(BSA)
• TNT Buffer— 1M Tris-HCl pH7.5, 0.15M NaCl, 0.5% Tween®20
• Biotinyl-Tyramide reagent — lOmg biotinamidocaproic acid 3-sulfo-n-
hydroxysuccinimide ester (Sigma) and 3mg tyramine hydrochloride (Sigma),
make up to 4ml with 50mM Borate buffer pH 8.0. Allow to conjugate with low-
speed stir overnight, and filter for use.
• 50mM Borate buffer pH 8.0 & pH 8.5 — 0.3lg Boric Acid, make up to 100ml
with distilled water. Adjust pH as required with NaOH
Protocolfor Avidin-Biotin Complex (ABC) technique:
After rehydration, antigen retrievals were applied as required depending on the
antibody we used (Table 2. 3). Sections were immersed in 3% H2O2 (Fisher Scientific
International Company) for 10 minutes in order to block endogenous enzyme,
followed by washing in tap water for 5 minutes. Sections were then blocked with
normal serum (SAPU) for 10 minutes. Endogenous biotin was blocked using Vector
Blocking kit (SP-2001, Vector Laboratories ) as described in section 2.6.3, followed
by primary antibody incubation. Details of the working conditions of antibodies are
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summarised in Table 2. 3. After excess primary antibody was removed with washing
buffer, sections then incubated with biotin labelled secondary antibody for 30
minutes at room temperature. Subsequently, the biotin site on the secondary antibody
was bound by incubation with an enzyme labelled streptavidin-biotin complex (such
as horseradish peroxidase (HRP)- or alkaline phosphatase (AP)-ABC, Dako) for
another 30 minutes. The end point detection was by a colour reaction with a
chromogen, such as diaminobenzidine (DAB), Vector Blue and Vector Red (Vector
Laboratories), which gave dark brown, blue, red and purple colours respectively.
After visulisation by chromogen, sections were counter stained in Meyer's
haematoxylin for approximately 20 seconds and finally mounted with mounting
medium (DPX). The results were observed by light microscope.
Protocolfor Conventional Immunofluorescence (IF):
Same steps as ABC technique until finishing primary antibody incubation, but
biotin blocking was dispensable. After primary antibody incubation, a fluorochrome
(such as FITC) conjugated secondary antibody, was used instead of the biotin
labelled secondary antibody for 30 minutes room temperature incubation. Sections
were washed thoroughly with washing buffer and then mounted with vectashield
fluorescence mounting medium (Vector Laboratories). These results were observed
under an UV fluorescence microscope (fluoroscope).
Protocolfor Tyramide Signal Amplification Technique (TSA):
Alternatively, after the incubation of biotin labelled secondary antibody,
sections were blocked with TNB buffer for 30 minutes at room temperature, followed
by incubation with HRP labelled streptavidin (SA-HRP, Dako) for 30 minutes.
Excess reagent was washed away using TNT buffer, followed by incubation with
biotinyl-tyramine reagent for 5 to 7 minutes. Washed thoroughly using TNT buffer,
followed by 30 minutes incubation with enzyme labelled streptavidin (SA-HRP or
SA-AP, Dako) at room temperature. End point detection was the same as ABC
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method, using a chromogen (DAB, Vector Blue or Vector Red), followed by counter
stained in Meyer's haematoxylin for approximately 20 seconds, mounted with
mounting medium (DPX), and then observed by light microscope.
Protocolfor TSA Immunofluorescence Technique (TSA-IF):
Same steps as TSA technique until finishing biotinyl tyramide incubation,
followed by a fluorochrome conjugated streptavidin (SA-FITC, SA-Taxes Red).
After 30 minutes incubation, sections were washed thoroughly with TNT buffer and
mounted with vectashield fluorescence mounting medium. Then, observed under an
UV fluorescence microscope.
Protocolfor Double-immunolabelling Technique:
In general, the first antibody staining was carried out following the normal
staining procedure until end point detection. After washed in buffer for at least 30
minutes, second antibody labelling was started from normal serum blocking,
followed by normal staining procedure.
Table 2. 3. Information of antibodies
(A) Secondary Antibodies
Antibody Source Dilution
Biotinylated rabbit-anti-mouse (RAMBO) Dako 1:200
Biotinylated swine-anti- rabbit (SARBO) Dako 1:200
HorseRadish peroxdase labelled streptavidin Dako 1:500
FITC-conjuated anti-mouse SAPU 1:10
FITC-conjuated anti-rabbit SAPU 1:10
Texas-Red conjugated streptavidin Dako 1:500
FITC-conjugated streptavidin Dako 1:500
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(B) Primary Antibodies
Antibody Source Type* Antigen retrieval Method/ Dilution













































































*Mono — monoclonal antibody, which usually raised from mouse
Poly — polyclonal antibody, which usually raised from rabbit.
2.6.4.1 CD4 Antibody
The CD4 molecule is confirmed as a major target of HIV-1 infection, and
therefore of particular interested in this study. Unfortunately, antibody currently
available did not provide reliable in paraffin sections in our lab despite rapid fixation.
In order to investigate the association between p24 and CD4 positive cells, a short
study using cryostat sections taken from known HIV-1 positive LNs have been made.
In this case the DuPont p24 antibody was not detectable in our cryostat sections, for
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reasons which are unclear but this was a consisted finding, and very few CD4
positive cells were detected in these sections.
Also, several p24 positive formalin-fixed, paraffin-embedded LN blocks have
been sent to other research group who has reported that CD4 antibody working well
in paraffin section. However, they were unable to have any CD4 staining in those
sections, either. Therefore, the detection of CD4+ cells was unavailable in the present
study.
2.7 Nucleotide Analysis
2.7.1 Extraction of Nucleic Acids
Reagents:
• TNE buffer — 0.11M NaCl, 55mM Tris pH 8.0, l.lmM EDTA pH 8.0, 0.55%
sodium-tt-lauroylsarcosine (SDS)
• Lysis buffer — 0.11M NaCl, 50mM Tris pH 8.0, l.lmM EDTA pH 8.0, 0.5%
SDS, 100jug/ml Proteinase K, 40pg/ml poly A
Protocol:
0.5-1 cm blocks of tissue were dissected from frozen material and placed into a
clean eppendorf tube with 500pl lysis buffer, mixed well by vortexing, and then
incubated at 65°C for two hours or until the tissue was completely dissolved.
Following this, 450pl phenol (Rathburn Chemicals Ltd) was added to the extraction
eppendorf and the contents mixed thoroughly by vortexing for 5 minutes. The
extraction eppendorf was centrifuged at 13000rpm at room temperature for 10
minutes. The upper aqueous layer was transferred carefully without disturbing the
interface into a clean eppendorf and phenol extraction was repeated as above. The
upper aqueous layer was again transferred carefully to a clean eppendorf with 450pl
of 50:1 (v/v) chloroform / iso-amylalcohol (AnalaR), mixed thoroughly by vortex for
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2 minutes and then centrifuged at 13000 rpm at room temperature for 10 minutes.
The aqueous layer was then transferred again to a clean eppendorf containing 800pl
of 100% ethanol (AnalaR) and 40pl 3M NaOAc pH 5.2, mixed well by inverting and
then left overnight at -20°C for precipitation of nucleic acid. Nucleic acid was
collected by centrifugation at 13000rpm at 0°C for 30 minutes. The supernatant was
discarded and the pellet was washed with 70% alcohol then centrifuged again at 0°C
for 10 minutes. The supernatant was discarded and the pellet was dried at 37°C for 5
to 10 minutes. The pellet was re-suspended in 40pl of DEPC water. The sample was
left at room temperature at least for 10 minutes to ensure adequate solubilization of
the pellet.
2.7.2 Quantitation of Extracted DNA
The concentration of DNA in each sample was quantified using
spectrophotometric UV absorbance readings at wavelengths of 260nm and 280nm.
Samples were diluted 1 in 200 with DEPC water and absorbance measured in a
spectrophotometer. The ratio of optical density (OD) at 260nm to 280nm gave an
indication of purity of each preparation. An A260 /A280 ratio of approximately 1.8
indicated a relatively pure DNA preparation. The concentration of DNA was
calculated from the equation: A260 x D x 50 = DNA concentration (jag/ml), where
A260 = OD value at 260nm, D is the dilution factor (=200) and 50 is equivalent to the
concentration (pg/ml) of double-strand DNA at A260 of 1-0.
2.7.3 Polymerase Chain Reaction
HIV-1 proviral DNA was amplified employing the nested polymerase chain
reaction (PCR). Nested PCR involved a double round of PCR with the primary PCR
amplification by an outer set of specific primers, followed by an secondary PCR
using an inner set of specific primers, which was used to amplify the first PCR
product. Compared with using only one set of primers, nested PCR can increase the
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sensitivity of amplification by 10,000 times, and can also increase the specificity.
Reagents:
• 10X PCR reaction buffer — 200mM Tris-HCl solution pH 8.8, 500mM KC1,
15mM MgCb and 0.5% Triton X-100 (Promega)
Protocol:
Primary PCR using the outer set of primers was carried out in a 50pl volume.
Each reaction contained lpg of DNA, 0.4 units of Taq polymerase (Promega), 5jal of
10X PCR reaction buffer, 30pM of nucleoside triphosphate (dGTP, dATP, dTTP,
dCTP) (Boehringer Mannheim), and 0.25pM of each of the outer nested primers,
finally made up to 50pl with DEPC water. The secondary PCR, using an inner set of
primers, was carried out in a 20p.l volume, lp.1 of primary PCR product was
transferred to a second tube containing 19pl of reaction mixture of which conditions
were the same as for the primary reaction. One to two drops of mineral oil was used
to cover each reaction prior to transfer to the thermal cycler, in order to prevent loss
of sample due to evaporation.
Both primary and secondary PCR were subjected to a thermal cycle of
denaturation at 94°C for 36 seconds, primer annealing at 50°C (for V3 region) or
55°C (for Pl7gag region) for 42 seconds, and an extension step at 72°C for 90 seconds.
Each template strand was amplified for 30 cycles in the primary reaction, and 25
cycles for secondary reaction. At the end of the last cycle in every reaction, samples
were heated at 72°C for 5 minutes for terminating uncompleted strands. The
nucleotide sequences of PCR primers are described in Table 2. 1. All positions are
numbered according to the HXB2 genome (Myers et ai, 1991).
Known positive and negative DNA samples (lpg) were included in every
reaction to provide a comprehensive check for contamination. An additional negative
control was included which contained no DNA in the reaction mixture ensuring no
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buffering contamination occurred.
Table 2. 4. Primer sequences
Primer Sequence 5' to 3' Position of 5' base
P17gag (sense) GCG AGA GCG TCA GTA TTA AGC GG 795
P17gag (sense) GGG AAA AAA TTC GGT TAA GGC C 835
P17gag (antisense) CTT CTA CTA CTT TTA CCC ATG C 1248
P17gag (antisense) TCT GAT AAT GCT GAA AAC ATG GG 1296
V3 (sense) TAC AAT GTA CAC ATG GAA TT 6957
V3 (sense) TGG CAG TCT AGC AGA AGA AG 7009
V3 (antisense) CTG GGT CCC CTC CTG AGG 7331
V3 (antisense) ATT ACA GTA GAA AAA TTC CCC 7381
2.7.4 Visualisation of Amplified PCR Products
Reagents:
• 10X TBE — 108g Tris base (AnalaR), 55g boric acid (Molecular Biology
certified; Kodak), 40ml 0.5M EDTA (Molecular Biology certified; Kodak).
Make up to 1 litre with distilled water
• Agarose gel — agarose (Sigma) make up with IX TBE containing ethidium
bromide.
Protocol:
2 to 3 % agarose gel containing ethidium bromide was used to demonstrate PCR
results. Ethidium bromide as a DNA intercalating agent, which exhibits fluorescence
under ultraviolet light, allowing any positive PCR products to be detected as bright
fluorescent bands. Agarose gel was run for 20 minutes at 150V and analyzed under
ultraviolet light.
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2.7.5 Quantification ofHIV-1 Proviral DNA
Quantitation of proviral DNA was carried out using the nested PCR limiting
dilution method (Simmonds et al., 1990). The number of copies of provirus per
million cells was determined by nested PCR amplification of serial ten-fold dilutions
of DNA using the pl7gag primers. Ten replicates at last positive dilution were used to
indicate the minimum proviral load in the sample, assuming a Poisson distribution
for each sample by -\n(\-p)ld (where p= proportion of positive samples and d=
dilution). Viral load was expressed as copies per million cells on the basis that a
human diploid cell contains 6.6pg DNA.
2.7.6 PCR Product Cloning
One of the benefits of the nested PCR is producing a clear and unique band as a
positive result. This PCR product was available for direct cloning using a Promega
pGEM-T Easy Vector system, followed by transformation using blue/white colony
screening.
2.7.6.1 Ligation
Ligation reactions were set up based on Promega T4 DNA Ligase system and
pGEM-T Easy Vector system (Promega). The reactions were set up as in Table 2. 5.
Mix the reaction by pipetting and incubate the reaction overnight at 15 °C.





T4 DNA Ligase 10X Buffer lpl ljxl
PGEM-T Easy Vector (50ng) lpl lpl
PCR product lfil -
Control Insert DNA (4ng/pl) - 2pl
T4 DNA Ligase (3 Weiss units/pl) lpl lpl




• SOC Medium pH 7.0 (100ml) — 2.0g Bacto®-tryptone, 0.5g Bacto®-yeast
extract, 1ml 1M NaCl, 0.25ml 1M KC1, 1ml 2M Mg2+ Stock (1M MgCl2-6H20,
1M MgSCL *7H20), 1ml 2M Glucose
• LB medium pH 7.5(1L) — lOg Bacto®-Tryptone, 5g Bacto®- yeast extract, 5g
NaCl
• LB agar pH 7.5 (1L) — lOg Bacto®-Tryptone, 5g Bacto®- yeast extract, 5g
NaCl, 15g agar
Protocol:
JM109 Competent Cells (Promega) were employed for transformation. The
blue/white colony method was used as a screening method for transformation. 2pl of
each ligation reaction was added to sterile 1.5ml eppendorf on ice. A known quantity
of purified, supercoiled plasmid DNA was set up as a transformation control. 50pl of
competent cells were carefully aliquoted into each eppendorf, mixed gently and
placed on ice for 20 minutes. The cells were heat shocked at exactly 42°C in a water
bath for exactly 45 seconds. The eppendorf was then returned immediately to ice for
2 minutes. 950pl of SOC medium was added to the tubes containing cells that had
already transformed with ligation reactions. The transformed cells were grown for 1
to 2 hours at 37°C. lOOp.1 of each transformed culture mixture was plated on to
LB/ampicillin/IPTG/X-Gal plates. The culture mixture was left to stand at room
temperature for 10 to 15 minutes and then incubated overnight at 37°C. After
overnight culturing, these pates were stored at 4°C ready for miniprep. Generally,
white colonies contained inserts.
Ligation Positive Control
To determine whether the ligation was proceeding efficiently, a positive control
was always included as a standard reaction. Theoretically, more than 60% of the
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colonies should be white and ideally less than 30% of the colonies should be blue.
Those blue colonies were a useful internal transformation control. If no colonies were
obtained finally, the transformation had failed. If only blue colonies were obtained,
without whites, this suggested that the ligation step had failed.
Transformation Control
To determine the transformation efficiency of the competent cells, an uncut
plasmid (supercoiled plasmid DNA) was used as a control. cfu/pg-DNA was
o
calculated in the transformation control plate. If a figure of lower than lx 10
cfu/pg-DNA was obtained, the reaction was deemed inefficient and it was necessary
to prepare fresh competent cells in order to repeat the entire process.
2.7.7 Plasmid DNA Minipreps
Reagents:
• GTE (100ml) — 0.9g Glucose, 2ml of 0.5M EDTA, 2.5ml of 1M Tris-HCl pH8
• Solution I — GTE with Lysozyme (Sigma)
• Solution II (10ml) — 400ul of 5M NaOH, 1ml of 10% SDS
• Solution III (100ml) —9.5ml glacial acetic acid adjust the pH to 4.8 with KOH
• TE — lOmM Tris-HCl, pH 8.0, ImM EDTA
Protocol:
3 to 4ml of LB medium containing 100pg/ml of ampicillin were inoculated with
a single, white bacterial colony which was then cultured in a 15ml sterile tube to
ensure adequate aeration. The bacterial culture was incubated at 37°C with rigid
agitation for 12-16 hours.
After 12-16 hours, 1.5ml of bacterial culture medium was transferred into an
eppendorf and centrifuged at 12000 xg for 5 minutes. The supernatant was discarded
into the waste bottle containing 10% HC1, and then pellets resuspended in lOOul of
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Solution I. This destroyed the bacteria exposing their DNA. 200 pi of freshly made
Solution II was added to the eppendorf that contained well-mixed solution I, and the
mixture inverted. The mixture was allowed to stand on ice for 5 minutes, then 150 pi
of ice cold solution III was added to precipitate the bacterial protein debris. After
mixing well the mixture was allowed to stand on ice for another 5 minutes to
complete the precipitation then spun down at 13000 rpm for 10 minutes.
The top aqueous layer was carefully transferred to a tube, which contained
290pi isopropanol (AnalaR), gently mixed and incubated at room temperature for at
least 30 minutes for DNA precipitation. The precipitated DNA was centrifuged at
13000 rpm for 20 minutes. The supernatant was discarded and the pellet was washed
with 500ul of ice cold 70% ethanol. The DNA was then dried at 37 °C for 10 to 15
minutes and finally resuspended in 40ul of TE, containing 20ug /ml RNAse and
stored at -20°C.
2.7.8 Nucleotide Sequence
The sequence reaction used was the T7 Sequenase version 2.0 DNA polymerase
system (Amersham, Life Science). This system was modified from the bacteriophage
T7 DNA polymerase. Initially, a pair of primer was annealed into the DNA template,
followed by radiolabelling the annealed primer. Finally, a very fast elongation was
processed and every reaction terminated by the addition of stop solution.
2.7.8.1 Pre-sequence Denaturation
Reagents:
• Deneturation buffer — 2M NaOH and 2pM of EDTA pH 8.0
Protocol:
2pl of denaturation buffer was mixed well with 18pl DNA. This mixture was
incubated at 37°C for 30 minutes. The denatured DNA was then precipitated by
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adding 0.1 volume of 3M NaOAc pH 5.2 and 3-4 volume of 100% ethanol, and
incubated at -20°C for at least 3 hours. Precipitates were then collected by
centrifugation at 13000rpm for 30 minutes at 4°C. The supernatant was carefully
discarded, the pellet was washed with 70% ice cold ethanol and then centrifuged at
13000rpm at 4°C for another 20 minutes. After discarding the supernatant the pellet
was dried at 37°C for 5 to 10 minutes and re-dissolved in 13pi distilled water. The
sample was now ready for sequencing.
2.7.8.2 Annealing
After pre-sequence denaturation, DNA was ready for primer annealing. For each
template, the annealing reaction was set up as Table 2. 6, and the nucleotide
sequences of primers were listed in Table 2. 7. Each reaction was mixed well, pre-
warmed at 65°C for 2 minutes, and then cooled slowly to room temperature. Briefly
centrifuge these reaction tubes to collect the contents after they returned back to room
temperature.





Primer 0.5 pmol 0.5 pmol
DNA 6.5pl 6.5p.l
5X T7 sequenase reaction buffer 2pl 2pl
Adjust total volume to lOpl with dH20 10pl lOpl
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Table 2. 7. Primers for sequence
Direction Sequence




2.7.8.3 Labelling and Termination Reaction
Reagents:
• 5X sequenase reaction buffer — 200 mM Tris-HCl pH 7.5, 100 mM MgCh, 250
mM NaCl
• 5X labelling mixture — 7.5pM dGTP, 7.5pM dTTP, 7.5pM dCTP, 5pCi [a-
35S]dATP
• Termination nucleotide mixture — 80pM dATP, 80p.M dTTP, 80p.M dGTP,
80pM dCTP
• Stop solution — 95% formamide, 20mM EDTA, 0.05% xylene cyanol, 0.05%
bromophenol blue
Protocol:
The labelling reaction was set up as shown in Table 2. 8. Because T7 DNA
polymerase is temperature sensitive, the procedure must be carried out rapidly after
addition of the T7 DNA polymerase. 4 tubes were labelled G, A, T, C, and filled with
2pl of the appropriate dideoxy termination nucleotide and 0.5pl of DMSO. These
tubes were pre-warmed at 37°C and 3.5pl of labelling mixture were transferred into
each tube. After 2-4 minutes incubation at 37°C, 4pl of stop solution were added to
terminate the reaction. These reactions were ready for loading on to the gel.
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Table 2. 8. Labelling reaction
Annealing reaction mixture lOpl
0.1MDTT ljxl
IX Labelling Mix (diluted from 2pl
5X Labelling Mix with dPEO)
[a-35S] dATP 0.5pl (0.5pCi)
T7 Sequenase DNA polymerase 3.25 units
Total 15.5pl
2.7.8.4 Acrylamide Gel Electrophoresis
Reagents:
• 10X Sanger TBE — 324g Tris base, 85g boric acid, 19g EDTA, make up to 2L
with distilled water
• 6% Acrylamide gel — 21 g Urea (AnalaR), 6ml 50% Long Ranger gel solution
(Flowgen), 5ml 10X Sanger TBE, 0.05g APS (Sigma), make up to 50ml with
distilled water
Protocol:
The sequencing reactions were run on a 6% acrylamide gel. Glass plates were
cleaned with Methanol then acetone. A pair of flat spacers was used to assemble the
plates. The gel mixture was poured carefully to avoid producing bubbles and left to
polymerise for at least 2 hours.
The gel was pre-run at 75 volts for 10 minutes using IX Sanger TBE as the
electrophoresis buffer. The samples were heated to 90-95°C for 5-10 minutes then
loaded on to the gel. The gel was run at 75 volts. After electrophoresis, the gel was
disassembled and dried, followed by exposed to X-ray film for 1-2 days, depending
on the density of signal.
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2.7.9 Analysis of Sequence Gel
Sequencing gels were read and aligned using Simmonic 2000 Software, which
was developed in the department by Dr. P. Simmonds. Sequence data were then
analysed using the computing package MEGA (Molecular Evolutionary Genetics
Analysis). MEGA is one of the computer programs for analyss data from DNA, RNA
and protein sequences, and distance matrices. Also, it includes the neighbour-joining
method, distance matrix method, a branch and bound parsimony method, and
bootstrapping.
Phylogenetic trees were constructed using the HIV HXB2 sequences as the
outgroup unit (OUT), and the Jukes-Cantor method was employed to count the
multiple substitutions. The bootstrap resampling method (100 replicates) was used to
assess the confidence of each node in the tree constructed.
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Chapter 3: Development and Optimisation of The
Tyramide Signal Amplification Method in The
Detection of HIV-1 Viral Proteins
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3.1 Introduction
3.1.1 HIV-1 Detection and Immunohistochemistry
Acquired immunodeficiency syndrome (AIDS) was first described in
homosexual men and intravenous drug users during 1981 and 1982 (refer to section
1.1). Several epidemiologic studies then indicated that the pathogen of AIDS, later
termed human immunodeficiency virus (HIV), was transmitted mainly by intimate
sexual contact and contaminated blood (Jaffe et al., 1983). Because of concern
generated by the reported transmission of AIDS by contaminated blood, blood
products and contaminated medical equipment, major efforts were made early in the
study of HIV-1 to quantify virus in blood samples.
The detection techniques for HIV-1 in blood and other body fluids include the
measurement of viral p24 antigen (Goudsmit et al., 1987a), and of HIV-1 RNA by
reverse-transcriptase polymerase chain reaction (RT-PCR) (van Kerckhoven et al.,
1994) and quantitative competitive PCR (QC-PCR) (Menzo et al., 1992), and of the
detection ofHIV-1 proviral DNA by PCR. The results of these studies indicated that
both free virus particles and infected cells were present in blood, and HIV-1 infected
cells appeared to be more commonly found than infectious virus particles
(Embretson et al., 1993b). These virus-infected cells were observed to remain in the
human body longer than free virus particles, and normally serve as a continual source
of new virions (Levy, 1998). It was found, also, that transmission by these virus-
infected cells to new cells was much more effective than by free virus particles (Levy,
1998). All this evidence suggested that HIV-1 infected cells might be more important
in the transmission and progression of the disease than free virus particles. Therefore,
it was postulated that investigation of the localisation and classification of these
HIV-1 infected cells, especially their distribution in organs, might assist in the
understanding ofHIV-1 pathogenesis.
There have been a small number of studies devoted to the investigation and
quantification of HIV-1 in a variety of organs, employing the PCR technique
(Donaldson et al., 1994a; Nakata et al., 1995). This gene amplification technique has
3-2
been widely used as the most powerful tool in rapidly detecting virus or rearranged
genes, and allowed the detection of low-level viral RNA and DNA. However, based
on the presence ofHIV-1 nucleic acid, it has proved difficult to correlate PCR results
with the pathological features of the material being tested. In order to demonstrate
productive infection and cellular localisation of HIV-1, the application of
immunohistochemical staining for viral antigens was believed to be the best method.
Immunohistochemistry (IHC) is an indispensable technique in investigative and
diagnostic histology and pathology. The reagents and protocols for different IHC
applications are improving rapidly. Initially, the usage of IHC was limited by the
sensitivity of the staining technique. Soon the production of monoclonal antibodies
and the introduction of indirect staining techniques, from the three-stage
immunoperoxidase or alkaline phosphatase staining technique to the five-layer
immunostaining procedure (Peroxidase-Anti-Peroxidase (PAP), or Alkaline
Phosphatase-Anti- Alkaline Phosphatase (APAAP)), greatly enhanced the staining
signal. A more exciting development was the discovery of the biotin-avidin complex
assay (ABC) (Hsu et al.} 1981). It was found that biotin can be attached to a variety
of compounds and then simply detected by binding it with high affinity and
specificity to avidin that was conjugated with an enzyme or a fluorochrome (Adams,
1992). This practical application of the biotin-avidin system not only gave a
remarkable improvement of staining sensitivity, it also provided a useful basis for
developing other enhancing techniques.
Following the improved staining technique of IHC, another problem, the so-
called antigen-masking effect of fixation, remained to hinder the methodology. For
histological examinations, formalin is the general fixative of choice. However during
the process of formalin fixation, the tertiary and quaternary structures of tissue
proteins are believed to be altered by extensive cross-linking, while the primary and
secondary protein structures are well preserved by aldehyde-linked protein
aggregates (Merz et al., 1995). The cross-linking barriers are presumed to restrict the
accessibility of antigenic epitopes. Many methods have been used in an attempt to
retrieve the antigenicity from formalin-fixed tissues, including treatments with
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detergents, trypsinization or the use of other proteolytic enzymes, and the use of
formic acid (Munakata & Hendricks 1993; Merz et al., 1995; Pileri et al., 1997; Shi
et al., 1997). A more recent development has been the use of microwave irradiation
(McQuaid et al., 1995; Shi et al., 1997). Its ability to contribute to maximum
immunoreactivity in formalin-fixed tissues has greatly increased the range of
histological investigations possible with IHC.
Bringing these improvements of staining and retrieval techniques together, IHC
has now been widely applied in many investigative and diagnostic fields. However,
in the field ofHIV-1 detection, there has been a shortage of optimal procedures and
antibodies, and the application of IHC in specific detection of HIV-1 viral proteins
was not well developed, particularly for tissues containing a low viral load.
3.1.2 Anti-HIV-1 Antibodies
The design of antibodies for HIV-1 diagnosis first focused on the HIV-1 core
p24 protein (Langedijk et al., 1990). HIV-1 p24 protein is encoded by the gag gene.
It is the major component of the viral capsid, and its amino acid sequence is highly
conserved (refer to section 1.2.3.1). In clinical practice, the HIV-1 p24 antigen is one
of the markers for measuring viral activity (Fahey et al., 1990; Langedijk et al., 1990)
and a useful tool for monitoring antiviral drug therapy (Goudsmit et al., 1987b;
Andrieu et al., 1988). A more important finding is that an elevated level of HIV-1
p24 antigen or infectious virus in the blood has been proved to link with HIV-related
disease progression (Allain et al., 1987; Tsiquaye et al., 1988; Sei et al., 1989; Fahey
et al., 1990; Ujhelyi et al., 1990; Chargelegue et al., 1995).
In the 1980s, the DuPont Company registered the first success in antibody
development for HIV-1 immunoassay, an anti-p24 antibody for an enzyme-linked
immunosorbent assay (ELISA) assay (DuPont HIV p24 Core Antigen ELISA kit).
Subsequently, other anti-p24 antibodies, reacting against different epitopes or raised
in different species, were designed and employed in serological antigen capture
studies, such as ELISA, enzyme immunoassays (EIA) and Western Blot (Baroni et
al., 1986; Pumarola-Sune et al., 1987; Housset et al., 1990). However, an antibody
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which was suitable and consistently effective for examining formalin-fixed tissues
did not become available until the late 1980s when the DuPont company introduced
an advanced HIV-1 monoclonal antibody (mAb) (NEA-9283) to p24 core protein for
paraffin embedded tissues. This commercially available anti-HIV-1 p24 monoclonal
antibody required a pepsin retrieval procedure to unmask antigen, and overnight
incubation for the primary antibody. Although it did have better labeling ability in a
comparison study with other anti-p24 mAbs (Cartun et al., 1988), the method was
time-consuming, and the presence of greater background staining due to overnight
incubation limited its application. Later studies reported that this antibody did not
work in paraffin-embedded brain tissues in their trials, suggesting that this antibody
did not work consistently despite pepsin retrieval and overnight incubation (Kure et
al., 1990).
At the same time, Genetic Systems designed a mouse monoclonal anti-gp41
antibody for HIV-1 detection (Genetic Systems, Seattle, WA). It was raised against
the relatively conserved portion of the HIV-1 envelope protein, gp41. This antibody
also required an overnight incubation but no antigen retrieval. It gave apparently
reproducible and consistent staining results. Therefore, this anti-gp41 mAb was
frequently employed in the subsequent HIV-1 IHC studies at this stage possibly
because difficulties had been encountered in p24 IHC (Chad et al., 1990; Kure et al.,
1990). However, this monoclonal antibody showed some cross-reaction with an
irrelevant epitope in Alzheimer neurofibrillary tangles (Kure et al., 1990; Morgello
et al., 1998), and stained occasional macrophages in multiple sclerosis lesions
(Sinclair & Scaravilli, 1992). The specificity of this anti-gp41 mAb is questionable.
Other immunohistochemical studies, most of them performed in animal models,
which detected other HIV-1 viral proteins, such as Nef, Tat, and envelope gpl20
(Ranki et al., 1995; Lin et al., 1997) were published occasionally. However, the
staining results were not always reproducible.
Recently the development of antigen retrieval by microwave irradiation
provided a dramatic improvement in immunohistochemical staining for HIV-1 viral
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proteins. It helped to shorten the incubation period of the primary antibodies, for both
anti-p24 (DuPont) and anti-gp41 (Genetic Systems) antibodies, and also increased
the staining density. With the application of microwave irradiation in our lab, the
DuPont anti-HIV-l-p24 mAb gave consistent and reproducible results with the
routine ABC technique, although positive cells were rare in some tissues. Initial
studies in our lab showed that, in correlating p24 IHC results with quantitative PCR
within the same tissue, most of the PCR positive tissue blocks proved to be p24 IHC
negative even when the PCR proviral loads were high (Donaldson et al., 1994a). It
was not clear whether these negative results were due to low or absent p24 antigen,
or to the limitation of routine IHC staining technique (ABC method) in use at that
time. In addition to the application of microwave retrieval, a signal-enhanced
technique was required to investigate this problem.
3.1.3 Study Objectives
Based on a novel tyramide signal amplification system which was established
by Bobrow et al. (Bobrow et al., 1989; Bobrow et al., 1991), this study was aimed to
develop a more satisfactory and sensitive IHC technique for HIV-1
immunohistochemistry using formalin-fixed paraffin-embedded tissue samples.
Tyramine amplification technique is a further important development for IHC,
which gives a promising improvement in sensitivity and extends the possible
applications of IHC to new targets. In this signal enhancing technique, which was
originally termed catalyzed reporter deposition (CARD), Horseradish-Peroxidase
(HRP) was employed to catalyze the phenolic portion of biotinylated tyramide with
the help of hydrogen peroxide (Bobrow et al., 1992). This reaction produced highly
reactive tyramide radicals that then bound covalently to electron-rich moieties (i.e.
tyrosine and tryptophan) contained in tissue protein molecules. According to the
very short half-life of tyramide radicals, the deposition occurred extremely close to
the activating enzyme site. This property made it very useful in providing a localised
staining pattern (Bobrow et al., 1992). The biotin on the bound tyramide could then
be visualised either by fluorochrome or by enzyme labelled streptavidin.
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(a) Tyramide Signal Amplification technique (TSA)
Stage 1. General labelling procedure
1. Primary antibody recognising
specific Antigen X
2. Biotinylated secondary antibody
recognising primary antibody species.









Stage 2. Increased biotin sites
4. Catalytic deposition of
biotinyl-tyramide by HRP and H202
5. Covalent deposition of
biotinyl-tyramide onto surfaces
blocked with proteins close to the
enzyme site.










Stage 3. End point detection
For colour reaction:
7. Addtion of ensyme labelled streptavidin (i.e. Alkaline Phosphatase or HRP) which bind to
amplified biotin sites
8. Development of colour reaction by chromogen (i.e. DAB)
For fluoresence:
7. Addition of flurochrome lablled streptavidin.
8. Observed using fluroscope
Tissue Surface
3-7
(b) Avidin-Biotin complex technique (ABC)
Emzyme Labelled Streptavidin




















Figure 3. 1. Diagrammatic representations of staining techniques, Tyramide
Signal Amplification techniques (a), Avidin-Biotin complex technique (b),
and ordinary Immunofluoresences (c). Amplified signal in TSA technique is
resulted from the increased biotin sites for enzyme labelled streptavidin.
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This signal enhancement was first applied in the Enzyme-Linked
Immunosorbent Assay (ELISA) (Bobrow et al., 1989), and then in membrane
immunoassays, such as Western or Southern blots (Bobrow et al., 1991; Bobrow et
al., 1992), and finally introduced for histochemistry. The first attempt was made in
Lectin immunohistochemistry (Adam, 1992) and resulted in a tremendous increase
in sensitivity. Following this successful trial, CARD has now been adapted for many
applications, including the amplification of in situ hybridization signal, and the
detection of antigens using a primary or secondary biotin labelled antibody
employing immunohistochemical or Western blotting (Berghorn et al., 1994;
Kerstens et al., 1995; deHaas et al., 1996).
No reliable data were available for the detection ofHIV-1 antigens. However, it
was hoped that the combination of antigen retrieval with optimized tyramide signal
amplification would greatly enhance the results ofHIV-1 immunohistochemistry.
In this study, one known HIV-1 p24 positive autopsy case was employed for
optimising this signal-enhanced assay with DuPont anti-p24 antibody, which we
termed tyramide signal amplification (TSA) technique. To examine the sensitivity
and reproducibility of the TSA technique, this optimised signal enhancement was
compared with the standard immunohistochemical Avidin-Biotin Complex (ABC)
assay employing two commercially available primary antibodies, anti-P24 antibody
(DuPont) and anti-gp41 antibody (Genetic systems), in a cohort HIV-1 positive
autopsy cases using brain tissue. Subsequently, the applicability of the TSA
technique was investigated for other antibodies including some specific cell markers,
and with immunofluorescence (IF).
3.2 Modification and Optimisation of TSA Assay
A commercial DuPont NEN TSA kit was used to initiate the optimisation of
anti-p24 antibody (DuPont). Known HIV-1 p24 positive frontal brain blocks taken
from HIV encephalitis (HIVE) cases and processed with standard routine procedures
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as previously described in section 2.2 were used as specimen cases. One cortical
brain block from a normal HIV negative autopsy was included as a negative control.
Serial sections were taken from each tissue block following the standard protocol
(refer to section 2.5).
3.2.1 Optimisation of HIV-1 Anti-p24 Antibody
EXPERIMENTAL DESIGN. Both ABC and TSA methods were applied with
serial dilutions of the primary mouse monoclonal anti-HIV-1 p24 antibody. The
dilution of the secondary rabbit-anti-mouse biotinylabelled antibody (RAMBO) was
fixed at 1 in 200. For the TSA assay, the streptavidin-HRP (SA-HRP) and biotinyl-
tyramide reagent (BT) were applied following the instructions of the commercial
TSA kit. The end point detection in both ABC and TSA techniques was carried out
with the chromagen diaminobenzidene (DAB).
Tissue sections taken from a known HIV-1 negative normal cortex were
exposed to exactly the same procedures as HIV-1 positive sections to serve as a
negative control. In addition, one known p24 IHC positive section with omission of
the primary antibody was also included as a negative control.
Moreover, to investigate the reproducibility of staining results, this set of
experiments was repeated several times on different days with the same working
conditions.
RESULTS. P24 positive cells were characterized by a strong cytoplasmic
granular staining pattern. Staining results using serial dilutions of the anti-HIV-1 p24
rnAb on serial sections are summarised in Table 3. 1. The staining results were
graded by a self-defined system from 0 to 4, which was validated by sections
examined blindly by at least three of a panel of individuals comprised of a technician,
a collaborating post-doctoral researcher working in this field, a neuropathologist and
myself. Score 0 represented no positive signal detected through the whole section.
Score 2 represented the optimal ABC staining pattern as judged by long experience
of the HIV-1 p24 ABC technique which was standard and reproducible in our lab,
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and this standing pattern was used for comparative reference. Score 4 was given to a
strongly positive staining pattern, which presented either more intense staining or
more positive signals than the reference ABC section. If the staining intensity was
lighter or the positive areas were decreased when compared with the reference ABC
section, slides were graded 1. In contrast, slides were graded 3 when the staining
intensity was slightly increased but the positive areas were similar with reference to
the comparable ABC stained section.
Table 3. 1. Optimisation of anti-HIV-1 p24 antibody in serial sections using
commercial purchased TSA kit and routine ABC technique parallel.
Dilution 1:100 1:200 1:400 1:800 1:1600 1:3200 1:6400 1:12800 1:51200
ABC 2 2 1 1 1 1 0 0 0
TSA 4 4 4 4 4 4 3 1 1
Key for Table 3.1:
Staining results were read as — 4: strong positivity; 3: moderate positivity; 2: equal to
optimal p24 ABC staining pattern; 1: weakly positive; 0: negative
Shaded area: dark background observed
Anti-HIV-1 p24 immunohistochemistry with microwave pretreatment using the
TSA technique gave a greatly enhanced staining result when compared with the
routine ABC technique. The optimal dilution of the anti-p24 mAb (DuPont)
producing maximum performance was 1 in 3200 using the TSA and 1 in 200 using
the ABC technique, which represents signal enhancement by a factor of 16.
Moreover, the staining pattern detected by the TSA technique with a much lower
concentration of anti-p24 mAb was even more intense and positive than the staining
pattern of the ABC technique using higher concentration. At dilutions between 1 in
100 up to 1 in 1600 using the TSA technique, and 1 in 100 using the ABC technique,
very high background staining was present. This dark background seriously
interfered with the analysis of results, but was decreased at the higher dilutions
described above as optimal for the two techniques. Generally, this background
problem has been observed elsewhere with the increased sensitivity afforded by the
biotin-tyramide amplification system (Bobrow et al., 1992; Adam, 1992; deHaas et
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al., 1996; von Wasielewski et al., 1997). One probable reason is the presence of
abundant endogenous biotin in tissues. This can be overcome by pretreating the
tissue sections with a Vector biotin blocking kit. In fact, brain sections contain
relatively little biotin and showed also less background than non-CNS tissues
suggesting that endogenous biotin does bind reagents in the TSA technique leading
to non-specific signal and high background. Other factors, including the
concentrations of primary antibody, secondary antibody, streptavidin-HRP,
biotinyl-tyramide, and the duration of incubation times, even the diluents, might also
contribute to the increased background staining (Bobrow et al., 1992; Adam, 1992;
deHaas et al., 1996; von Wasielewski et al., 1997). Therefore, to eliminate the
problem of severe background staining is a major task for the further optimisation of
the TSA technique.
Negative controls, in which the primary antibody was omitted, and the normal,
HIV-1 negative controls, showed no positive p24 signal with the ABC and TSA
techniques. This confirmed the specificity of this anti-p24 mAb (DuPont) and
showed that non-specific signals were not amplified when the TSA technique
applied. All of the results were reproducible using the same techniques with the same
conditions in our lab.
3.2.2 Optimisation of Streptavidin-HRP
EXPERIMENTAL DESIGN. Although the commercial DuPont NEN TSA kit
was convenient, it was costly. Other reagents, including either in-house or singly
purchased, were considered for use in order to replace the original reagents contained
in the TSA kit. A single purchased reagent, streptavidin-horseradishperoxidase
(SA-HRP) from the Dako Company, was used in order to replace the SA-HRP
included in the DuPont NEN TSA kit. The SA-E1RP reagent was used in two steps of
the TSA procedure and the kit suggestion was to use it in a dilution of 1 in 500
diluted in TNB buffer for both steps. For the purpose of reducing background
staining and seeking an optimal performance, different pairs of dilution of the Dako
Streptavidin-HRP reagent were investigated in this optimisation. The conditions
which were examined are described in Table 3. 2.
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One section was stained using the complete set of the commercial NEN TSA kit,
and was included as a positive control. Another section was stained using the ABC
technique and this was also included as a basic reference. In addition, a section that
was not exposed to the anti-HIV p24 mAb was required as a negative control.
RESULTS. The Dako SA-HRP reagent successfully replaced the SA-HRP
reagent contained in the NEN TSA kit. The staining results are summarised at Table
3. 2. Again, the staining results were graded by a self-defined system from 0 to 4,
which was validated by sections examined blindly by at least three of a panel of
individuals comprised of a technician, a collaborating post-doctoral researcher
working in this field, a neuropathologist and myself. Score 0 represented the pattern
similar to the section following p24 ABC procedure, and score 4 represented the
pattern either similar or stronger to the section using the complete set of the NEN
TSA reagent. The scores 1 to 3 were given according to the positivity observed and
compared to these two reference sections.








































Results 4 4 4 2 2 1 0 0
Key for Table 3. 2:
a. The staining pattern of Anti-HIV-1 p24 diluted in 1:200 using ABC technique was
scored " 0 " as a basic point of reference.
b. The staining pattern of Anti-HIV-1 p24 diluted in 1:3000 using the full commercial
NEN TSA kit was scored " 4 " as a optimal point of reference.
c. Scores between 0 and 4 refer to the level of positivity observed.
d. Shaded areas: presence of background staining.
e. Bold character: the optimal staining pattern
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The optimal performance was obtained when both SA-HRP (Dako) steps
employed a 1 in 500 dilution in TNB buffer. At a dilution of 1 in 100 either at the first
or second SA-HRP step, excessive background staining was observed. At a dilution
of 1 in 1000 for the second SA-HRP step, weak enhancement was observed when the
paired dilution of the first SA-HRP was 1 in 100 or 1 in 250. In contrast, at a dilution
of 1 in 1000 for the first SA-HRP step, no signal enhancement occurred. The
dilutions using 1 in 250 then 1: 500, or 1:500 then 1:250 gave a similar staining
pattern as using 1 in 500 in both steps. For reasons of economy and convenience of
working manoeuvres, it was concluded that the application of 1 in 500 dilution in
both steps was the optimal protocol. Slight background staining was observed in
some of these conditions. According to the literature (Bobrow et al., 1992; Adam,
1992; deHaas et al., 1996; von Wasielewski et al., 1997), the use of biotinyl-
tyramide itself may be a factor leading to background staining in addition to
changing concentrations of primary antibody, secondary antibody and SA-HRP.
3.2.3 Optimisation of in-house Biotinyl-Tyramide
EXPERIMENTAL DESIGN. As considered above, the concentration of
biotinyl-tyramide reagent, its diluent and the incubation time might contribute to the
unpredictable background staining. In an attempt to reduce background staining and
the cost of using the commercial DuPont NEN TSA kit while maintaining the
advantage of increased sensitivity, in-house biotinylation of tyramide was
undertaken according to the protocol published in Kerstens et al., 1995. In this
investigation, the dilutions of anti-p24 antibody, the secondary antibody, and SA-
HRP (Dako) were carried out with the optimised conditions, but the dilution of in-
house biotinyl-tyramide (BT) was varied. Also, several diluents for BT, including
phosphate-buffer saline (PBS) containing 0.01% H202 (Kerstens et al., 1995), Tris-
buffered saline (TBS) containing 0.05% H202 (Macechko et al., 1997), and 0.1 M
Borate buffer pH 8.5 containing 0.01% H202 (Bobrow et al., 1989) were examined.
Moreover, the duration of BT incubation, which was recommended as 7 minutes in
the commercial kit instruction, was varied from 1 minutes up to 15 minutes.
3-14
Sections were also stained using the commercial BT reagent and the diluent
included in the NEN kit as reference positive controls and sections omitting the
primary antibody were required as negative controls.
RESULTS. The maximal staining result was obtained when in-house biotinyl-
tyramide reagent was diluted 1 in 200 with 0.1M Borate buffer pH 8.5 containing
0.01% H202. Compared with the biotinyl-tyramide contained in the NEN TSA kit,
which was applied in a dilution of 1 in 50, in-house biotinyl-tyramide reagent gave a
crisper and more condensed staining pattern. Surprisingly, the in-house BT reagent
diluted in 0.1M Borate buffer pH 8.5 containing 0.01% H202 gave no background
staining. This result was consistent and reproducible. Furthermore, long-term
consistent results were obtained even when this homemade BT reagent was stored
for 6 months at 4°C. The dilution of home-made BT needed to be re-optimised each
time when making up a new batch of reagent.
Bringing these optimal conditions into the investigation of duration of BT
incubation, the optimal results were obtained when sections were incubated for 4
minutes up to 8 minutes. When the section was incubated with BT reagent over 10
minutes, the staining pattern was blurred and background staining appeared. When
the section was incubated with BT reagent for less than 3 minutes, little IHC
enhancement was observed.
3.2.4 Short Summary of Applying TSA in p24 Detection
Thus far, the optimal conditions for the anti-HIV-1 p24 mAb (DuPont) TSA
technique appeared to include a 1 in 3200 dilution for anti-FIIV-1 p24 mAb (DuPont),
1 in 500 dilutions for both SA-HRP (Dako) steps, and in-house BT reagent diluted 1
in 200 in 0.1M Borate buffer phi 8.5 containing 0.01% fl202 for 7 minutes.
All of the optimisations were repeated several times on different days with the
same working conditions and long-term consistent and reproducible IHC staining
results were obtained.
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Figure 3. 2. Detection ofHIV-1 p24 antigen in serial sections of brain tissue
from three cases (I, II and III) demonstrating increased sensitivity of
antigen detection by TSA. The p24 antibody for TSA is 1 in 3200 and for
ABC is 1:200. (DAB with haematoxylin counter stain; magnification, x25 for
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3.3 Comparison Between the TSA and the ABC Methods
In order to compare the sensitivity of the ABC- and the TSA-IHC staining
techniques, a comparison study was undertaken using serial sections of left frontal
lobe brain tissue from cases described below. In addition to anti-HIV-1 p24 antibody,
another mouse monoclonal antibody, anti-HIV-1 gp41 (Genetic Systems) was
examined in parallel. This additional comparison using anti-HIV-1 gp41 mAb
provided a further opportunity not only to compare the sensitivity between the ABC
and the TSA technique, but also to investigate the applicability of the TSA method to
other HIV antibodies.
TISSUE SAMPLES. The analysis was performed in frontal lobe tissue blocks
taken from fifty randomly selected HIV-1 infected individuals, which have been
described previously in Bell et al., 1993 and Bell et al., 1996a. These HIV-1 positive
patients died either of AIDS-related illnesses or in the pre-symptomatic stage of
infection. Tissues were processed following the standard procedure as described in
sections 2.2 and 2.5.
EXPERIMENTAL DESIGNS. At least 6 serial sections were taken from each
tissue block. Each set of slides was given the number 1 to 6, stained as negative
control/ABC, p24 ABC, p24 TSA, gp41 TSA, gp41 ABC, negative control/TSA
respectively. These immunohistochemical techniques were carried out with
optimised conditions following the standard protocol (refer to chapter 2). The end
point was visualized with diaminobenezidine (DAB) followed by haematoxylin
counter stain.
Sections from a known HIV-1 positive tissue block were examined in parallel as
positive controls. The first and sixth of each set of test slides were negative controls
for the ABC and the TSA assays respectively. These controls were important for the
confirmation of the staining results, because some of the tissue sections might non-
specifically bind the secondary antibody or other reagents involved in the procedure.
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3.3.1 Results of the Technical Comparison
3.3.1.1 Consistent Improvement in Staining Intensity
According to the observed intensity of staining pattern, the results of test
sections were graded from 0 to 4. Score 0 representing negative, and 1 representing
very sparse, to 4 representing very strongly positive signal observed in the whole
section. Because of the likely different significance for pathogenesis, the intensity of
antigen staining was assessed separately in white and grey matter (Table 3. 3 & Table
3.4).




Negative with ABC becomes
weakly positive with TSA (sections)
Remains negative
with TSA (sections)
Anti-p24 mAb 17 16 16
Anti-gp41 mAb 5 18 25
In comparison with the ABC method, the TSA technique demonstrated a
reproducibly and considerably more intense staining pattern with both antibodies. As
summarised in Table 3. 3, seventeen out of fifty cases showed consistently and
significantly amplified signal in p24 antigen detection using the TSA technique. In
another sixteen cases that were negative by the ABC technique, a weak but positive
signal was demonstrated by the TSA technique. For anti-HIV-1 gp41 mAb (Genetic
System), five cases were greatly enhanced and 18 cases, which were negative by
ABC, showed weak positive signal with the TSA technique. The TSA technique also
gave a considerable and reproducible amplification of the anti-gp41 mAb, however
the performance of anti-gp41 mAb was not as good as the anti-p24 mAb in this trial.
Within these fifty random cases, 34 showed positivity with anti-p24 TSA IHC but
only 23 cases were detected by anti-gp41 TSA IHC. Moreover, in the cases, which
were positive with both antibodies using TSA technique, the anti-p24 mAb mostly
gave a stronger signal and showed a more localised pattern than the anti-gp41 mAb
did.
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Table 3. 4. The results of the comparison of ABC and TSA methods in
detecting HIV-1 p24 and gp41 antibodies in a cohort of HIV-l-infected
subjects.
TSA-P24 ABC-P24 TSA-GP41 ABC-GP41
NO WM GM WM GM WM GM WM GM
86-130 4 3 2 1 1 0 0 0
88-059 3 0 1 0 1 0 ND
89-215 1 1 0 0 0 0 0 0
89-397 1 1 0 0 1 1 0 0
90-096 2 1 1 0 0 0 0 0
90-275 3 2 0 0 2 1 0 0
90-353 3 1 1 0 1 0 0 0
91-114 4 2 2 1 1 1 0 0
91-193 0 1 0 0 0 0 0 0
91-246 0 0 0 0 0 0 0 0
91-420 2 1 1 0 1 1 0 0
92-118 3 1 1 0 0 0 0 0
92-259 1 0 0 0 1 0 0 0
92-278 0 0 0 0 0 0 0 0
92-334 1 0 0 0 1 0 0 0
92-337 1 1 0 0 1 0 0 0
92-400 1 0 0 0 0 0 0 0
92-415 2 3 2 0 1 0 0 0
92-451 1 0 0 0 1 0 0 0
93-016 1 1 0 0 1 0 0 0
93-089 0 0 0 0 0 0 0 0
93-176 3 1 1 1 2 1 0 0
93-184 0 0 0 0 0 1 0 0
93-320 4 2 1 1 2 1 0 0
93-357 1 1 0 0 1 0 0 0
93-358-1 4 4 1 1 1 1 0 0
93-358-2 2 1 1 0 1 0 0 0
94-034 0 0 0 0 1 0 0 0
94-038 3 2 2 1 2 1 0 0
94-116 0 0 0 0 0 0 0 0
94-132 0 1 0 0 0 1 0 0
94-170 0 0 0 0 0 0 0 0
94-171 0 0 0 0 0 1 0 0
94-172 0 0 0 0 0 0 0 0
94-186 0 1 0 0 0 0 0 0
94-271 0 0 0 0 0 0 0 0
94-276 0 0 0 0 0 0 0 0
94-277 ND 0 0 0 0 0 0
94-280 0 0 0 0 0 0 0 0
94-284 0 0 0 0 0 0 0 0
94-313 0 1 0 0 0 0 0 0
95-004 3 3 1 1 0 0 0 0
95-010 0 0 0 0 0 0 0 0
95-024 2 1 0 0 1 1 0 0
95-040 0 0 0 0 0 0 0 0
95-043 1 0 0 0 0 0 0 0
95-079 1 0 0 0 0 0 0 0
95-088 1 0 0 0 0 0 0 0
95-108 1 1 0 0 0 0 0 0
95-284 2 2 1 1 2 2 1 1
Key for table 3.4
Intensity of staining score 4: very strong; 3: strong; 2: moderate; 1: weak; 0: no staining
WM: white matter; GM: grey matter
For those sections showing p24 or gp41 positivity, the enhanced signal was
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observed both in WM and GM. No significant differences of enhancing capability
were found in these two areas.
3.3.1.2 Improvement in Staining Sensitivity
To assess whether the TSA method resulted in an increase in number of p24
positive foci when compared to the ABC method, eight cases were selected for
quantitation. The number of antigen positive foci was counted within a 4 X 3 inch
recticle (Olympus) in two separated areas of the tissue section and by two individuals
(Dr. Strappe and myself) (Table 3. 5). To ensure that the same area was examined in
each pair of serial sections, specific fields were selected either near the edge of the
section or related to a blood vessel.
In addition to increasing the staining intensity, the results in this trial
demonstrated an increased number of p24 positive foci with the application of the
TSA method. No positive signal was observed in the two negative control slides,
No.l and No.6 in each series suggesting that the signal amplification was specific.
Moreover, the additional positive cells detected by the TSA technique were
morphologically microglial cells or macrophages, which are known to be the major
targets ofHIV-1 in brain tissue. These findings provided the evidence confirming the
specificity of technical amplification with the TSA method. These findings have
been published in Strappe et al., 1997.
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Table 3. 5. Comparison of the number of p24 antigen positive foci detected by
TSA and ABC methods on serial sections of brain tissue from eight study
subjects.









































Two areas of each section were examined within a defined recticle
Wilcoxon Signed Ranks Test:
♦ Ranks
N Mean Rank Sum of Ranks
TSA - ABC Negative Ranks 0a .00 .00
Positive Ranks 16h 8.50 136.00
Ties 0C
Total 16







a Based on negative ranks. Results ofTSA method are significant increased,
b Wilcoxon Signed Ranks Test
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Figure 3. 3. Comparison of ABC and TSA staining techniques for HIV-1 p24
and gp41 antibodies in serial sections of brain tissue from two cases A
and B demonstrating increased sensitivity of antigen detection by TSA,
and the better labelling ability of p24 mAb. The dilution of p24 mAb is
3200 for TSA and 200 for ABC, and of gp41 mAb is 2000 for TSA and
100 for ABC. (DAB with haematoxylin counter stain; magnification, x25 for
case A, xlOO for case B).
3-22
A-p24-TSA
* t - V * *
\ ■.•* -'M--yu
♦ V ~V* i* J
•
, v • v./* v- /















• • Y? >, «
. >/ '> -.V'*-
- /:••' ; /i »•
.!
. / > . v
- >r
' * *'• ?! f-;>\ « " :
-■•v *' • * *' /
■ ¥ * .
r:• . •' ^ : ■'T-
i,». '■ " :
«
. • '• 4 . I '
»• « . t, - , * • -'
•. - ■. •" 4 ; "«-#
■•;. •',< "' : ■ V •■■ * '«"■• ''. . -'*.•*
.'v.-'. •/' ■ <* . ,.V
* .
A-gp41-TSA A-gp41-ABC
«. > v -
.* • •' > "
-■ tf *"■ *
■ '• •* - : .-
• v-v'
B-p24-TSA B-gp41-TSA
^>• 4',:. " J ;y .-: y-
V
A ■ ■ ■■"* ' ^ > <. '■*".* *■ * "ii"- ' ■
■' - 'u .t>» •• • * f •'












• ■ M"* .>•
- ' •. ;






•;• . \«. >. ^ m •
Fig. 3.3
3.4 Applications of TSA Signal Enhancing System
3.4.1 TSA in Various Cell Markers Staining
To evaluate the effects of the TSA technique with other antibodies, which might
be used for further cellular identification, immunohistochemistry was applied using
the TSA and routine ABC techniques for certain cell markers, including T cell
markers (CD3, CD8, MT1 and UCHL1), B cell markers (L26 and MB1), dendritic
cell marker (CD21), macrophage marker (PG-M1) and the astrocyte marker (GFAP).
EXPERIMENTA L DESIGNS. Routinely fixed paraffin-embedded positive
control tissues for each antibody examined in this trial were processed according to
the protocol of section 2.3. The TSA and the ABC techniques were performed
according to the protocols of section 2.5, and end point detection was carried out
with chromogen diaminobenzidene (DAB). For each primary antibody, at least six
different dilutions were examined. If the results were not conclusive, further
dilutions were examined.
For comparison of detection methods, the slides for a given marker using the
ABC and the TSA technique were carried out on the same day using identical
solutions, detection system, and substrate (DAB). Therefore, any variations caused
by factors other than the use or omission of TSA could be excluded.
RESULT. The dilution giving the best performance for each antibody is listed
in Table 3.6. All of these results were reproducible and consistent.
Generally, using the TSA amplified system allowed at least eight fold higher
dilution of primary antibodies in colour detection, but no extra positive signal was
observed when comparing the optimal ABC slides with the optimal TSA slides in
these antibodies. As listed in table 3.8, the dilution for the GFAP was dramatically
raised from 1 in 2000 for the routine ABC up to 1 in 32000 after the TSA method was
applied. And for the L26 antibody, the dilution was raised from 1 in 500 using the
ABC method up to 1 in 16000 using the TSA method, which was enhanced by a
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factor of 32. Moreover, for the antibodies, anti-CD8 mAb and MB1, which only
worked routinely with a very high concentration, the TSA technique showed much
improved performance using a lower concentration.
The staining intensity was improved consistently for most of the antibodies,
excluding GFAP, CD3 and UCHL1. For the anti-CD8 mAb and PG-M1, the staining
pattern with the TSA technique was much more intense and crisper compared with
the ABC technique. But for the anti-CD3 polyclonal Ab, GFAP and UCHL1,
although the positive signal could be detected with very low concentration, the
staining patterns with the TSA were slightly blurred and less sharp compared with
the ABC technique.
Moreover, background staining was observed with some of the cell markers,
such as L26, MT1 and UCHL1, and especially for anti-CD3 antibody and GFAP
with the TSA technique. This background problem could not be solved by using
Vector Biotin blocking kit. It was only reduced when a higher dilution was applied;
however the positivity of the staining signal was decreased at the same time.







P24 1:200 1:3200 N/A 1:150
CD3 1:150 1:1200 1:25 1:150
CD8 1:50 1:800 N/A 1:100
CD21 1:200 1:1600 1:100 1:400
PG-M1 1:200 1:6400 1:50 1:200
GFAP 1:2000 1:32000 1:250 1:2000
L26 (CD20) 1:500 1:16000 1:100 1:500
MB1 1:50 1:800 N/A 1:75
MT1 1:150 1:2400 1:25 1:150
UCHL 1 1:350 1:5600 1:25 1:300
N/A: undetectable with dilution 1:25.
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Figure 3. 4. Comparison of ABC and TSA techniques in cell surface markers
staining. TSA technique demonstrated an intense staining signal in CD8,
PGM1, and CD21. (DAB with haematoxylin counter stain; magnification,
x50).
♦ Dilutions of each antibody:
CD8-TSA: 1:800; CD8-ABC: 1:50 (in serial sections of tonsil)
PGM1-TSA: 1:6400; PGM1-ABC: 1:200 (in serial sections of brain tissue)
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3.4.2 TSA in Immunofluorescence
Immunofluorescence (IF) has been reported as a useful tool in multiple-labeling
detection for demonstrating the cellular localisation of viral proteins. However, the
detection sensitivity has seriously limited its application, especially in formalin-fixed
paraffin-embedded tissues. The optimising investigations described above suggested
that application of the TSA technique could assist in enhancing the staining
sensitivity. Therefore, to evaluate the effects of applying the TSA technique in
immunofluorescence, Texas red-conjugated streptavidin (SA-Texas Red) was
employed to replaced the second SA-HRP(refer to Figure 3.1), and as an end-point
labeling which was then visualised by the fluorescence microscopy.
EXPERIMENTAL DESIGNS. The TSA-IF and the conventional IF
techniques for anti-p24 mAb and a variety of cell markers, including T cell markers
(CD3, CD8, MT1 and UCHL1), B cell markers (L26 and MB1), dendritic cell
marker (CD21), macrophage marker (PG-M1) and astrocyte marker (GFAP) were
carried out according to the protocols of section 2.5. For comparison of detection
methods, the staining using a given marker and using the conventional IF and the
TSA-IF technique was carried out on the same day using identical solutions, and
detection system. Therefore, any variations caused by factors other than the use or
omission of TSA could be excluded. For each primary antibody, at least six different
dilutions were examined. If the results were not conclusive, further dilutions were
tested.
RESULT. The dilution giving the best performance for each antibody is listed
in Table 3. 6. All of these results were reproducible and consistent.
The application of TSA in immunofluorescence again demonstrated a great
enhancement. In general, the TSA-immunofluorescence (TSA-IF) allowed the use of
at least a four fold higher dilution of primary antibodies in fluorescence detection,
and the staining pattern using TSA-IF was much clearer and cleaner than using
conventional immunofluorescence. Commonly, the optimal dilution used for a
conventional immunofluorescence technique was very concentrated. For the
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antibodies, anti-p24, CD8 and MB1, signal was undetectable even with a
concentration of 1 in 25. The use of such high concentration was associated with
background staining and interfered with analysis of results. With the TSA-IF,
because lower concentration of antibody was used, the background problem was
curtailed. In this trial, background staining with the TSA-IF was only observed for
GFAP. However, since the positivity of its staining signal was very strong, in
contrast the background staining was acceptable in this case.
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Figure 3. 5. TSA-FIuorescence in p24 (a), CD8 (b) and PGM1 (c) detection
demonstrating clear background and intense signal. (P24 was labelled with




3.5.1 Enhancement of TSA Technique in HIV-1 Antigen Detection
Immunohistochemistry (IHC) has been widely used in diagnostic and
investigative histology and pathology. It is indubitable that IHC provides valuable
cellular information directly linked to cytopathology. Due to the limitations of
antigen masking and the relative insensitivity of staining techniques, its application
in HIV-1 research fields has been relatively restricted, especially in the study of
paraffin-embedded samples of non-CNS tissues. Only partial success has been
reported previously using enzymatic antigen retrieval and overnight incubation with
monoclonal antibodies to HIV-1 gag p24 antigen or envelope gp41 antigen in certain
cryostat and paraffin embedded tissues (Chad et al., 1990; Kure et al., 1990; Esiri et
al., 1991; Martin et al., 1992). When the antigen retrieval technique of microwave
irradiation was developed recently the sensitivity of immunohistochemical staining
was increased because of its great potential to solve some problems of antigen
masking (McQuaid et al., 1995). However, it was clearly not ideal for the
immunohistochemical detection ofHIV-1 viral antigens, in that PCR positive tissues
often remained IHC negative.
In this investigation, the biotin-tyramide amplification system (TSA) combined
with microwave antigen retrieval was employed for the first time in the detection of
HIV-1 viral proteins in formalin-fixed paraffin-embedded tissue sections. The
protocol, which was optimised in this study, gave a consistent and considerable
enhancement in the detection of HIV-1 viral antigens, especially for anti-p24 mAb.
Compared with the routine ABC method, the p24 TSA IHC constantly gave a more
intense and crisp staining pattern, and the most exciting finding was that the TSA
technique revealed more positive signals indicating that productive infection was
more widespread than previously detected. In addition, a much lower concentration
of anti-p24 mAb proved to be of a great benefit in economical use of research
antibodies. For instance the DuPont HIV-1 p24 antibody was withdrawn during the
progress of this research despite being a satisfactory antibody for commercial use.
Use of the TSA technique has allowed the continued use of reserve stocks of
antibody.
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With the biotin detecting system, background staining was usually associated
with the increased intensity. Surprisingly, with optimal conditions, the TSA
technique demonstrated a clear background in the p24 and gp41 IHC staining.
Moreover, no staining was shown in sections in which the primary antibody was
omitted, and the normal HIV-1 negative cortex control. This evidence confirmed that
the amplification via tyramine detection was specific.
When the TSA technique was utilised with the two currently reliable HIV-1
antibodies, anti-gp41 TSA IHC did not perform as well as anti-p24 TSA IHC. Much
higher dilution was possible (from 1 in 100 using the ABC technique to 1 in 2000
using the TSA technique), and the results obtained in the technical comparison study
(section 3.3) showed that more cases presented positive gp41 signal after the TSA
technique was applied, and the intensity of gp41-staining pattern was also improved.
However, carefully comparing the staining results of gp41 with p24 in the same case,
p24 TSA IHC gave a consistently more intense and localised staining than gp41 TSA
IHC did. In the previous HIV-1 IHC studies, the anti-gp41 mAb (Genetic System)
was frequently employed, which works consistently with a routine ABC technique,
but sometimes binds non-specifically to macrophages (Sinclair & Scaravilli, 1992)
and an irrelevant epitope in Alzheimer neurofibrillary tangles (Kure et al., 1990;
Morgello et al., 1998). The anti-p24 mAb (DuPont) was relatively specific (Kure et
al., 1990; Sinclair & Scaravilli, 1992), and was considered to be associated with
disease progress being a good prognostic marker (Allain et al., 1987; Sei et al., 1989;
Fahey et al., 1990). However its application was restricted by the complicated
staining protocol and inconsistent results (Chad et al., 1990; Kure et al., 1990). But
now, according to the present results, when combined with the microwave irradiated
pretreatment, p24 TSA IHC gave superior staining results for viral proteins and was
the best choice for screening paraffin sections in HIV-1 IHC studies.
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3.5.2 Application of TSA Technique with Other Cell Marker Antibodies
The TSA technique gave an added benefit for the anti-p24 mAb IHC in
paraffin-embedded tissues, however the advantages of using TSA technique for
other antibodies examined in section 3.2.3 were limited.
There is no doubt that the TSA technique consistently allowed a considerable
reduction in primary antibody concentration with all these cell markers. However the
improvement in staining intensity was variable. Some antibodies, such as the anti-
CD8 mAb and PG-M1 showed more intense staining patterns with the TSA
technique, while anti-CD3 polyclonal Ab and GFAP showed less well-localised
staining patterns. The differences in enhancement between the different antibodies
were difficult to explain. Possibly, the composition of the surrounding tissue may
affect the deposition of activated tyramine because this substance is known to react
with electron-rich moieties on the tissue surface (Bobrow et al., 1989; von
Wasielewski et al., 1997). Thus, each antibody requires individual modifications for
achieving optimal results. The conclusion in this study was that if results with the
primary antibody are inconsistent using a routine technique, such as with anti-p24
mAb, and anti-CD8 mAb, then TSA was effective in improving the staining results
both in reducing antibody concentration and in improving staining intensity.
However, for cell markers such as anti-CD3 and GFAP which gave good and
consistent results with routine IHC, the advantage of using the TSA technique was
solely in using higher dilutions. Coincidentally, anti-CD3 and GFAP are polyclonal
antibodies, which are generally less specific and purified. Whether the relatively
small improvement for these two antibodies implies that the TSA technique is
unsuitable for use with polyclonal antibodies cannot be deduced from the number of
cases provided in this study, but for future studies, these cell markers will not be
combined with TSA IHC unless a better protocol is developed.
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3.5.3 Advantages of Applying TSA Technique in Immunofluoresence
An exciting parallel finding was the significant improvement of applying TSA
in the immunofluoresence procedure. The TSA-immunofluorescence (TSA-IF)
method performed much better than the conventional immunofluorescence
technique. It allowed not only the use of higher dilutions, but also gave much clearer
staining patterns than conventional immunofluorescence. Previously the
conventional IF technique for p24 antigen detection using a fluorochrome labelled
secondary antibody was insensitive even applying a very high concentration of p24
antibody (1 in 5). The TSA immunofluorescence technique for p24 antigen detection
gave an intense fluorescence signal with no background staining and allowed the use
of a lower dilution of 1 in 150. Such improvement was also found in the TSA-IF
detection of cell markers. The ability of this tyramine amplification system to utilise
a lower concentration of primary antibody efficiently diminished the non-specific
signal, which was usually associated with higher concentration of primary antibody
required for conventional IF. A much clearer background coupled with more
intensive signal gave evidence of the optimal fluorescent performance. This benefit
of using TSA-IF provides an opportunity for the development of double-labelling
immunofluorescence (Wang et al., 1999a), which would be useful for the
identification of the cell type that is infected with HIV-1.
3.6 Summary
The TSA technique is an important step in the developmental progression of
IHC, especially in detection ofHIV-1 p24 antigen. Since the working conditions had
been optimised, the sensitivity of detection was greatly enhanced, and the TSA
technique was considered the best tool for the p24 screening investigation in various
organs.
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Chapter 4: Cell and Tissue Distribution of HIV-1 in
Different Stages of Infection
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4.1 Introduction
While several new insights in various fields ofHIV research have been gained,
especially over the last three years, a better understanding of HIV pathogenesis and
the mechanisms underlying HIV-1 related disease in specific tissues such as the
brain is still a high priority in tracking the medical impact of the pandemic.
Identification of the cellular host range of HIV-1 is important for
understanding the pathogenesis. Originally, the CD4+ lymphocytes were
recognised as a major target for HIV infection, and the destruction of CD4+
lymphocytes by HIV-1 was thought to be the major cause of the observed
pathological changes (reviewed in Levy, 1998). Recently, according to the
improved techniques, such as using the PCR detection with extracted tissues or
individual cells, or electron microscopy, or in situ hybridisation, HIV-1 proviral
DNA or virus particles have been found in several tissues, including cells of the
haematopoietic lineage (Schnittman et al., 1989; Bagasra et al., 1992; Bagasra et
al., 1993; Bagasra & Pomerantz, 1993; Embretson et al., 1993a; Embretson et al.,
1993b; Patterson et al., 1993; Donaldson et al., 1994a; Nuovo et al., 1994b;
Livingstone et al., 1996), brain (Wiley et al., 1986; Bell et al., 1993; Donaldson et
al., 1994a; Nuovo et al., 1994a; Bagasra et al., 1996), gastrointestinal tissue (Fox et
al., 1989; Kotler et al., 1991; Gill et al., 1992; Kotler et al., 1993; Donaldson et al.,
1994a), lung (Donaldson et al., 1994a; Dolei et al., 1996; Huang & Stansell, 1996),
and others (Tschachler et al., 1987; Nuovo et al., 1993; Bagasra et al., 1994;
Qureshi et al., 1995; Uittenbogaart et al., 1996), albeit at a very low level in some
(reviewed in Levy, 1998). Also, using cell culture systems, a wide variety of human
cell lines have been demonstrated to be susceptible for HIV-1 infection, including
tissue macrophages, NK cells, dendritic cells and other CD4-negative cell lines
(reviewed in Levy, 1998). These observations implied the polytropic nature of this
virus, and revealed a wider range of possibilities for virus to be concealed in
different tissues.
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Macrophages are CD4+ migratory cells derive from bone marrow precursors.
They are found in most tissues of the body, and have been found to propagate the
HIV-1 infection (reviewed in Levy, 1998). These large mononuclear phagocytic
cells are important in innate immunity, in early non-adaptive phases of host defense,
as antigen-presenting cells, and as effector cells in humoral and cell-mediated
immunity (Janeway & Travers, 1996). Generally, infection of macrophages is
associated with low-level production of virus, and the HIV-1 virion is found
sequestered in intracellular vacuoles (Gendelman et ah, 1989). It is postulated that
macrophages might be the first cells infected at the mucosal barrier in the case of
sexual transmission and that infection of this cell type could be responsible for the
systemic dissemination of the virus found during primary infection (Levy, 1998).
The observation of infected macrophages in lamina propria has provided evidence
of HIV-1 infection in the intestinal system (Kotler et ah, 1991; Kotler et ah, 1993).
Moreover, cells of the monocyte/macrophage lineage in the central nervous system,
including microglial cells, multinucleated giant cells (MGCs) and brain
macrophages have also been found to be the major targets of HIV-1 infection,
which can be demonstrated by immunohistochemical staining (reviewed in Bell,
1998). However in lymphoid tissues, relatively small numbers of infected
macrophages were detected (Embretson et al., 1993a; Chun et ah, 1997).
Sharing a stem cell precursor origin with macrophages, dendritic cells (DC)
are specialised antigen-presenting cells that are widely distributed in the body
except in the CNS, and which are named Langerhans cells in the skin, vagina and
cervix, interdigitary cells in the LNs, dendritic cells (DC) in thymus, interstitial DC
in the heart, lungs and intestine, and blood-derived DC in the peripheral circulation
(Janeway & Travers, 1996). Certain of these related cells appear to be susceptible
to HIV infection (Tschachler et ah, 1987; Cameron et ah, 1996; Knight, 1996;
Knight & Patterson, 1996). Monocyte-derived cultured DC and DC obtained
directly from blood have been shown to be susceptible for HIV-1 infection in cell
culture (Tsunetsugu-Yokota et ah, 1995; reviewed in Knight, 1996). Weissman et
ah demonstrated that one subpopulation of DC was susceptible to infection with
HIV-1 in vitro (Weissman et ah, 1995). HIV-1 proviral DNA and mRNA have
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been detected previously in Langerhans cells from skin of infected patients
(Dusserre et al., 1992). Their presence in genital mucosa identified them as
potentially the primary target cell infected by HIV-1 in heterosexual transmission
(Hussain & Lehner, 1995; Soto-Ramirez et al., 1996), and there might be a specific
tropism of HIV-1 for Langerhans cells that correlates with the geographical
distribution of the HIV isolates and with the HIV-1 subtype (Soto-Ramirez et al.,
1996). Some investigators suggested that a small portion of DC in various tissues of
the body could be productively infected (Dusserre et al., 1992; Weissman et al.,
1995; Knight, 1996), However others suggested that DC could not be infected but
might transfer bound virus particles to T lymphocytes in the blood and lymphoid
tissue (Cameron et al., 1996).
HIV-1 proviral DNA has been found frequently in LN (Pantaleo et al., 1991;
Embretson et al., 1993a; Embretson et al., 1993b; Pantaleo et al., 1993a; Pantaleo
et al., 1994). Histological and electron microscopic examinations have indicated
that in the early stages of HIV-1 infection, large amounts of viral particles can be
visualized in the villous processes of follicle dendritic cells (FDC) in the germinal
centres of LNs (Pantaleo et al., 1991; Spiegel et al., 1992; Pantaleo et al., 1993a).
FDC is a specialised cell type within the lymphoid follicles, which are mainly
constructed of a dense network of closely packed B cells forming the germinal
centre, and which function to promote the maturation of the humoral immune
response (Knight, 1996; Janeway & Travers, 1996). Unrelated to other types of the
dendritic cells, the cellular origins of these branched FDC are obscure. They are not
bone marrow derived but probably mesenchymal (Knight, 1996; Janeway &
Travers, 1996). Whether the large number of viral particles observed in association
with FDC processes reflects their infectability or merely represent HIV-1 trapped
on the surface of these cells is not known. Some groups failed to detect productive
HIV-1 infection of the FDC (Embretson et al., 1993a; Pantaleo et al., 1993a;
Reinhart et al., 1997), while other investigators reported an average of 20% of these
CD21+ cells showing HIV-1 proviral DNA (Stahmer et al., 1991; Spiegel et al.,
1992).
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Other cells, including astrocytes, oligodendrocytes, neuron, goblet cells,
columnar epithelial and enterochromaffin cells, have shown susceptibility for HIV-
1 infection in vitro, although they are CD4-negative (Gill et al., 1992; Moses et al.,
1993; Nuovo et al., 1994a; Albright et al., 1996; Strappe et al., 1998). Similarly,
mature cytotoxic T cells (CTLs) do not express surface CD4 molecule, yet
infection of CD8+ T lymphocytes in the peripheral circulation and in lung has been
demonstrated (Sadat-Sowti et al., 1994; Bofill et al., 1995; Semenzato et al., 1995;
Livingston et al., 1996; Yang et al., 1998). In general, the mechanisms of HIV-1
infection of these CD4-negative cells remain speculative. HIV-1 may infect cells
through a different receptor or, in the case of CD8-positive lymphocytes, infection
may occur during maturation or on antigenic stimulation where the CD4 molecule
may be transiently expressed (Flamand et al., 1998; Yang et al., 1998).
Previous studies had postulated that the CD4 molecule expressed alone was
not sufficient for HIV-1 infection (Maddon et al., 1986; Li et al., 1990; Chesebro et
al., 1990; Cao et al., 1990). A number of proteins from a superfamily of G-protein-
coupled seven-transmembrane-domain chemokine receptors were found to be co-
factors required for HIV-1 entry (Alkhatib et al., 1996; Berson et al., 1996; Deng et
al., 1996; Dragic et al., 1996; Feng et al., 1996; Kozak et al., 1997). Generally,
NSI/macrophage tropic HIV variants use the P-chemokine receptor (CCR5) and
Sl/lymphotropic variants use the a-chemokine receptor (CXCR4) (refer to section
1.3.1.2). In 1996, Paxton et al. reported that a small proportion of the population
who expressed defective CCR5 receptors were highly resistant to infection with
HIV-1 even after repeated exposure through sexual intercourse with HIV-positive
partners (Paxton et al., 1996). How these co-receptors contributed to
cytopathogenicity and disease progress is not yet clear. It has been found that
various human cells could only be infected with specific HIV-1 variants, and
different HIV-1 strains retain different cytopathogenicity and replicating abilities in
specific human cells. The differences in in vivo cellular tropism have been
hypothesised to be controlled by the usage of co-receptors (Dragic et al., 1996;
Kozak et al., 1997).
4-5
The exact interaction between HIV-1 and different cell types is poorly
understood. It was believed that direct and productive infection of these tissues in
vivo might be responsible for the clinical abnormalities observed in HIV-1-infected
individuals. This part of the study was aimed to investigate the cellular distribution
and localisation of HIV-1 infection in various tissues. As discussed in chapter 3, the
IHC staining assay can provide valuable cellular information directly linked to
cytopathology, especially within formalin-fixed paraffin-embedded tissue samples.
However the application in HIV studies was apparently limited by insensitivity of
the technique. In order to determine the distribution and localisation of the HIV-1
infection in vivo, a improved technique for HIV-1 immunohistochemistry has been
established, namely the tyraminde-signal amplification (TSA) system. According to
the results shown in the previous sections (refer to chapter 3), the TSA technique
showed better performance than the ABC technique in HIV-1
immunohistochemistry, especially with the anti-HIV-1 p24 antibody (DuPont) in
our lab. Moreover, a few cases in the comparison trial (refer to section 3.3), which
showed negative staining with the ABC method became weakly positive with the
TSA method. Therefore, it was considered potentially valuable to apply the TSA
technique to a more extensive set of organs and tissues for which HIV-1
immunostaining had been previously unsuccessful. Also, the general distribution of
the co-receptors CXCR4 and CCR5 was investigated in these tissues using the
ABC technique.
4.2 Study Subjects
Study cases were obtained from the MRC funded brain bank in Edinburgh as
described in section 2.1. Fifty-three patients were selected randomly for this trial,
including 43 patients who died of AIDS-related illness and 10 patients who died
before the onset of AIDS. Tissue blocks were taken, if available, from colon, ileum,
kidney, liver, LN, left frontal lobe of brain, lung, spleen, and thymus from each
study subject, and processed following the standard procedure as described in
section 2.2. The selection of tissue blocks was more restricted in pre-AIDS cases
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which were generally fiscal autopsies. Clinical information for each patient is
briefly summarised in Table 4. 2.
4.3 Immunohistochemistry Investigations
4.3.1 Using TSA Enhancing Technique in Detecting HIV-1 p24 Antigen in
Various Organs
At least two serial sections were taken from each tissue block following the
standard procedure as described in section 2.5. The screening detection of p24
antigen was carried out following the TSA technique with optimised conditions. To
avoid mis-reading a false positive pattern, one of the two serial sections was not
exposed to the anti-HIV-1 p24 antibody, and this served as a negative reference for
the sequential section. Additional positive control using a block of blown HIV-1
p24 positive tissue, and negative control that using normal brain cortex tissue from
the non-HIV-positive individual were required for each run of experimental
staining.
4.3.2 Analysis of Cellular Localisation of HIV-1 Infection
Tissue blocks that showed p24 immunopositivity were selected for
investigating the cellular localisation by double-labeling IHC or serial staining with
anti-p24 antibody and various cell markers. At least 6 serial sections were taken
from each block and staining for various cell markers was undertaken as described
in Table 4. 1.
Generally, antibodies for T cells (CD3 and CD8), macrophages and brain
microglia (PG-M1), B cells (L26), and follicle dendritic cells (CD21) were used.
Any p24 positive cells that were not recognised by the cell markers listed above
were stained using other cell markers, such as GFAP (for astrocyte), depending on
the observed morphology.
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Table 4. 1. Working plan of immunocytochemistry on serial sections for the
investigation of HIV-1 cellular localisation.
No. Antibody Target
1 L26 (CD20) Reacts with the majority of B cells
2 CD21
A restricted B cell antigen expressed on mature B cells. This antibody shows
strong labelling of FDC in paraffin sections.
3 P24 HIV-1 p24 antigen
4 PG-M1 (CD68) Macrophage lineage, including Brain microglial cells
5 CD3 Majority of T cells
6 CD8 Cytotoxic/suppressor CD8 T cell subset
* Details of working conditions for each antibody were listed in section 2.5
4.3.3 Investigations of in vivo Distribution of CXCR4 and CCR5 Receptors
Staining with co-receptor antibodies proved unpredictable unless fixation time
was short. Therefore short-fixed samples from nine recent cases were used for
investigating the general distribution of CXCR4 and CCR5 co-receptors. At least
three sections were taken from each tissue block, and stained with CXCR4, CCR5
and normal blocking serum (as a negative control) respectively using the ABC
technique.
4.4 Results and Discussion
Evidence of HIV-1 replication in each tissue was demonstrated by
immunocytochemical staining for p24 antigen. The application of the TSA
technique gave a great enhancement in p24 antigen detection in various organs.
Especially in formalin-fixed, paraffin-embedded non-lymphoid tissues, such as
lung, liver and kidney, which were previously p24 negative, weak but positive
signals were detected while using the TSA technique.
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Key for Table 4. 2:
a: Risk Groups: PDM — pre-AIDS Drug Misuser; ADM — AIDS Drug Misuser
PH — pre-AIDS Homosexual; AH — AIDS Homosexual
P-Hetero — pre-AIDS heterosexual; A-Hetero — AIDS heterosexual
A-Btrans — AIDS blood transmission; A-Haem — AIDS haemophilia
b: Drug Therapy: 0 — None
1 — Less than 6 weeks AZT in total
2 — More than 6 weeks but not in last year of life
3 — More than 6 weeks within one year of death
N/A — not available
c: Cognitive Impairment: Cognitive function has been described using a range of
neuropsychological measures, including an estimate of premorbid IQ, measures of performance
speed, current intellectual function, memory and mood. A neurophysiological test, the auditory
event-related potential test, was also used to determine the onset of a subcortical dementing
process. This test offers a non-specific physiological assessment of cognitive function,
sensitive to the effect of subtle early brain disease, which has been shown to be abnormal in
latency and amplitude in individuals with cortical and subcortical dementias. Depending on the
results of sequential tests, patients were assessed as having normal cognitive function or as
having mild, moderate or severe impairment if the auditory event-related potential was delayed
at least 2 SD from the mean (summarised from Bell et al, 1998).




LF — Left frontal lobe of brain
LI — Liver




SA — Salivary Gland
SP — Spleen
TY — Thymus
e: IHC results: 0: p24 negative; 1: p24 weakly positive
2: p24 intermediately positive; 3: p24 strongly positive
f: The number of tissue blocks examined from each organ is indicated in brackets.
Shaded area: pre-AIDS patients
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Table 4. 2. The results of p24 TSA detection in a variety of organs in 53 HIV-





























48/F 703 None 0 SP: 0 (xl)
LN: 3 (x4); 1 (xl)






40/M 496 None 0 SP: 3 (xl)
93-094
PDM
31/M 425 None 0 SP: 1 (xl)
98-025
P-Hetero
43/M 297 None 0 SP: 3 (xl); 1 (xl)
LN: 3(x8); 1 (xl);
0 (xl)
LU: 1 (xl); 0 (xl)





























29/F 150 None 0 LN: 1 (xl); 0 (xl)
LF: 0 (xl)
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Table 4. 2. The results of p24 TSA detection in a variety of organs in 53 HIV-












49/F 137 Severe 2 SP: 3 (xl)
LN: 3 (xl)






















34/M 80 Severe 1 SP: 2 (xl)



















27/F 67 None 1 SP: 1 (x2)


















32/F 28 Mild 2 SP: 1 (x2)
LN: 1 (x3)
LU: 1 (x2); 0 (x3)
CO: 0 (xl)
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Table 4. 2. The results of p24 TSA detection in a variety of organs in 53 HIV-














94-286 45/M 23 None 0 SP: 0(xl)
ADM LI: 0 (xl)
LF: 0 (xl)
96-267 36/F 23 None 2 SP: 0 (x2)






93-087 38/M 22 None 2 SP: 1 (xl)






95-108 52/F 22 Severe 3 SP: 3 (xl)





94-186 41/M 19 Mild 2 SP: 0(xl)
ADM LF: 0 (xl)
96-013 35/M 18 None 0 SP: 0 (x2)






97-017 32/M 16 None 3 SP: 0(xl)




91-420 27/F 12 None 1 SP: 1 (xl)








Table 4. 2. The results of p24 TSA detection in a variety of organs in 53







































30/M 4 Moderate 0 SP: 2 (xl)







29/M 3 Mild 2 SP: 3 (xl)








TY: 1 (xl); 0 (xl)
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32/M 2 Mild 2 SP: 1 (xl)





Table 4. 2. The results of p24 TSA detection in a variety of organs in 53 HIV-



















32/M 1 Mild 0 SP: 3 (xl)
LN: 1 (xl)
















22/M 0 None N/A SP: 1 (xl); 0 (xl)
LN: 1 (x3); 0 (xl)










49/M 0 Mild 0 SP: 1 (xl)








TY: 1 (xl); 0 (x2)
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This immunohistochemistry study demonstrated a close association between
p24 detection in brain tissue and advanced disease, although this kind of
association was not observed within LN and spleen, which were positive at all
stages of infection. In summary, during the clinically latent stage, p24 signal was
often detected within lymphoid organs and occasionally in lung and colon sections;
once advanced to the symptomatic stage, p24 signal was detected within a wider
range of organs, including LN, spleen, lung, intestine, liver, kidney and brain
(Table 4. 2 & Table 4. 3).
Table 4. 3. Summary of the HIV-1 p24 antigen detection in various organs
Pre-AIDS AIDS
No. of positive /No. of tested
(%)*
No. of positive /No. of tested (%)*
Spleen 8/12(67%) 33/51 (65%)
Lymph Node 20/24 (83%) 43/75 (57%)
Lung 3/8 (38%) 14/59(24%)
Ileum N/A 1/16(6%)
Colon 2/13 (15%) 2/25 (8%)
Left Frontal Block 1/7(14%) 10/23 (43%)
Liver 0/2 (0) 1/13 (8%)
Kidney N/A 2/11 (18%)
Thymus 1/2 (50%) 4/19(26%)
Salivary Gland N/A 1/4 (25%)
Muscle + Bv** 0/3 (0) 1/4 (25%)
Pancreas 0/1 (0) 0/2 (0)
* Number was counted according to the tissue blocks, not by patients
** Bv: blood vessel
N/A: Not Available
4-15
4.4.1 Cellular Localisation and General Distribution of HIV-1 p24 Antigen in
the Lymphoid Organs
Lymph Node and Spleen
In this study, immunohistology revealed the presence of p24 positive signal in
LN and spleen sections throughout the course of infection, even in recently
deceased individuals who had received effective trial suppression therapy (Table 4.
2, Table 4. 3 & Table 4. 4). The staining pattern of HIV-1 p24 was characterized by
strong cytoplasmic granular staining. The majority of p24 immunopositive cells in
spleen and LN sections were observed primarily in germinal centres of lymphoid
follicles. Only in a few instances, p24 positive cells were present in the paracortical
area.
The level of p24 staining intensity varied between and within individuals
(Figure 4. 1), however, the difference neither correlated with risk group nor with
AIDS-related illness (Table 4. 2 & Table 4. 4). For example, varying intensity and
positivity of p24 staining was detected and distributed evenly in the spleen and LN
sections taken from pre-symptomatic and symptomatic in the drug misuser risk
group. In each risk group, there existed patients who were p24 negative in
lymphoid tissue, and also, there were sections that stained p24 strongly positive.
One interesting finding is that the intensity of p24 staining was slightly correlated
with last CD4+ cell counts (Spearman rank correlation coefficient 0.8 (LN) & 0.4
(spleen); Table 4. 5). Most sections from patients with higher CD4+ cell counts
present a higher level of p24 positivity, and sections from those whose last CD4+
cell counts were zero were usually p24 negative. In general, relatively normal
histology, or follicular hyperplasia, was observed in these spleen and LN sections
taken from individuals with higher CD4+ cell counts, usually from pre-
symptomatic individuals. When patients advanced to the symptomatic stage, the
CD4+ cell counts decreased, and most cases were reported to show atrophy and
severe lymphocyte depletion in LNs and spleen. Because the HIV-1 p24 positive
signal was localised in the germinal centres of follicles, the destruction of follicles
therefore resulted in reduced p24 positivity within sections taken from symptomatic
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individuals, and this could explain the correlation observed between last CD4+
counts and the intensity of p24 immunopositivity. However, not all germinal
centres in a section were equally affected. Generally, in a section, the level of the
germinal centre destruction, and the intensity of p24 staining varied from follicle to
follicle (Figure 4. 1).
Table 4. 4. Comparison of the p24 staining positivity and the risk group in












No. of positive No. of positive No. of positive No. of positive







































* positive cases / total examined cases of spleen/LN from pre-AIDS individuals
** positive cases / total examined cases of spleen/LN from AIDS individuals
Table 4. 5. The correlation between p24 immunopositivity and the CD4
counts at death in LN and Spleen.
Score 0 Score 1 Score 2 Score 3 Spearman rank correlation
coefficient
CD4 counts* in Spleen 57.4 95.6 28.6 126.18 0.4
CD4 counts in LN 43.53 83.52 269.5 236.23 0.8
* the average of CD4+ cell counts in each range
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Figure 4. 1. The detection of HIV-1 p24 in LN and spleen. In general, p24
immunopositivity is localised in the germinal centres of lymphoid follicles. The staining
pattern is characterised by strong cytoplasmic granular staining. The level of p24
staining intensity varied between and within individuals. (DAB with haematoxylin
counter stain. Magnification: x25 (A-D); x50 (E); x200(F)).
(A): LN section from pre-AIDS drug misuser
(B): LN section from AIDS drug misuser with lymphocyte depletion
(C) & (D): Two different areas from one spleen section taken from AIDS
heterosexual individual. A high level of p24 positivity in view (C), but only
few cells stained (with indicators) in view (D).
(E): LN section with pre-AIDS drug misuser with lymphocyte depletion
(F): A representative p24 staining pattern, usually cytoplasmic granular




Lymphoid organs are the anatomic sites where the generation and propagation
of antigen-specific immune responses occur (Pantaleo et al., 1993b; Pantaleo et al.,
1994). During acute infection, peripheral antigen-activated T lymphocytes
(predominantly CD4+ cells) or other antigen presenting cells (APC) migrate from
the circulation and the lymphatics into the interface between the paracortex (T-cell
zone) and the germinal center (B-cell zone) in order to provide help for the
generation of antigen-specific B-cell responses against HIV (Pantaleo et al., 1993b;
Pantaleo et al., 1994). There are various cell populations in the spleens and LNs,
including B and T lymphocytes, macrophages, interdigitating cells and FDCs.
Some of these resident cells, such as CD4+ T lymphocytes, macrophages,
interdigitating cells are susceptible to HIV-1 infection (Embretson et al., 1993a;
Pantaleo et al., 1994; Mcllroy et al., 1996; Reinhart et al., 1997; Patterson et al.,
1998; Soontornniyomkij et al., 1998). However, in this study, the viral reproductive
signal was found primarily in the germinal centres of lymphoid follicles. Germinal
centers contain resting B cells clustered around a dense network of processes
extending from follicular dendritic cells, and a few macrophages. Most of the p24
positive signals in the germinal centres co-localised with large mononucleated or
binucleated cells with elaborate cytoplasmic extensions. According to the staining
results of serial sections, the pattern of p24 staining was similar to the FDC
network shown by anti-CD21 (Dako) staining, which is well suited for detection of
FDCs in formalin-fixed paraffin-embedded tissues (Figure 4. 2). Later using a
double-immunolabelling technique, p24 and CD21 staining patterns could be
evaluated simultaneously (Figure 4. 2). In contrast to the p24 staining of varying
frequency which was readily shown in the germinal centres in almost all specimens,
isolated p24 positive cells were rarely observed elsewhere in sections. For example,
in the T-cell-dependent areas of spleen and LN sections, which stained intensely for
CD3 and CD8, limited CD3-positive cells were double-stained with anti-p24 mAb,
but no co-localisating signal was observed between CD8 and p24 (Figure 4. 3).
Although CD4 detection was not successful in this study (refer to section 2.6.4.1),
the rare observation of p24 positive cells outside the germinal centres suggested an
infrequent productive infection of T lymphocytes and macrophages.
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Figure 4. 2. A panel of serial sections of lymph node stained with p24, CD21, CD3,
PGM1, CD8 and L26 demonstrating the staining pattern of p24 is similar to the
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Fig. 4.2
Figure 4. 3. Double immunolabelling staining for p24/CD21, p24/CD8 and
p24/CD3 in LN section.
Top: p24 positivity (Vector Blue) is colocalised with CD21 positivity (DAB).
(Magnificant: left: x200, right: xlOO).
Middle: p24 positivity (DAB) is infrequently observed within CD3 positive
cells (Vector Blue) (with indicators). (Magnification: left: x400; right:
x200).
Bottom: No colocalisation was observed between p24 (DAB) and CD8
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Unlike the bone-marrow derived dendritic cells that present peptide antigens
to CD4+ T lymphocytes and comprise a system that occupies discrete portions of
non-lymphoid and lymphoid organs (Knight, 1996), FDCs do not express MHC
class II molecules and are found only in the germinal centres of lymphoid follicles
in the LN, spleen and mucosa-associated lymphoid tissues (Abbas et al., 1999).
Basically, FDCs express high-affinity receptors for complement proteins and for
the Fc regions of IgG molecules, therefore they are able to capture intact virus
particles or viral antigens in antigen-antibody complexes on their surfaces soon
after seroconversion (Abbas et al., 1999). Antigens or intact virus particles can
persist in this form of immune complexes for long periods (Janeway & Travers,
1996). Whether FDCs are infected in vivo with HIV-1 or merely have FIIV-1
trapped on their surfaces as immune complexes has not been resolved. Several
studies have found evidence of in vivo productive infection of FDCs, such as virus
particles budding from FDC membrane (Armstrong & Home, 1984; reviewed in
Tenner-Racz et al., 1994), HIV-1 envelope messenger RNA detected in FDCs, and
HIV-1 RNA detected in FDC perinuclear cytoplasm (Spiegel et al., 1992; reviewed
in Levy, 1998). However, most investigators believed that HIV particles were
trapped on the villus processes of FDCs as immune complexes (virus:complement-
antibody complexes) and that the cells were not infected (Pantaleo et al., 1993a;
Embretson et al., 1993a; Schmitz et al., 1994; Tenner-Racz et al., 1994; Tsunoda et
al., 1996; Orenstein et al., 1997b; Reinhart et al., 1997). In my study, a non¬
uniform immunostaining for HIV-1 p24 was observed in all LN and spleen sections
and this observation is similar to that of Soontornniyomkij et al., who used double
immuno fluorescent staining followed by confocal microscopy for HIV-1 p24
detection (Soontornniyomkij et al., 1998). In general, within a section, some
follicles were found to be heavily stained but adjacent follicles were negative.
Soontomniyomkij et al. concluded that such a non-uniform staining pattern,
together with the observed intimate colocalisation of p24 and CD21, gave evidence
that FDCs could be infected and could express p24 in their cellular processes, and
did not support the hypothesis that HIV-1 was bound to FDCs surface as
extracellular antibody-coated complexes. In that regard, a rather uniform
involvement of all follicles within an individual lymphoid structure would be
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predicted. Nevertheless, using an immunostaining technique alone, it is difficult to
state whether or not FDCs are productively infected.
The observation that high levels of p24 immunopositivity were persistently
confined within the FDCs in the LN and spleen from presymptomatic and
symptomatic subjects is similar to previous reports, which used different
methodologies to detect productive signal in LNs from various stages of disease
(Pantaleo et al., 1993a; Pantaleo et al., 1993b; Embretson et al., 1993a; Haase et
al., 1996; Blauvelt et al., 1997; Pantaleo et al., 1998), and these FDC-entrapped
virus were highly infectious (Heath et al., 1995). These observations suggest that
HIV infection is active and progressive in lymphoid tissues throughout the course
of HIV infection (Haase et al., 1996; Blauvelt et al., 1997; Pantaleo et al., 1998).
Although it is difficult to determine whether FDCs are capable of being infected
whether or not the infection is rare or inefficient, it is believed that these cells do
play an essential role in HIV-1 pathogenesis. Clinically, a common finding in end-
stage disease is that the lymphoid organs lose their normal architecture owing to the
slow but persistent destruction of CD4+ cells and FDCs (Rosok et al., 1997;
Pantaleo et al., 1998). A loss of FDC might reduce efficient antigen presentation
and the ability of the host to generate strong antiviral immune responses with
consequent risk of severe diseases (Knight, 1996). The cause of the degeneration
and death of FDCs is not yet clear, which could be a cytopathic effect of HIV-1 or
T-cell-mediated cytotoxicity (Gray et al., 1996; Esser et al., 1998). Nevertheless, it
is believed that releasing virus from intercellular trapping in the FDC network or
producing virus from infected cells could be a continuing source of infection
(Pantaleo et al., 1993a; Pantaleo et al., 1993c; Pantaleo et al., 1995; Haase et al.,
1996; Reinhart et al., 1997). Recent studies have found that FDC-entrapped virions
are not affected by antiretroviral therapy (Haase et al., 1996; Pantaleo et al., 1998).
Even using a combination regimen, the effects are limited (Montaner et al., 1998b;
Orenstein et al., 1999b). Thus, FDCs have been though to be a reservoir for HIV-1,
so that on progress to the symptomatic stage of disease, the persistent FDC-
entrapped viruses released because of the disruption of the FDC network, and then
transmitted to surrounding CD4+ cells, or released into the circulation leads to the
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rapid HIV-1 viremia rebound observed after the interruption ofHAART (Orenstein
et al., 1999b). In this regard, the development of new therapeutic strategies should
focus more on these cells.
Thymus
Most of the thymus sections showed considerable thymic atrophy and severe
lymphocyte depletion. In one section taken from a pre-symptomatic individual
(NA97097), lymphofollicular hyperplasia was observed. Using the enhancing TSA
technique, HIV-1 p24 antigen was detected in five of twenty-one blocks, four
blocks taken from AIDS cases and one from a pre-AIDS individual. The intensity
of p24 immunopositivity observed in the four sections taken from symptomatic
stages was very low. P24 signal was only detected in a few scattered cells, in which
p24 immunostaining overlapped CD3 positivity and morphologically the positive
cells appeared to be lymphocytes. In the section taken from the pre-symptomatic
stage, p24 positive cells were observed in the lymphoid follicles. The staining
pattern, similar to the LN and spleen, was reticular and irregular suggesting the
labeling of the follicular dendritic cells and their cytoplasmic processes. It was
confirmed later in a serial staining with various cell surface markers that these p24
positive cells were found much closer to CD21 positive cells, although the CD21
staining is weak. Also, various degrees of B-lymphocyte infiltration were observed
in these p24-positive sections, especially in the one with lymphofollicular
hyperplasia.
As the primary site of T-lymphocyte development during ontogeny, the
thymus is another important area of study in HIV-1 infection. It has been proposed
that the thymus could be the earliest target tissue infected by HIV-1 (Aldrovandi et
al., 1993). In one study, loss ofprecursor T cells and destruction of lymphoid tissue
structure have been observed while directly infecting the human fetal thymus with
HIV-1 in SCID-hu mice (Aldrovandi et al., 1993; Bonyhadi et al., 1993). Their
result suggested that, in addition to the gradual disruption of the lymphoid
microenvironment, direct impairment of stem cells and early T lymphocyte
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precursors in the thymus may also lead to the progressive decrease or dysfunction
in CD4+ T lymphocytes (Aldrovandi et al., 1993; Bonyhadi et al., 1993; Calabro et
al., 1995; reviewed in Gaulton et al., 1997). Most infected cells detected in the
thymus were of the early precursor type (Valentin et al., 1994; Gaulton et al.,
1997). Several in vitro studies disclosed that intrathymic T cell precursors are
readily infected by HIV-1, and that double positive (CD4+CD8+) cortical
thymocytes, and the major thymic cell subsets are permissive to HIV-1 infection
and replication (Valentin et al., 1994; Calabro et al., 1995; Gaulton et al., 1997).
Direct evidence of in vivo thymic infection was rarely documented, despite the
thymic involution observed in autopsy specimens from AIDS individuals,
especially in studies of paediatric patients (reivewed in Gaulton et al., 1997).
It is known that the thymus is essential for formation of the T-lymphocyte
repertoire during ontogeny. In contrast to fetal life, healthy children, adolescents
and adults rely primarily on peripheral, thymic-independent pathways to replenish
the daily turnover ofmature T cells (Gaulton et al., 1997). Children and adolescents
may go back to regenerate a thymic-dependent functional immune repertoire under
conditions of extreme immune cell depletion, but adults display a reduced capacity
for T-cell regeneration overall (Gaulton et al., 1997). There is no evidence that
adults can reactivate thymic-dependent pathways of T-cell maturation even under
extreme demand. However, the few instances in this study presenting p24
immunopositivity in the thymus gave direct evidence of thymic HIV-1 infection
and suggested that follicular dendritic cells were also involved in HIV-1 infection
in the thymus. Strong p24 positivity detected in a pre-symptomatic individual
suggests that viral entry to thymus could occur at the early stage in HIV-1
infection. Whether thymic infection could lead to more rapid disease progression or
serve only as a virus reservoir, needs further investigation.
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P24 PGM1
Figure 4. 4. Serial staining (p24, PGM1, CD3, L26) in thymus sections taken
from a presymptomatic subject (DAB with haematoxylin counter stain.
Magnification: xlOO). The staining pattern of p24 mAb is granular and
cytoplasmic, which is similar to CD21 staining pattern (data not shown).
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4.4.2 Cellular Localisation and General Distribution of HIV-1 p24 Antigen in
the Brain Tissue
The detection of HIV-1 p24 immunopositivity in the brain is strongly
correlated with the stage of disease. HIV-1 p24 was detected in 11 study subjects,
of whom one was pre-symptomatic and ten were symptomatic patients (Table 4. 2).
The ten sections taken from symptomatic subjects showing p24 immunopositivity
were defined as having HIV-encephalitis (HIVE). Seven of the ten symptomatic
individuals who showed p24 positivity in the brain had severe cognitive
impairment. HIVE has been confirmed as a major HIV-related neuropathology in
AIDS brains in the Edinburgh cohort (An et al, 1996; Bell et al., 1996a; Price et al.,
1996; reviewed in Bell, 1998), and is usually found in patients with severe AIDS
related dementia (ARD). Besides severe immunosuppression and other clinical
syndromes, many untreated HIV-1-infected individuals develop ARD, which may
involve not only cognitive dysfunction, but also motor difficulties, coordination
abnormalities and other neurological signs and symptoms (Bagasra et al., 1996;
Price et al., 1996; reviewed in Bell, 1998). A close association between HIV-1
productive infection and HIVE has been established, although less so with ARD.
However, details of molecular mechanisms involved in these HIV-1-induced
dysfunctions of the CNS remain unclear.
The major HIV-1 infected cell population in the brain is the
monocyte/macrophage lineage with little or no lymphocyte involvement in AIDS.
This observation is different from those in the other organs, in which the p24
positive cells are usually associated with lymphoid follicles. In the brain frontal
lobe sections, p24 was detected primarily in mutinucleated giant cells (MGCs),
perivascular mononuclear macrophages and microglial cells, all of which could be
double-stained with PGM1 (anti-CD68 mAb), a macrophage marker. The staining
is granular and cytoplasmic, and is present not only in cell bodies but also in the
processes of microglial cells (Figure 4. 5).
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Figure 4. 5. General p24 staining patterns (DAB with haematoxylin counter
stain) and double-labelling with microglial cells (DAB for p24 and Vector
Red for PGM1 with haematoxylin counter stain) in the brain tissue in low
magnification (x25, A to D) and in high magnification (x200, E & F; x400,
G to I).
♦ General p24 staining pattern in grey matter A & E and in white matter B & F.
♦ P24 (brown) double-stained with PGM1 (red) in grey matter C and in white
matter D. Most of the p24 positive cells were double-stained with PGM1, but
some microglial cells remained p24 negative (as indicated with arrows).
♦ MGC was observed in G & I (indicated with arrow).
♦ Typical p24 staining in microglial cell H.
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Fig. 4.5
Most of the HIV-1-infected microglial cells, macrophages, and some of the
MGCs are concentrated in perivascular areas (Figure 4. 5). These findings, similar
to those in previous studies (Gartner et al., 1986; Wiley et al., 1986; Sinclair et al.,
1994; Bagasra et al., 1996; Gray et al., 1996; Ghorpade et al., 1998; reviewed in
Bell, 1998), suggest that microglial cells are the major cell type to harbor the virus
in the CNS.
Microglia comprise between 5 and 20 % of the total glial cell population, and
form a network of rather uniformly shaped and sized cells in which each cell
occupies its' defined territory (Graeber & Streit, 1990). Due to the great mutability
of microglial morphology and immunophenotype, their nature as intrinsic CNS
macrophage precursors has long been controversial (Graeber & Streit, 1990).
Infection with HIV-1 in these cells causes a productive and cytopathic effect, and
may lead to the release of several viral proteins, cytotoxic cytokines or other
neurotoxic moieties from infected microglia and brain macrophages resulting in
neuropathological abnormalities. Some investigators hypothesised that these
neurotoxins or virotoxins, which released from infected cells will reactivate glial
cells to release a number of soluble factors that are either toxic to neurons or cause
chemotaxis of monocytes into brain (Nath, 1999). As the glial cells outnumber the
neurons by 10 in 1, this is an important mechanism by which the virotoxins amplify
their toxic potential and initiate a self-perpetuating cascade of events, resulting in a
"domino effect" on the brain (Nath, 1999). However, the exact mechanisms need
further investigation.
Cells of neuroectodermal origin, such as oligodendrocytes, astrocytes and
neurons have been found could probably be infected with HIV-1 (Li et al., 1990;
Esiri et al., 1991; Zauli et al., 1993; Nuovo et al., 1994; Tornatore et al., 1994;
Bagasra et al., 1996; Strappe et al., 1998; Brack-Werner, 1999; Hao & Lyman,
1999). No evidence of p24 positivity was observed within cells of neuroectodermal
origin in this study except the observation in one case, patient 86-130 that HIV-1
p24 positive cells were double-stained with GFAP, a cell marker for astrocytes.
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Figure 4. 6. Special event of p24 positivity within Astrocytes in brain tissue.
(Vector Blue for p24, and DAB for astrocytes without counter stain.
Magnification: x50 in A & B, x200 in C to H, and x400 in I & J).
♦ A portion of astrocytes in these sections was double-stained with HIV-1 p24
mAb (panel C to E), although some of them remained p24 negative (as
indicated with arrows in J).
♦ Most of the p24 immunopositivity was not colocalised with astrocytes (as
indicated with arrows in panel F to H), but morphologically to be microglia.
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Fig. 4.6
Astrocytes are the most abundant cell type in the CNS forming a complex
network which provides essential metabolites for neurons, and function to regulate
K+ ion and neurotransmitter concentrations in the neuronal extracellular milieu, and
which maintains physiological barriers between the brain parenchyma and the
blood or cerebrospinal fluid (CSF) (Brack-Werner, 1999). In general, direct CNS
infection with HIV results in a reactive astrocytosis (Brack-Werner, 1999). Much
work has been done to investigate the complex role the astrocyte seems to play in
HIV infection. As we know, microglial and multinucleated giant cells are
productively infected with virus during HIVE, and these infected cells produce high
levels of cytokines (Nottet et al., 1995) such as Tissue Necrosis Factor-oc (TNF-a)
and Platelet Activating Factor (PAF) both thought to be neurotoxic (Gelbard et al.,
1994). It has been postulated that released cytokines or viral protein (gpl20) leads
to the activation of surrounding astrocytes resulting in reactive astrogliosis (Epstein
& Gendelman, 1993; Benos et al., 1994), and this would cause the outflow of K+
and glutamate from the astrocyte leading to neuronal damage and loss which has
been demonstrated in AIDS brains (Brack-Werner, 1999). Some studies have
demonstrated that astroctyes could be infected occasionally by HIV-1 (Nuovo et al.,
1994; Saito et al., 1994; Tornatore et al., 1994; Brack-Werner, 1999; Nath, 1999),
but the infection is silent (Ranki et al., 1995; Bagasra et al., 1996; Nath, 1999).
Previous work in paediatric AIDS brains has demonstrated that some astrocytes are
persistently infected with HIV-1 such that HIV-1 early gene products, tat, rev and
nef are produced but structural viral proteins are not (Saito et al., 1994). However
such findings are not observed in the adult CNS. In this regard, and with the
unexpected result found in this study, the infection status of astrocytes should be re¬
examined more carefully.
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Productive HIV-1 replication in the CNS is believed to occur only at a very
low level in the asymptomatic stage, although by using the PCR technique, HIV-1
proviral DNA was occasionally detected in brain tissue in asymptomatic patients
(Sinclair et al., 1992; Sinclair et al., 1994; An et al., 1996). Similar to the previous
studies (Gray et al., 1992; Bell et al., 1993; reviewed in Bell, 1998), the only
salient neuropathology present in the pre-AIDS subjects was a significant T-
lymphocytic infiltration, most often CD8+ cells, in the meningeal and perivascular
areas of brain tissues. The raised lymphocyte numbers in the pre-symptomatic HIV-
1 positive patients might represent an immune response to early invasion of the
CNS by HIV-1. Some studies have found that CD8+ lymphocytes are vulnerable to
HIV-1 infection in lung and peripheral circulation (Sadat-Sowti et al., 1994; Bofill
et al., 1995; Semenzato et al., 1995; Livingston et al., 1996). However, no HIV-1
p24 antigen was detected in these areas or in the brain tissue during the clinically
latent stage, apart from one particular case, subject NA97097, who showed focal
p24 positivity in the meningeal lymphocyte infiltration, and the positive cells were
confirmed as CD8+ lymphocytes. According to previous studies, HIV does not
enter the CNS in a cell free form but rather as a proviral form within an infected
cell (Achim et al., 1991). The most likely candidate for the "trojan horse" (Peluso
et al., 1985) that carries HIV into the brain is the blood-derived
monocyte/macrophage, whereas virus expressing lymphocytes were not observed
within the brain (Achim et al., 1991). This unique case that was observed in this
study appears to challenge this previous hypothesis. These infiltrating T-
lymphocytes did provide some evidence that they might also serve as a carrier of
virus into brain tissue. But, again this is a rare event and would require further
study in seeking replication of this observation.
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Figure 4. 7. P24 immunopositivity was observed in CD8-lymphocytic
infiltration area in brain tissue in one particular pre-symptomatic subject
(DAB with haematoxylin counter stain. Magnification: x400 (a), xlOO (b) &
(c), x50 (d) & (e)).
♦ A typical p24 staining pattern was observed in the meningeal areas with
CD8+ lymphocytic infiltration (panel (a) & (c) demonstrated p24 staining, (b)
demonstrated CD8 immunopositivity). Cytoplasmic staining was observed
within most of the cells (panel (a), as indicated with arrows).
♦ CD8+ lymphocytic infiltration is an often event within pre-symptomatic
individuals in meningeal (b) and perivascular (d) areas. In general, these areas
within lymphocytic infiltration were p24 negative (e).
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Fig. 4.7
4.4.3 Cellular Localisation and General Distribution of HIV-1 p24 antigen in
the Lung Tissue
AIDS-related respiratory diseases have often been reported and usually as the
cause of death through bacterial and opportunistic infections. The lung has been
reported to be a central organ in HIV-infection, becoming infected perhaps during
the asymptomatic period of the disease (Agostini et al., 1996). In general, alveolar
macrophages and monocytes within the lung parenchyma and dendritic cells within
the airway epithelium are potential APCs, which, together with T lymphocytes,
provide the lung with its defense against certain opportunistic and non-
opportunistic infections. Pathological examination of the lungs from HIV-1
infected individuals revealed prominent lymphocytic infiltration in lung tissue and
formation of lymphoid follicles adjacent to bronchioles.
Previously using PCR technique or in cell culture studies suggested that the
majority of lung infections with HIV-1 was in pulmonary macrophages, CD4+ and
CD8+ lymphocytes (Agostini et al., 1995; Clarke et al., 1995; Semenzato et al.,
1995; reviewed in Agostini et al., 1996). However in this cohort study, HIV-1 p24
antigen detection was restricted to lymphoid follicles and most of the p24 positive
cells were morphologically mononucleated. In these follicles that showed p24
immunopostitivity, CD3 and CD68 positive cells were stained and distributed
homogeneously, and CD20 positive cells were generally identified around the edge
of these follicles. P24 positive cells were morphologically lymphocytes and
macrophages. Not all but some mononucleated cells in these areas showed CD21
positivity, and if CD21 could be detected, its staining pattern generally fits the
staining pattern of p24 well. Only in one particular case NA91246, a large number
of infected multinucleated giant cells, which double-stained with anti-p24 mAb and
the PGM1 marker, was observed. Interestingly, no other p24 immunopositivity was
detected in other lung blocks taken from this patient, although high levels of
macrophage infiltration were also observed. Since most of the studies demonstrated
that alveolar macrophages were infected latently (reviewed in Agostini et al., 1995),
this case provides the evidence of productive infection within cells of macrophage
lineage in lung tissue.
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Figure 4. 8. P24 staining patterns in the lung tissue from different study
subjects.
♦ In general, p24 immunopositivity was colocalised in the lymphcytic follicles (A to E).
The staining pattern is similar to that in LN organs (DAB with haematoxylin couter stain
A to E. Magnification: x50, A to C; xlOO, D; x200, E).
♦ A high level of macrophage infiltration and HIV-1 infected MGCs were observed in one
particular case (F to J), which was demonstrated by double immuno-labelling technique.
(DAB for p24 and Vector Red for PGM1 with haematoxylin counter stain. Magnification:
x200, F & G; xlOO, H to J). However, another section taken from the same subject was
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It is difficult to precisely identify the host range of p24 positive cells in lung
sections using immunostaining techniques. At present, double-immunolabelling
technique was not entirely successful in this tissue. High background and confusing
signals highlighted the difficulties of result interpretation. Moreover, in some
sections that showed a relatively lower level of p24 positivity, p24 antigen could be
detected in one level of the block but further sections generally showed loss of the
lymphocytic infiltrated structure, or the p24 immunopositivity disappeared
suggesting this was a highly focal event.
4.4.4 Cellular Localisation and General Distribution of HIV-1 p24 Antigen in
the Gastrointestinal Tract and Other Organs
HIV-1 proviral DNA has been detected in bowel using PCR technique (Kolter
et al., 1991; Donaldson et al., 1994a; van der Hoek et al., 1998), but the p24
positivity in the gut was not often reported. Previous studies have demonstrated that
lamina propria might be the major site for HIV infection, most probably in infected
macrophages (Kotler et al., 1991; Smith et al., 1997), perhaps because very few
CD4+ lymphocytes are present in the GI at the time of bowel symptoms. The
frequency of p24 TSA positivity in the present study was relatively low. In this
screening detection, the HIV-1 p24 positive staining pattern in gut was similar to
that in the lung. HIV-1 p24 antigen was detected rarely, but was restricted to
lymphocytic follicles in the bowel. Generally, the p24 positive cells were
morphologically mononuclear. As assessed by serial section staining, the p24
positive staining pattern does not match T cells staining, but some of the cells
showing abundant cytoplasm and large nucleus are morphologically macrophages.
Also, similar to the lung section, if any CD21 positivity could be detected, the p24
staining pattern generally colocalised closely with those CD21 positive FDCs.
Moreover, heavy background staining and confusing signal raised by double-
labelling technique disturbed the result reading in this tissue. Thus, the precise
identification of cellular host ofHIV-1 in gut is difficult.
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Figure 4. 9. P24 immunopositivity in the ileum.
♦ Panel A and B demonstrated a serial staining of p24 (A-l), CD21 (A-2), L26
(A-3), PGM1 (A-4) and CD3 (A-5). P24 positive pattern (B-l) was similar
with the CD21 positive patter (B-2), although the intensity of CD21 staining
was low. (DAB with haematoxylin counter stain. Magnification: x50 for panel
A, and xlOO for panel B).
♦ Double immunolabelling of p24 (DAB) and PGM1 (Vector Red)
demonstrating that some of these p24 positive cells were macrophages
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Gastrointestinal dysfunction is prevalent in patients infected with the HIV.
Many enteric diseases occur in patients with the late stage of AIDS (Kotler et al.,
1991; Sharpstone & Gazzard, 1996; Kearney et al., 1999). It has been reported that
the gut-associated lymphoid tissue (GALT) consists of organised lymphoid tissue
(Peyer's patches and solitary lymphoid follicles) as well as large numbers of
activated memory T lymphocytes diffusely distributed throughout both the
intestinal lamina propria and epithelium, and presents as a substantial target for
HIV in all phases of infection (Kraehenbuhl, 1998; Kresina & Mathieson, 1999). A
recent study in the macaque model has reported a massive CD4+ depletion
occurring soon after intravenous simian immunodeficiency virus (SIV) infection
(Veazey et al., 1998). Similar to the infection in LN or spleen, the death of these
HIV-infected cells resulted in the release of viral particles, which were captured by
FDCs as the staining results demonstrated above. These FDC-entrapped viruses
could then represent a source for infection as they did in other organs (Kresina &
Mathieson, 1999). Unlike lymphoid organs, such an event seems not to occur
regularly in the gut, since p24 immunopositivity was not detected often. However,
p24 positivity might also be rare because the gut is such a large organ that
representative tissues were not sampled regularly.
The HIV-1 p24 antigen was also detected occasionally in salivary gland, liver
and kidney, although the frequency was rare and the level of positivity was minor.
AIDS-related liver or kidney disease has rarely been reported. In the liver and
kidney sections, p24 antigen was rarely identified. When present p24 positive
granular staining of occasional cells was restricted to the lymphocyte aggregated
areas. Most of the positive cells in the liver appeared morphologically to be
sinusoidal macrophages, but a few of them had round nuclei and were CD3 positive,
suggesting that they may have been lymphocytes. These few instances of p24
positivity observed in the screening detection in these particular organs could be a
result of wide spread virus in the end stages of disease.
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4.4.5 General Distribution of CXCR4 and CCR5 Receptors in Various
Organs in HIV-1 Infected Individuals
The discovery that infection with HIV required a secondary receptor is an
important advance in recent HIV research. Since the first finding in 1996 that
CD4+ cells with defective CCR5 receptors from highly exposed but uninfected
individuals are resistant to infection with M-tropic isolates (Paxton et al., 1996),
this field has continued to undergo rapid progress. Most of the focus was on the
usage of chemokine receptor and the interaction between viral envelope proteins
and coreceptors (reviewed in Broder & Collman, 1997; Moore, 1997). There were
few articles demonstrated the localisation of HIV-1 co-receptors in the brain (Vallat
et al., 1998; Zhang et al., 1998), intestine (Zhang et al., 1998; Dwinell et al., 1999)
and other tissues (Zhang et al., 1998).
In this study, immunohistochemistry staining was employed to investigate the
general distribution of chemokine receptors, CXCR4 and CCR5. In general, the
staining pattern of both antibodies was diffuse and cytoplasmic, and the distribution
of these two receptors showed overlap. They picked up similar cell populations but
the staining of CXCR4 was more intense than CCR5 in general.
Although these two molecules have been found recently to be co-receptors for
HIV-1 entry, the IHC staining pattern is complicated. Generally, in the brain tissue,
neurons are the only cell type consistently stained (Figure 4. 10). Other cells of
neuroectodermal origin and blood vessel endothelial cells were stained occasionally.
In some brain sections, most of the cells, including microglia, astrocytes and
oligodendrocytes were CXCR4 and CCR5 positive, however, in other sections,
immunopositivity was only observed in neurons. In spleen and LNs, both
antibodies appear to localise in cells with round nuclei and abundant cytoplasm,
which are located scattered outside the follicles. These positive cells are
morphologically of macrophage and lymphocytic appearance. Also, endothelium
cells are occasionally stained. However, none of the cells inside the follicles was
stained.
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Figure 4. 10. Immunohistochemical localisation of CXCR4 (A to F) and
CCR5 (G & H) receptors in the brain tissue (DAB with haematoxylin
counter stain. Magnification: x50, A to C; x200, D to f; xlOO, G & H).
♦ In general, neuron is consistently stained with CXCR4 (A and D) and CCR5
(G).
♦ The staining patterns of cells of neuroectodermal origin were various. In some
cases, most of the cells showed CXCR4 (B & E) and CCR5 (data not shown)




Figure 4. 11. Immunohistochemical localisation of CXCR4 receptor in the
spleen (A & B), lung (C & D) and Ileum (E & F). (DAB with haematoxylin
counter stain. Magnification: xlOO).
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Fig. 4.11
In lungs and intestine, a high level of CXCR4 and CCR5 was visualised in
epithelial cells, blood vessel endothelial cells, tissue macrophages and lymphocytes.
Interestingly, in the lymphoid aggregates or lymphoid follicles where p24 antigen
was generally detected, very low level of CXCR4 nor CCR5 expression was
detected. No correlation was observed between the distribution of CXCR4 and
CCR5, and HIV-1 p24 detection in the present study. However, these staining
results were not quite reproducible. Whether this lack of correlation resulted from
the use of less than optimal antibodies to chemokine receptors or reflects the
likelihood that the in vivo mechanisms are more complex requires further
investigation.
4.4.6 Limitations of The Detection Methods
Although the application of TSA in p24 IHC detection did improve the
staining results, there were still some limitations to the technique. One problem is
the application of the double immunolabelling technique. The purpose of this study
was not only viral detection but also the identification of the cellular host of HIV-1,
and the best technique should be double-labelling. Several technical problems have
occurred while applying this technique, such as different pretreatments required for
the two working antibodies, cross-reaction because of the antibodies raised in the
same species, and also in balancing the intensity of the two positive signals. The
problem of pretreatment was particularly acute when working with CD21 and p24.
CD21 mAb is extremely heat-resistant and requires protease for antigen retrieval,
but p24 could not be stained without heat-pretreatment. Most of the sections failed
to adhere to the slides during staining because of the application of the two strong
antigen retrievals. The serial section assay was applied to resolve this problem, but
the results were difficult to correlate because staining was performed in different
sections. Also, the recombination of the colours in end point detection was a
problem, since most of the time, the two colours were mixed causing confusion in
reading the results. Double immunofluorescence has also been employed. However,
the different antigen retrievals, and cross-reaction between antibodies limited the
4-42
success of this technique.
Sampling is another problem, which has been highlighted in some autopsy
cases. For example, in patient 96-160, two spleen tissue blocks were taken for
examination. One showed strong p24 positive staining, which the other was
completely negative. Further evidence was found in non-lymphoid tissue blocks,
where p24 antigen was detected in the first few sections taken, but as the block was
examined at deeper levels, the p24 positive areas disappeared. Therefore, the
localisation and the level of viral activity in large organs, such as intestine and lung,
were difficult to determine. Some important information might be omitted. Within
these organs, multisampling is indispensable.
Moreover, a problem that might contribute to negative results is tissue fixation,
especially in tissue blocks which had been fixed in formalin for several weeks. As
described in section 3.1, formalin fixation preserved the best morphology for
histological examination; on the other hand, it decreased the sensitivity of IHC
detection. For some antibodies, such as CXCR4 and CCR5 that did not work
consistently, short-fixed samples were required.
Also, the interpretation of negative results is difficult. HIV-1 p24 protein is a
viral structural protein, which is only expressed during productive infection. A
different technique will be required to investigate the frequency and distribution of
latently infected cells. According to other in vitro studies (refer to section 4.1),
HIV-1 is able to infect several different cell lines non-productively without
expression of structural proteins. In addition, the advent of HAART, which has
been found to suppress viral replication in vivo very considerably, might have
predisposed to some negative results found in some recent cases.
To investigate further, frozen tissues from the nine recent autopsies were
subjected to molecular analysis. Details of the molecular information and the basis
for comparison between histopathologic and genetic information is described in
chapter 5.
4-43
Chapter 5: Genetic Characterisation ofHIV-1
Infecting the Lymphoid and non-lymphoid
organs in Different Stages of Infection
5-1
5.1 Introduction
A noticeable feature ofHIV-1 is the extraordinary diversity of the viral genome.
Usually, an HIV-1 infected individual harbours a swarm of closely related but
genetically distinct viruses, which comprise the HIV quasispecies. These HIV-1
variants demonstrate great heterogeneity in their biological properties, such as
syncytium-inducing capacity, replication rate, and cellular tropism (Cheng-Mayer et
ah, 1988; Fenyo et ah, 1988; Tersmette et al.t 1989a; Tersmette et al., 1989b). It is
believed that differences in these properties may contribute to the pathogenesis of
HIV-1 infection.
An apparent redistribution of virus upon disease progression was observed to
occur at the same stage of disease as the change from a non-syncytium-inducing
(NSI) to a syncytium-inducing (SI) phenotype. During the pre-symptomatic stage of
infection, a highly restricted distribution of HIV-1 was confined to cells of the
lymphoid system (Donaldson et al., 1994a). HIV-1 isolates from patients in this
stage were relatively homogeneous, more slowly replicating, preferentially
macrophage-tropic NSI strains (Schuitemaker et al., 1992; Zhu et al., 1993; van't
Wout et al., 1994; Moore, 1997). With the development of symptomatic disease,
proviral DNA was widely recovered from both lymphoid and non-lymphoid organs
(Donaldson et al., 1994a). HIV-1 isolates from these patients who died of
complications associated with AIDS were more likely to be rapidly replicating,
preferentially T cell tropic SI strains (Zhu et al., 1993; Coffin, 1995; Moore, 1997).
Moreover, the emergence of SI variants has been reported to precede a rapid decline
of CD4+ lymphocytes in the peripheral circulation and a more rapid onset of AIDS
(Keet et al., 1993; Koot et al., 1993; Karlsson et al., 1994). Thus, the wide spread of
viruses throughout the body, the switch in virus phenotype from NSI strains to SI
strains, together with CD4+ cell numbers and virus load were thought to be the
important prognostic markers of disease progression.
The possible determinants which governed the SI capacity and cell tropism
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were presumed to lie within the hypervariable regions (VI to V5) of the HIV-1 env
gene, particularly in the V3 region (Shioda et al., 1991; Groenink et al., 1992;
Donaldson et al., 1994b; Broder & Collman, 1997). The V3 domain contains 35
amino acids arranged in a disulfide loop involving Cys301 and Cys336, and serves as
a major target for neutralizing antibodies (LaRosa et al., 1990; Robert-Guroff et al.,
1994). This domain has been presumed to be important for HIV-1 escaping from
antibody neutralization or cytotoxic T cell elimination (LaRosa et al., 1990; Barre-
Sinoussi, 1996) (also refer to section 1.4). Sequence comparisons have demonstrated
considerable diversity in the V3 region. Usually, nonsynonymous nucleotide
substitutions, which resulted in a change of an amino acid, were more frequent than
synonymous ones which did not lead to a change of the amino acid within the V3
domain. Some of these nonsynonymous substitutions might be related to resistance
to neutralization, some might be related to antibody enhancement, and certain amino
acid substitutions in the V3 domain were associated with the appearance of SI virus
strains (Lukashov et al., 1995). For example, analysis of natural variants of HIV-1
indicated that basic amino acids in one or more of positions 11, 24, 25 and 32 (from
the first cysteine) confer a SI phenotype, whereas neutral or negatively charged
amino acids in these positions correspond with a NSI phenotype (Chesebro et al.,
1992; de Jong et al., 1992; Fouchier et al., 1992; Milich et al., 1993). Generally, the
V3 sequences from SI isolates presented a broad range of substitutions, insertions,
and deletions at most positions between the disulfide-bridged cysteine residues of the
putative V3 loop; in contrast, those from NSI isolates showed relatively less diversity
(Donaldson et al., 1994b). Moreover, NSI/macrophage tropic isolates are commonly
associated with a lower charge by calculation of the overall net charge of the V3
sequence between the disulfide-bridged cysteine residues, while SI/ T cell tropic
isolates were associated with higher charge (Milich et al., 1993; Donaldson et al.,
1994b).
A wide range of V3 sequence variants was recovered from various organs from
AIDS patients but only from lymphoid organs from pre-AIDS individuals
(Donaldson et al., 1994a). A general observation was a common set ofV3 sequences
being presented at varying frequencies throughout the body; however, there were
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distinct V3 populations existing in different organs (Donaldson et al., 1994b).
Whether the V3 domain operated as the principle determinant of tissue tropism was
uncertain. Some researchers suggested that the consistent sequence differences in the
V3 region provided indirect evidence for specific cellular tropisms (Hwang et al.,
1991; Ball et al., 1994; Korber et al., 1994; Reddy et al., 1996); however, others
suggested that these sequence variants merely represented the differences in the rate
of virus turnover in different organs (van der Hoek et al., 1996; van der Hoek et al.,
1998).
Genetic diversification in the V3 and pl7gag regions occurs under different
selection pressures. Unlike the V3 region, where nonsynonymous substitutions are
commonly observed, most nucleotide differences in pl7gag region appear to be
synonymous (Kasper et al., 1995). In contrast to nonsynonymous substitutions that
may arise in escape mutants through selection pressures exerted by the host immune
system, synonymous substitutions do not cause changes of amino acids and are
therefore less subject to positive selection pressures. As synonymous substitutions
are more likely to be caused by a random fixation of mutations (neutral theory), they
presumably reflect the underlying mutation rate, allowing reliable estimates of
divergence times to be calculated (Holmes et al., 1993). The rate of sequence
changes in the pl7gag region has previously been determined from haemophiliacs in a
Bonn cohort (Kasper et al., 1995). As a constant rate of synonymous substitution was
observed in pl7gag across evolutionary time, this region was proposed as a useful
marker for constructing epidemiological relationships between HIV-1 infected
individuals (Kasper et al., 1995). These synonymous changes in pl7gag can also be
used as a type of molecular clock allowing estimates of the divergence time between
any two sequences to be carried out, and can be extended to the comparison of
variants within a single infected individual (Hughes et al., 1997).
Studies in genomic diversity have also suggested that recombination of HIV-1
genomes may play a role in producing new viruses with different biological and
pathological properties (Robertson et al., 1995). This recombination of viral
genomes could also introduce new strains into the population and thereby challenge
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vaccine approaches to HIV. The extent of recombination between strains is not clear,
but it is believed to be a frequent event during the course of infection (Robertson et
al.t 1995), and appears to occur most often within the gag and env regions
(Cornelissen etal., 1996; Kampinga et al., 1997).
To investigate the association between virus distribution, phenotype, nucleotide
sequence diversity and the progression of disease, this study was carried out using
the nested PCR limiting dilution and nucleotide sequences in V3 and pl7gag regions
from various organs obtained at autopsy.
5.2 Materials and Methods
5.2.1 Study Subjects
Frozen samples of lymph node (LN), lung, colon, and left frontal lobe of brain
(LF) were obtained from nine HIV-1-infected autopsies, including six symptomatic
individuals (NA96425, NA97021, NA97020, NA97017, NA96272 and NA96371)
and three pre-symptomatic individuals (NA98025, NA98028 and NA97097). The
patients had died shortly before this study commenced. Most of them were in the risk
group of intravenous drug user, excluding NA96371 and NA97020 who were male
homosexuals. Their ages ranged from 32 to 49, and with a history ofHIV-1 infection
lasting 4 to 13 years before death. General information for each study subject is listed
in Table 5. 1. For details of the pathological findings refer to appendix II.
DNA from each sample was extracted according to the protocol described at
section 2.6. Total DNA concentration was estimated by spectrophotometer at 260nm.
One microgram aliquots of extracted DNA were amplified in the V3 and pl7gag
regions using primers as previously described (refer to section 2.7). PCR amplified
DNA was then used for further molecular investigations.
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Table 5. 1. Clinical information for study subjects.
Studv Gender Risk Yrs since first _ . ,, „aiuuy
. .
„ a _____ ... b CD4C CD8c Rx AIDS-Related IllnessSubject / Age Group HIV-positive
NA96425 M/32 ADM 12
NA96371 M/34 AH 4(2.5)
1 298 No No AIDS-related illness
(AIDS was diagnosed on the
CD4 counts alone)
3 100 Yes KS
NA97020 M/49 AH 6 (2.5) 8 388 Yes MAI
NA97017 M/32 ADM 11(1.5) 16 120 Yes PCP
NA96272 M/32 ADM
NA97021 F/49 ADM 12(4)
126 636 No No AIDS-related illness
(AIDS was diagnosed on the
CD4 counts alone)
137 1620 Yes HIVE
NA98025 M/43 P-Hetero 297 323 No Clinically in Pre-AIDS
NA98028 F/48 PDM 13 703 4091 No Clinically in Pre-AIDS
NA97097 M/36 PDM 11 NA NA NA Clinically in Pre-AIDS
Key for Table 5. 1:
a: Risk Groups: ADM — AIDS Drug Misuser; AH — AIDS Homosexual;
PDM — pre-AIDS Drug Misuser; P-Hetero — pre-AIDS heterosexual
b: The years of patient living with HIV, the number in the brackets indicates the number of
years between the first AIDS presenting illness and death.
c: CD4, CD8: The last CD4 counts and CD8 counts
d: Rx: Antiretroviral Therapy. Details of the history of treatment are listed in appendix II
e: MAI — Mycobacteria avium-intracellulare;
PCP — Pneumocystis carinii pneumonia;
KS— Kaposi's Sarcoma;
HIVE — HIV encephalitis.
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5.2.2 Estimation of Viral Load
Quantitation of proviral DNA was carried out using the PCR limiting dilution
method. The number of copies of provirus per million cells was determined by
nested PCR amplification of serial ten-fold dilutions of DNA using the pl7sag
primers. Ten replicates at last positive dilution were used to indicate the minimum
proviral load in the sample, assuming a Poisson distribution for each sample by -
ln(l -p)ld (where p= proportion of positive samples and d= dilution). Viral load was
expressed as copies per million cells on the basis that a human diploid cell contains
6.6pg DNA.
5.2.3 Genetic Analysis
PCR amplified DNA was cloned into pGEM-T vector using poly (T) overhangs
(refer to section 2.8). Proviral DNA from clones was sequenced using the Sequenase
version 2.0 kit (USB) following the manufacturers' protocol (refer to section 2.7).
The sequence dataset for the pl7gaB region extended from positions 405-795 in the
HIVlai genomic sequence (GenBank accession number K02013), while the V3
sequences were compared from positions 7017-7322. Sequences were then aligned
and diversity estimated using the Simmonic 2000 Sequence Editor package. Unless
shown otherwise, ten clones from each of the positive samples were sequenced.
Phylogenetic analysis was carried out using MEGA program. Distributions of
pairwise distances were plotted using the Systat statistical package.
pl7gag and V3 sequences from each of the study subjects were monophyletic
upon comparison with sequences from other individuals in the study, from
previously described HIV-infected individuals in Edinburgh, and from the following
published sequences of clade B isolates: HIVSF2 (K02007), HIVRF (Ml7451),
HIVOYI (M26727), HIVLAI (K02013), HIVJRFL (M74978), HIVYU2 (M93258),
HIVCAM1 (D10112), HIVNY5CG (M38431), HIVHAN (U43131), HIVWMJ22
(Ml2507), and HIVSFAAA (M65024). This comparison provided no evidence for
inter-sample or exogenous laboratory contamination.
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5.3 Results
5.3.1 HIV-1 in vivo Distribution and Sequences Variability in Various Organs
Obtained from Presymptomatic and Symptomatic Autopsies
Two regions of HIV-1 proviral DNA, pl7gag and V3 were successfully
amplified by nested PCR from all LN and lung samples, and from five colon samples
(NA97021, NA97017, NA96425, NA96272 and NA98025), and five LF samples
(NA97021, NA97020, NA96371, NA98025, NA97097). Proviral DNA
quantification, and the diversity of cloned sequences was estimated as described in
section 5.2.2 and section 5.2.3. Estimated viral load and sequence diversity was
listed in Table 5. 2.
Proviral load varied considerably between individuals (Table 5. 2). In general,
high levels of HIV-1 proviral DNA were consistently detected in the lymph nodes
and lungs, except in patients NA97017 and NA96272 in whom low viral load was
detected throughout the four examined organs. In contrast, the presence of proviral
DNA in samples from colon and brain tissues was only within a minority of
symptomatic individuals.
No association between the detection of HIV-1 proviral DNA and the disease
progression or risk groups was observed within samples from LN or lung. However,
the detection of HIV-1 proviral DNA in the brain demonstrated a close correlation
with the pathological appearance of HIV encephalitis (HIVE). This was observed
within subjects NA97021, NA97020 and NA98025, but not in NA96371 or
NA97097 in whom low levels of proviral DNA were detected in the brain without
evidence of HIVE. As for the colon samples, a high level of proviral DNA was
generally found within symptomatic subjects, although no specific pathology
appearance was observed.
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Each PCR amplified DNA was cloned and ten clones from each library
sequenced. Mean intra-sample pairwise p distances ranged from 0.0038 to 0.0504 in
the V3 region, and from 0.0026 to 0.0397 in pl7gag (Table 5. 2). Amongst the 28
PCR-positive samples, the observed heterogeneity within eight (underlined samples
indicated in Table 5. 2) was within the range introduced by Taq errors during
template amplification. Assuming a frequency of 0.5 x 10"4 misincorporations per
base, and 40 effective copying cycles during nested PCR, the expected diversity
resulting from Taq error is 0.004 (Saiki et al., 1988; Ennis et al., 1990; Leigh Brown
& Simmonds, 1995). The possibility that nucleotide sequences derived from a single
template was supported by the association between low sequence diversity (within
the range of Taq error) and low virus load in these samples. For example, the
estimate for virus load in the brain sample from NA97097 was 3 copies per 106 cells,
calculated from the frequency of 4 positive reactions from testing 10 replicate one pg
aliquots ofDNA with the pl7gag primers. As one pg amounts of DNA were used for
sequencing, it is highly likely that each of the cloned sequences ultimately derived
from a single proviral copy. Moreover, these sequences derived from a single
proviral copy were monophyletic and clustered as a unique lineage, which gives rise
to a misleading impression of tissue specificity.
This problem of single templates is likely to prevent estimates of true
population diversity being made, and to generate mis-interpretations of the genetic
relationships between virus variants that isolated from various organs (Leigh Brown
& Simmonds, 1995). Furthermore, as described in a previous study (Donaldson et al.,
1994a), it was impossible to determine whether the sequences obtained from samples
with low virus loads derived from the tissue itself or from residual blood. For more
accurate analysis of the genetic relationships between these virus isolates, sequence
data should be examined carefully before they are subjected to phylogenetic or
evolutionary analysis. Those samples showing little diversity together with low viral
load have therefore been excluded from the subsequent analysis.
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Intra-sample sequence diversity in the pl7gag region correlated with that in the
V3 region (Figure 5.1: Spearman rank correlation coefficient 0.31; /?=0.085). No
association was observed between the sequence variability and risk groups, disease
progression or any known risk factors. However, samples from non-CNS organs,
including lung, colon and LF commonly showed greater sequence diversity than
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Figure 5. 1. Intrasample sequence diversity in the pl7gag and V3 regions of LN
(•), lung (♦), colon (■) and brain (A) from nine study subjects (Spearman
rank correlation coefficient: 0.31; p=0.085).
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5.3.2 Prediction of Viral Phenotype
In this study, viral phenotype was predicted according to the translation of the
nucleotide sequences between positions Cys301 and Cys336 in the V3 region. This is
the method commonly used for phenotype prediction directly from sequences. In
general, if the positively charged amino acids arginine (R) or lysine (K) were
observed at positions 11 or 25 counted from the first cysteine (Cys301) in the V3
loop, variants were predicted as SI strains, otherwise they were predicted as NSI
strains. In general, SI strains were also known as T cell tropic using CXCR4 as co-
receptor whereas NSI strains are preferentially macrophage-tropic and use CCR5 as
co-receptor. Details of the V3 amino acid sequence of each sample are listed in
Figure 5. 2).
Most variants contained neutral amino acids at position 11 and acidic residues at
position 25, and were predicted as CCR5-dependent (NSI) strains. Variants
recovered from NA96371 and NA97020 (LN and lung) and from NA96425 (LN and
colon) which contained basic amino acid substitutions at position 11 were identified
as CXCR4-dependent (SI) strains. The presence of CXCR4-dependent strains
correlated well with disease progression. In general, CXCR4-dependent variants
were found preferentially in sympomatic individuals, in whom low CD4 cell counts
were found at death (NA96425, NA96371 and NA97020), and in the male
homosexual risk group (NA96371 and NA97020). In contrast, all of the variants
isolated from pre-symptomatic subjects (NA97097, NA98025, and NA98028) and
from those with higher CD4 cell counts at death (NA97021 and NA96272) were
identified as CCR5-dependent strains.
Alternatively, the viral phenotype could be predicted according to the overall
net charge and the similarity to the subtype B consensus within V3 loop. Previously,
the net charge and the number of amino acid changes within V3 sequences were
calculated from 59 isolates with known phenotype in vitro (Donaldson et al.t 1994b).
Most of the NSI/macrophage isolates were consistently associated with lower net
charge and higher similarity with consensus sequence, and the SI/T cell tropic strains
were commonly associated with higher net charge but were more diverse. A
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diagnostic line (y=-5x+25; x: overall V3 charge; y: number of amino acid changes)
was then designed, which clearly separated the known NSI and SI populations
(Donaldson et al., 1994b). To further investigate whether or not the method they
designed could also be applied to the variants which are directly recovered from
tissues, the sequence data obtained in this study were also analysed using the same
parameters. The overall net charge was calculated by assigning a unitary negative
charge to each aspartic acid (D) and glutamic acid (E) and a unitary positive charge
to each lysine (K) and arginine (R) between the two cysteine residues. The similarity
was expressed as the number of amino acid changes compared to the consensus
sequence (Table 5. 3 & Figure 5. 2).
The results of viral phenotype prediction using the two different methods were
similar (Table 5. 3). Those predicted as SI strains are primarily associated with
higher net V3 charge and less similarity to the subtype B consensus. For example, in
patient NA96425, most of the sequences containing basic amino acid substitutions at
position 11, which predicted them as SI strains, were associated with a net charge
higher than 4, and had at least 7 amino acids different from the consensus, and were
commonly located to the right of that diagnostic line. In contrast, predicted NSI
strains show lower charge and greater similarity to the subtype B consensus, as
observed in patient NA98028, whose isolates were generally found to have a charge
lower than 3, showed no difference to consensus V3 sequences, and were located to
left of diagnostic line. At present, most groups predict viral phenotype according to
the translation of the nucleotide sequences between positions Cys301 and Cys336 in
the V3 region. The results demonstrated here suggest that a system involving net
charge and amino acid changes within the V3 loop could also be used as a predictive
method.
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Table 5. 3. Comparison of viral phenotype prediction in lymph node, lung,
colon and LF brain tissues using two different predicting systems. Study
subjects are listed in the first column according to the last CD4+ cell counts
with the lowest CD4 counts first.
LN LU CO LF
NA96
425
X4 (5/9); R5 (4/9)a
*X4 (8/9); R5 (l/9)*b
R5






R5 (8/12); X4 (4/12)
* R5 (8/12); X4 (4/12)*
R5 (9/12); X4 (3/12)



























































Keys for Table 5. 3:
Prediction according to the amino acid at positions 11 and 25.
b Prediction according to the diagnostic line (Donaldson et al, 1994b).
R5: CCR5-dependent (NSI); X4: CXCR4-dependent (SI). The figure in brackets represents
this strain as a fraction of the total.
N/A: no data available (the viral load was less than 0.5 per 106 cells, or the diversity
was within Taq error).
Shaded-area: pre-symptomatic individuals
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5.3.3 Partitioning of HIV-1 Variants in Different Tissues
Phylogenetic analysis was carried out using sequences from the V3 and pl7gag
regions from a range of lymphoid and non-lymphoid tissues, including LN, lung,
colon and LF brain tissue. Divergence between nucleotide sequences was estimated
using Jukes-Cantor distances (scale indicated below tree), and the phylogenetic tree
constructed from the distance matrix by the neighbor-joining method. The
robustness of groupings was indicated by bootstrap resampling of 100 datasets, with
values of >70% indicated on branches. The tree was rooted using the sequence of
HXB2 as an outgroup.
Phylogenetic analysis of nucleotide sequences for the V3 and pl7Bag regions
revealed a variety of relationships between variants recovered from different tissues.
In general, most of the HIV-1 variants amplified in both the V3 and pl7gag regions
from lung were interspersed with those from LN (Figure 5. 3). However, in subject
NA98025, the majority of lung variants were interspersed with those from colon but
separated from LN variants in the V3 region. Separate groupings of lung variants
were observed within subjects NA96425, NA96371 and NA96272, although in
subject NA96371, lung-specific lineage was only detected in the V3 region. There
was evidence of a lung-specific lineage in subject NA96425, in whom all of the lung
variants clustered separated from other variants isolated from colon and LN in the V3
region. Although a relatively restricted sequence diversity was observed in the V3
region (0.0093), the high level of proviral load measured in this lung sample
indicates this homogeneous lineage did not result from restricted template copying.
The viral quasispecies from brain tissue were relatively homogeneous and
commonly clustered separately from all other sequences, but occasionally with some
colon and lung variants interspersed. For example, in subject NA97021, pl7gag
sequences of brain variants were extremely diverse and polyphyletic, but could be
roughly divided into two clades. One clade contained most of the brain variants, all
of the variants from LN and lung and most of the colon variants. The other clade was
constructed with a minority of brain and colon variants. As for the V3 sequences,
brain isolates were clustered into two distinct clades, both ofwhich shared sequences
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similar with the majority of colon variants, but separated from variants isolated from
LN or lung. Also in subject NA98025, a separate grouping of brain isolates was
observed inpl78ag and V3 regions. Similar to the findings in subject NA97021, pi 7gag
sequences of brain variants from subject NA98025 were diverse and polyphyletic.
The majority of brain isolates clustered separately with variants isolated from LN
and lung, but closely associated with the colon-specific lineage. Two distinct brain
clades were identified in the V3 region, both of which were closely associated with
two colon-lung lineages independently of each other (figure 5.3).
Sequence relationships between variants in the colon and those in other tissues
were more complex. Evidence of a colon-specific lineage was observed within
individuals NA97021, NA96272, NA96425 and NA98025, in whom part or all of the
colon variants clustered separately from those isolated from lung or LN. In the latter
two study subjects, a separate grouping was detected only in the pl7gag region. In
addition to those separately grouped, the remaining colon isolates were occasionally
interspersed with those from lung (NA96272, V3; NA98025, V3), from LN
(NA96425, V3), or interspersed with variants from LN and lung (NA96272, pl7gag;
NA97021, V3).
Briefly summarising, variants recovered from LN, lung and colon are often
interspersed. In contrast, variants recovered from brain are relatively homogeneous
and clustered separately from those recovered from LN, but occasionally sharing
sequences similar to colon and lung variants. Tissue specific groups were observed,
most often within V3 region, although some of these occurred in the pl7gag region,
for example the colon-specific lineage in subject NA96425.
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Figure 5. 3. Phylogenetic analysis of the nucleotide sequences from the V3 and
pl7gag regions of (I) NA96425, (II) NA96271, (III) NANA97020, (IV)
NA96272, (V) NA97021, (VI) NA98025, (VII) NA98028, (VIII)NA97097.
Trees shown in rooted form using the sequence ofHXB2 as an outgroup.
Bootstrap values of >70% indicated on branches and highlighted in bold.
Symbols: O indicates LN isolates
■ indicates colon isolates
▲ indicates left frontal brain isolates














































































































































5.4.1 Validity of the Nucleotide Sequence Results for Phylogenetic Analysis
It has been reported that the most effective thermostable DNA polymerase, Taq
enzyme is often associated with a high misincorporation rate during nucleotide
synthesis (Saiki et al., 1988; Ennis et al., 1990). Investigators have found that if the
PCR product is cloned, the inserted DNA will be derived from sequences that may
have been copied several times during the PCR, and such cumulative effects in
sequence analysis could interfere with phylogenetic or evolutionary analysis (Leigh
Brown & Simmonds, 1995).
The problem of single templates was highlighted by the observations of low
sequence diversity (within the range of Taq error) together with low virus load within
eight samples examined in this study. Cloned sequences of these samples were
homogeneous, and produced a misleading indication of tissue-specific lineage.
As described at section 5.3.1, the estimate for virus load in the brain sample from
NA97097 was calculated from the frequency of 4 positive reactions from testing 10
replicate one pg aliquots ofDNA. While this PCR product was cloned, it was likely
that inserted DNA was derived from a single proviral template, and this resulted in a
brain-specific lineage which actually represented only one molecule of proviral
DNA from the tissue. Also in subjects NA96371 and NA97020, CXCR4-dependent
variants were recovered from LF brain tissues, and these apparently grouped together
as a brain-specific lineage. This is an unusual finding within isolates from brain
tissue, since most of the published brain sequences are CCR5-dependent (reviewed
in Ghorpade et al., 1998). However, low viral load and little heterogeneity was
observed within these two samples, and the amino acid sequences in the V3 region
of these brain SI isolates demonstrated certain similarity with those SI strains
recovered from LN and lung within these individuals (Figure 5. 2). It is difficult to
determine whether the sequences obtained from samples with low virus loads are
derived from the tissue itself or from residual blood within the tissue (Donaldson et
al., 1994a). Shared similarity in V3 sequences with variants recovered from other
tissues suggested blood contamination as an origin for these SI brain variants. The
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Figure 5. 4. Phylogenetic analysis of the V3 nucleotide sequences of individual
NA97020. O indicates LN isolates; ♦ indicates lung isolates; ▲ indicates left
frontal brain isolates. The sequences involved in the observed brain-specific
lineage (a) were relatively homogeneous and similar to those from LN in
lineage (b). Due to the extremely low viral load in brain tissue (6 copies per 106
cells), and the similarity with LN isolates in branch b, this brain lineage (a) is
highly likely to represent one of the lymphoid variants.
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In addition, in patient NA97017, well-defined tissue specific grouping was
observed in lung, LN and colon (Fig. 5.4). However, the presence of low viral load
(approximately 10 copies per 106 cells) and less heterogeneity within variants
isolated from colon and LN suggested that these variants might originate from a
single template. The presence of extremely diverse lung sequences (0.0504 in V3)
and (0.0137 in pl78ag) suggested that this high degree of heterogeneity could not
result from Taq error. However as the proviral load was low (10 copies per 106 cells),
these variants may have been amplified from residual blood within lung tissue and
represent the general infection in circulation. Thus, in this case, the apparent tissue














Figure 5. 5. Phylogenetic analysis of the V3 nucleotide sequences of individual
NA97017. O indicates LN isolates; ♦ indicates lung isolates; ■ indicates
colon isolates. The problem of single template produces a mis-leading
indication of tissue-specific lineages. As discussed above, lineage (a) and (d)
were possibly derived from single proviral template.
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To overcome the problem raised from the single template, limiting dilution PCR
followed directly by cycle sequencing could be employed instead of cloning the
sequence. Using limiting dilution PCR, a single molecule from the original sample
pool can be amplified sufficiently for direct sequencing. The Taq errors could
therefore be prevented, although the problem of contamination with residual blood is
still difficult to solve.
5.4.2 Proviral Load, Sequence Relationships and Disease Progression
It is important to determine the dynamics of HIV-1 spread throughout the body
in order to understand the mechanism of disease progression. Previous studies have
detected HIV-1 proviral DNA in both lymphoid and non-lymphoid organs in patients
who died in the symptomatic stages, but for those who died before the onset ofAIDS,
proviral DNA could only be detected within lymphoid organs (Donaldson et al.,
1994a). These findings provided evidence that spread of HIV outside cells of the
lymphoid system is a late event in HIV infection (Donaldson et al., 1994a; van't
Wout et al., 1998a). However, recent studies in evolutionary analysis of sequences
from the pl7gas region have demonstrated great sequence diversity in the brain,
which showed several years of divergent evolution (Hughes et al., 1997; Morris et al.,
1999), and this provided evidence of early entry ofHIV-1 into CNS.
In this study, a highly sensitive, specific and accurate quantitative nested PCR
was used for the detection of HIV-1 infection in various organs. Proviral DNA was
persistently detected in LN and lung samples obtained from study subjects including
both symptomatic and asymptomatic individuals, but was present in brain and colon
only in symptomatic individuals. These findings, in agreement with previous studies
(Donaldson et al., 1994a; Reddy et al., 1996) suggest that the detection of proviral
DNA in non-lymphoid organs is sensitive to the degree of immunosupression in the
patients. However, no evidence was observed for early entry of HIV-1 into CNS or
colon in this group of patients.
As lymphoid organs have long been recognised as major virus reservoirs
(Embretson et al., 1993a; Pantaleo et al., 1993c; Pantaleo et al., 1997), it is not
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surprising that proviral DNA was recovered from all lymph nodes in both
presymptomatic and symptomatic stages. Most of the variants isolated from LN were
predicted as CCR5-dependent/NSI strains, however there were some CXCR4-
dependent/SI strains identified in those study subjects in a severely
immunosuppressed condition. It has been reported that virus isolated in the early
asymptomatic phase of infection is predominantly slowly replicating, macrophage
tropic/NSI strains (Schuitemaker et al., 1992; Zhu et al., 1993; Blaak et al., 1998).
During disease progression, rapidly replicating, T-cell tropic viruses appear in about
50% of infected persons and are associated with the emergence of SI variants
(Cheng-Mayer et al., 1988; Tersmette et al., 1989b; Schuitemaker et al., 1992; Koot
et al., 1993). Some investigators suggested these SI strains might evolve from NSI
strains (Tamalet et al., 1994; van't Wout et al., 1998b). It is still unclear in which
compartment the generation of SI variants occurs, since SI isolates recovered in this
study are coincidentally associated with extremely low CD4 counts at death,
suggesting that the emergence of SI strains might be accompanied by high levels of
cytotoxicity in vivo, and then speed up the progression of disease to death.
In addition to the detection of HIV-1 in lymph node, HIV-1 proviral sequences
were also detected at considerable levels in the lung tissues. Lung is an organ which
is in particularly close contact with blood and is also known as a mucosa-associated
lymphoid organ. Pulmonary complications are common in patients infected with
HIV-1 and the correlation between the detection ofHIV-1 proviral DNA in lung cells
and progression to death has been observed in previous studies (Clarke et al., 1995).
In the present study, proviral DNA was consistently detected in the lung of all study
subjects, including all three presymptomatic subjects, even in subject NA98028 who
was without apparent abnormality observed in lung and still in the clinically latent
stage at death. This observation, in agreement with Clark et al., suggested the
possibility of an early entry ofHIV-1 into the lung (Clarke et al., 1995). Most of the
variants isolated from lung were interspersed with those from LN, but some were
demonstrated unique lung lineages (NA96425) or interspersed with colon and brain
isolates (NA98025). According to previous findings, where HIV-1 was present in
both alveolar macrophages and alveolar lymphocytes (Clarke et al., 1995; Agostini
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et al., 1995; Nakata et al., 1995; Semenzato et al., 1995; Agostini et al., 1996;
Semenzato et al., 1996), the different phylogenetic associations observed in this
study might represent the different cell subtypes infected by HIV-1. CXCR4-
dependent strains were identified in two study subjects, who had low CD4 counts at
death, but were not present in the patient with the lowest CD4 count (NA96425).
These SI strains were similar in sequences and phylogenetically interspersed with
LN SI variants within the two individuals. Whether this represents a systematic viral
re-invasion during the late stage of disease, or resulted simply because of the NSI/SI
switch event happening at the end stage of disease, or was induced by other
opportunistic infections needs further investigation.
HIV-1 infection in the gastrointestinal system has recently received more
attention. Some investigators have reported that isolates recovered from the bowel
can differ in biological and serological properties from HIV-1 strains recovered from
serum (Barnett et al., 1991; van der Hoek et al., 1996). It has been reported that in
homosexuals and infants, the gastrointestinal mucosa is the major route by which
HIV-1 first enters host tissues (Smith et al., 1997). However, the present study failed
to detect HIV-1 in the colon in the two male homosexuals in the symptomatic stage.
The colon variants recovered in this study demonstrated a high level of heterogeneity
and a complicated relationship with variants from other tissues. In general, a portion
of colon variants appeared to be interspersed with LN isolates within individuals, and
others were similar in sequences with variants recovered from the brain (NA97021;
NA98025). Also, there was evidence of colon groups observed in the pl7gag region
(NA96425 and NA98025), and in the V3 (NA97021) region. Interestingly, all of the
colon isolates from subject NA96425 were identified as CXCR4-dependent strains.
These V3 sequences from colon were interspersed with those from LN in NA96425,
who had been reported to have an extremely low CD4 count at death (CD4: 0),
providing evidence suggesting that a systemic dissemination of infection occurred at
the final stage. In a previous study, van der Hoek et al., also demonstrated SI strains
in two of their study group (van der Hoek et al., 1998). These two individuals had
been reported as having AIDS-related illness, however no other information was
given on whether they were in the middle or late stage of symptomatic illness. How
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these SI strains married to disease progression in this reported study is difficult to
predict.
HIV-1 infection in the brain is known to be closely associated with advanced
disease, particularly with HIV-encephalitis (HIVE), a neuroabnormality frequently
found in AIDS individuals (Bell, 1998; Gatanaga et al., 1999). Though HIV-1
proviral DNA was readily detected in some asymptomatic patients using the PCR
technique (Sinclair et al., 1992; Sinclair et al., 1994; An et al., 1996), the virus load
was generally observed to be extremely low. In this study, the association between
HIV-1 detection and HIVE was observed in subjects NA97021 and NA98025. The
patient NA98025 was clinically still in the presymptomatic stage. However, the
presence of occasional giant cells in the brain tissue suggested that this HIV positive
man was developing incipient HIVE. This and the other subject, NA97021 who
developed AIDS and HIVE, demonstrated similar sequence relationship between
different tissues. Both of them presented a general lineage containing all LN variants,
most lung variants, a small proportion of colon variants and few brain variants,
together with unique brain and colon lineages. Moreover, the brain grouping
demonstrated a close association with colon variants, in one case included some lung
variants (NA98025). These observations suggested two different types of sequence
associations between variants from various tissues, one of them appearing to be
generated by the lymphoid system, which contained at least some of the isolates from
each organ, the other was separate from a lymphoid origin, and closer to a
neurotropic strain, which generally included colon variants and occasionally lung
variants.
Three of the study subjects demonstrated a low viral load in the four examined
organs. One of them, NA98028, who died of illicit drug overdose in the
presymptomatic stage, had a high CD4 count close to death (CD4: 703) and appeared
to show no abnormalities in these four examined tissues. The relatively normal
histological appearances observed in this individual, fit well with the low level of
provirus detected. Two other subjects, NA97017 and NA96272 who died of AIDS-
related illnesses, had relatively low CD4 counts at death (16 and 126 respectively,
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which ranked in the middle of symptomatic individuals), one received anti-retroviral
therapy during the symptomatic stage (NA97017), the other was not treated. When
compared with the other subjects, no significant differences were observed in the
pathological conditions in these two subjects. The low levels of HIV-1 detected in
these two individuals are difficult to explain, seemingly not due to the antiretroviral
therapy, nor to the progression of disease or any other obvious cause. The possible
reason might be due to inappropriate sampling. The organs examined in this study
are made up of a large mass of solid tissue, where cellular movement is relatively
restricted, unlike the peripheral circulation. It is therefore highly likely that separate
populations could emerge within tissues following initial infection. Only a small
amount of tissue is sampled for examination and it is possible that the infected areas
were missed or that unrepresentative samples were selected. Similar problems were
also observed in the brain tissue from subject NA97020, who had developed HIVE
and showed p24 immunopositivity in brain, but PCR quantitation revealed only 6
copies per 106cells. It is unusual that cases with p24 immunopositivity but with low
viral load by PCR quantitation in brain tissue should develop. HIVE. For further
investigations, multiple sampling is clearly important.
5.4.3 Tissue-Specific Grouping
The HIV-1 population in an infected person often contains a diverse mix of
variants. Populations of these variants infecting different tissues in vivo are generally
distinct in the hypervariable V3 region of env gene (Ball et al., 1994; Korber et al.,
1994). Several studies have identified distinct isolates from lung (Itescu et al., 1994),
colon (Barnett et al., 1991; van der Hoek et al., 1996) and brain (Donaldson et al.,
1994b; Power et al., 1995; van't Wout et al., 1998a; Gatanaga et al., 1999; Morris et
al. 1999), indicating compartmentalisation ofHIV-1 in different tissues. In this study,
variants recovered from lung, colon and brain demonstrated consistent sequence
differences from those recovered from lymph node either in the V3 or pl7gag regions.
These tissue-specific groups provided evidence for specific cellular tropism, and
most of these tissue-specific groupings occurred more often in the V3 than in the
p 17gag regjon as described previously, genetic diversity in the V3 and pl7gag regions
is under different selection pressures. Being a major target for neutralising antibodies
5-48
(LaRosa et al., 1990; Robert-Guroff et al., 1994), the high degree of diversification
in V3 regions is believed to be driven by a strong immune pressure, whereas in pl7gag,
a bias for nonsynonymous substitutions suggests selection based on replication
fitness (Kasper et al., 1995). These observed tissue-specific groups might represent
the differences in the rate of virus turnover under immune pressure in different
tissues (van der Hoek et al., 1996; van der Hoek et al., 1998). They found that only
one out of seven in their study group showing specific clustering in faecal sample
(van der Hoek et al., 1998). In the present study, because comparison was made
within various tissues, an even more complicated pattern was observed. In general,
lung-specific clusters were observed within two subjects, colon-specific clusters
were observed in three and brain-specific clusters were observed in two. These
lineages frequently shared some sequences similarity with variants recovered from
other tissues, although they were separated from LN variants. Most of the variants
demonstrated a strong host-specific character rather than tissue-specific groupings
(data of phylogenetic trees were not shown). For example, other analysis of
phylogenetic trees prepared from all LN sequences, variants obtained from the same
subject always clustered tightly, and separated from other subjects. Similar
observations applied to lung, colon and brain. The heterogeneity between variants
obtained within subject was less than variants obtained between subjects. Therefore,
these tissue-distinct variants within individuals seemingly reflected the host immune
selection, or time-related factors (van der Hoek et al., 1998) rather than simple tissue
tropism.
5.4.4 Genomic Recombination
Genomic recombination is one of the most important mechanisms by which
new variants with different biologic and pathogenic properties can be produced. Also,
it may play an important role in the evolution of drug-resistant strains and new
envelope serotypes (Burke, 1997). It has been demonstrated earlier that
superinfection of two defective viruses in vitro could produce cytopathic virus
particles because of homologous recombination (Kishi et al., 1995). Moreover,
various types of recombinations, such as between different subtypes ofHIV-1 group
M (Gao et al., 1998), between HIVLAIand HIV-1SF2 (Wei & Fultz, 1998), and even
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between HIV-1 groups O and M (Takehisa et al., 1998), were confirmed at a rather
high frequency (Takehisa et al., 1998). Most of the genetic recombination was
observed occurring between gag and env regions (Carr et al., 1996; Cornelissen et al.,
1996; Kampinga et al., 1997).
A recent study demonstrated an extensive recombination between different
regions of HIV-1 genome in brain infection (Morris et al., 1999). In this study,
variants infecting multiple regions of the brain of an individual with HIVE were
assembled from two distinct pl7gag lineages and a limited number of distinct
hypervariable region lineages, often with different combinations within each
histological regions of brain (Morris et al., 1999). Similar to these observations,
discordant phylogenetic relationships between pl7gag and V3 region of HIV-1
genome were found in some of the present study subjects. For example, separate
grouping of pl78as region sequences from lymph node and colon were observed in
subject NA96425, whereas sequences in V3 from these tissues were interspersed.
Similar findings in subject NA97021 showed that pl7gag sequences from the brain
were extremely diverse and polyphyletic, while V3 sequences clustered into two
discrete clades. These observations support the previous findings that recombination
could occur within an infected individual between variants descended in each case
from the original infecting strain, and that different regions of HIV genome may
follow different evolutionary selection. However, the small patient numbers and the
limited genomic regions examined (only pl7gag and V3) are potentially limiting to
these results. For further investigation, multiple regions of the HIV genome in a
greater number of cases should be analysed to further substantiate these findings.
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Chapter 6: General Discussion
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The new therapeutic strategy, highly active antiretroviral therapy (HAART)
became available in the summer of 1996. Despite the fact that HAART has been
confirmed as effective in decreasing AIDS-related morbidity and mortality, and in
achieving sustained and progressive immunological reconstitution in both early and
late HIV-1 infection (Li et al., 1998; reviewed in Montaner et al., 1998a), increasing
numbers of reports have drawn attention to the severe long-term side effects of
HAART (Carr et al., 1998; Henry et al., 1998), and the rapid rebound of viral
replication occurring after cessation of drug therapy (Montaner et al., 1998b; Chun et
al., 1999). According to the latest annual world health report, AIDS is now ranked at
fourth place among all causes of death worldwide, and is the leading overall cause of
death in Africa and developing countries (UNAIDS/WHO, 1999). Moreover, the
HIV epidemic continues to spread at a rate of over 6000 new infections every day
(UNAIDS/WHO, 1999). Responding to the challenge of this devastating pandemic,
basic and clinical investigators in many regions of the world have rapidly advanced
our understanding of the biology, immunology, and virology of systemic HIV-1
infection. A better understanding of HIV pathogenesis and the mechanisms
underlying HIV-1 related disease in specific tissues is still a high priority in tracking
the medical impact of the pandemic.
Infection with HIV-1 is associated with a slow, progressive and irreversible
impairment of the immune system eventually leading to AIDS. Previous studies
suggested that CD4+ lymphocytes were the major target for HIV-1 infection, and the
dysfunction and depletion of CD4+ lymphocytes by HIV-1 was thought to be the
major mechanism responsible for the progressive disease (Klatzmann et al., 1984;
Becherer et al., 1990; Saksela et al., 1994; Ho et al., 1995). However, the recent
discovery of secondary receptors (Bleul et al., 1996; Deng et al., 1996; Feng et al.,
1996; Liu et al., 1996; Oberlin et al., 1996; Paxton et al., 1996; Samson et al., 1996),
and the demonstration of a wider range of host cells susceptible to HIV-1 in vitro
(refer to chapter 4) suggested that the mechanisms involved in HIV-1 pathogenesis
might be more complicated than previously thought. In the present study,
immunostaining techniques together with nucleotide sequencing and phylogenetic
analysis of viral isolates were employed in order to achieve a better understanding of
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the mechanisms for viral dissemination throughout the body, and of the histologic
and genetic characterisations of HIV-1 infection in the lymphoid and non-lymphoid
organs.
Gathering all the information from the immunohistology and sequence analysis,
the findings in this thesis document the complicated relationships between HIV-1
populations recovered from various organs within individuals, and suggest possible
mechanisms of spread of the virus into non-lymphoid tissues.
According to the phylogenetic analysis, nucleotide sequences from the V3 and
pl7sag regions revealed a complex variety of relationships between variants recovered
from different tissues, including lymph node (LN), lung, colon and left frontal lobe
brain tissues. In general, at least some of the variants from each tissue were
interspersed, and this observation suggested a shared population and target cell type
between these tissues. However, the majority of variants recovered from the brain
were found to be phylogenetically distinct from variants derived from LNs. Of the
variants derived from the colon, sequences were sometimes interspersed with lymph
node and lung isolates, but colon-specific variants were observed in two subjects
(NA97021 and NA98025). These colon-specific isolates were phylogenically distinct
from LN lineages but demonstrated certain sequence similarities with brain variants.
Most of the variants from the lung were interspersed with those from LN, but in one
case (NA98025), lung variants were clustered with colon isolates and
phylogenetically distinct from LN variants.
In contrast to these complex phylogenetic relationships, the pattern of
immunopositivity for HIV-1 p24 antigen was relatively simple. Most LN sections
obtained either from pre-symptomatic or from symptomatic patients displayed p24
immunopositivity within follicular dendritic cells. In brain tissues, the majority of
p24 positive cells were multinucleated giant cells (MGCs), microglial cells and
macrophages, and the presence of p24 immunopositivity were largely associated
neuropathological abnormalities, most often with a tissue damaging form of HIV
encephalitis. Other tissues, including lung and gastrointestinal tract were usually p24
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negative, and only in some symptomatic subjects, p24 signal was detected within
secondary lymphoid follicles in these organs.
These observations suggested at least two mechanisms for spread of HIV-1 into
non-lymphoid tissues. For tissues such as the lung and the gastrointestinal tract,
combined immunohistochemical and genetic observations suggest that infection of
these tissues arose directly from infiltration by lymphocytes. A different mechanism
seems likely for HIV-1 variants detected in the brain, which were found
predominantly in cells of macrophage lineage, and these formed genetically distinct
populations from those in lymphoid tissues. Moreover, the colon and lung variants
from subjects NA97021 and NA98025, which were distinct from LN lineages but
similar in sequences with brain lineages provide evidence suggesting that infection of
lung and colon may also occur through macrophage involvement, although there was
no immunohistological evidence for productively infected macrophages in lung and
colon in these individuals.
These finding confirm and extend the finding of previous studies (Donaldson et
al., 1994b), when the V3 region was sequenced from various organs, including brain,
colon, lung and LN from HIV-infected individuals. In one particular case, NA91246
(P4), frequent p24 antigen-expressing lung macrophages were found and these
infected cells formed pronounced multinucleated syncytia (MGCs), similar to the
pattern of brain infection. The predominant V3 sequence of provirus amplified from
lung tissue was identical to the major variants infecting the brain and to a proportion
of those in colon tissue, but distinct from those derived from LN. Interestingly, in
another subject NA92118 (P5), immunostaining demonstrated p24 positivity within
the lymphoid infiltration but not macrophages in lung, and sequences from V3 region
were interspersed with LN isolates but not brain isolates (Figure 6. 1 & Figure 6. 2).
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Figure 6.1. Morphology and double immuno-Iabelling detection of p24
antigen and macrophage cell marker in the lung section from subject
NA91246 demonstrating a high level macrophage syncytia (p24: DAB,
PGM1: Vecter Red, with haematoxylin counter stain. Magnification: (a) x200, (b)
x200). In this case, the predominant V3 sequence of provirus amplified from lung
tissue was identical to the major variants infecting the brain (c).
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Figure 6. 2. HIV-1 p24 detection in the lung section taken from subject
NA92118 demonstrating a high level of lymphocytic infiltration (DAB
with haematoxylin counter stain. Magnification: x200). In this case, the predominant
V3 sequence of provirus amplified from lung tissue was identical to the variants
isolated from PBMCs and LN, but distinct to the brain variants.
6-6
The finding that p24 positivity observed in lung MGC/macrophages showed a
close V3 phylogenetic relationship with brain isolates, whereas p24 positivity
observed in lung lymphoid infiltration showed a mixed LN/lung phylogenetic pattern,
correlated closely with the findings of the present study. Although p24
immunostaining failed to identify the infected cell type in lung and colon, these
similar V3 sequences observed between lung, colon and brain isolates suggests that
infection in these instances occurred through a transmission mechanism might be the
same in these three tissues.
Productive replication ofHIV-1 in brain MGCs, macrophages and microglia is a
critical component of viral neuropathogenesis (Bell, 1998; Ghorpade et al., 1998).
However, the formation of p24-positive-MGC is a rare event outside the CNS, and
p24-positive-macrophages were found only occasionally in the present study. In a
recent case report, this characteristic cell type was identified in hyperplastic gut-
associated lymphoid tissue of an HIV-infected patient (Lewin-Smith et al., 1999). In
this case, HIV-1 RNA expression and p24 positivity was demonstrated in MGCs,
macrophages and FDCs using in situ hybridisation and immunostaining.
Unfortunately, no sequence data was available for this patient (Lewin-Smith et al.,
1999), which might have helped to prove the macrophage-lineage hypothesis
described above. From the V3 region sequences, apparently these neurotropic-similar
HIV-1 isolates have commonly contained neutral amino acids at position 11 and
acidic residues at position 25, and were predicted as CCR5-dependent (NSI) strains.
CCR5-dependent strains have been found predominantly in acutely infected
individuals, and are most transmissible (Zhu et al., 1993; Zhu et al., 1995; Spira et
al., 1996). It has been postulated that these CCR5 dependent strains are the principal
virus type responsible for person-to-person transmission and viral persistence early
in infection (Collman & Yi, 1999).
A recent study cloning brain-derived and colon-derived viruses into an isogenic
(NL4-3) viral background has reported that CCR5 is a primary coreceptor for these
brain- and colon-derived viruses, and suggested that tissue infection may not depend
significantly on changes in coreceptor usage, but rather selects for CCR5 use
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throughout disease progression (Chan et al., 1999). In this regard, cells of the
macrophage lineage, such as microglia and tissue macrophages which present both
CCR5 and CD4 molecule on their cell surface, are possibly the principal cells that
establish and maintain virus populations in all tissues.
Several studies have demonstrated that the first targets of HIV-1 are cells of the
macrophage lineage, especially in mucosal areas, such as lung and colon (van't Wout
et al., 1994; Donovan et al., 1996; Goletti et al., 1996; Marx et al., 1996; Spira et al.,
1996; Kahn & Walker, 1998; Hirsch et al., 1998). Although Zhang et al. (1999)
demonstrated that soon after initial infection, macrophages can pass infection to
CD4+ T cells in cell-cell interactions that activate the T cells (Zhang et al., 1999),
these productively infected CD4+ T cells are later eliminated by the host immune
system (reviewed in Levy, 1998). As disease progresses, consistent loss of CD4+ T
cells leads to immunodeficiency and increasing susceptibility to a broad range of
opportunistic pathogens, and infections with opportunistic pathogens are usually
accompanied by mostly reversible increases in HIV-1 viremia (Ghassemi et al., 1995;
Goletti et al., 1996; also reviewed in Levy, 1998). A recent study by Orenstein et al.
demonstrated that while CD4+ lymphocytes decline dramatically in the later stages
of HIV-1 infection, macrophages were identified as highly productive sources of
HIV-1 (Orenstein et al., 1997a). Thus, with reference to the findings of this thesis,
the brain-derived, colon-derived and lung-derived CCR5-dependent isolates were
quite possibly derived from a common cellular source. Moreover, these isolates that
were distinct from those derived from lymphoid lineage were found coincidentally
within subjects who had developed systemic pathological abnormalities, including
HIVE (NA97021 & NA98025 in the present study and P4 (NA91246) in Donaldson
et al., 1994b). This observation suggests that this CCR5- or macrophage-dependent
lineage represent a disease-inducing lineage, which is responsible for the systemic
spread of infection throughout the body. As for the observed tissue-tropic property, it
might merely reflect differences in the rate of virus turnover in different cell types
under different selective pressures (van der Hoek et al., 1998; Morris et al., 1999.
Also refer to section 5.4.4).
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Although expressing much lower levels of cell surface CD4 molecules than
helper T lymphocytes, cells of the macrophage lineage could be infected through a
CCR5-dependent mechanism (Berger, 1997; Berger et al., 1999), or through an
efficient gpl20/gp41 -independent route, such as phagocytosis of other infected cells
or by Fc receptor-mediated endocytosis of antibody-coated HIV virions, since the
HIV-1 virion may be found sequestered in intracellular vacuoles (Gendelman et al.,
1989; Abbas et al., 1999). This mechanism has also been proposed for the latent
infection of astrocytes which may complicate productive HIVE in some cases (Hao
& Lyman, 1999). Infection of macrophage lineage cells is associated with low-level
production of virus, frequent latent infection, and relative resistance to the cytopathic
effects of HIV-1 (Stent et al., 1997; Abbas et al., 1999; reviewed in Levy, 1998). A
recent study demonstrated that protease inhibitors were less active in chronically
infected macrophages than in chronically infected lymphocytes, and when protease
inhibitors were removed, production of virus rapidly returned to the levels found in
untreated cells (Perno et al., 1998). This suggested that variants infecting
macrophages may be more resistant to antiviral treatment. These species, together
with follicular dendritic cell-associated viruses (refer to section 4.3.1), have been
thought to be responsible for the rapid rebound viremia after cessation of HAART
(Perno et al., 1998; Orenstein et al., 1999b), and form the most serious challenge to
HIV therapy.
As described above, most macrophages appear to be infected latently, except in
the CNS. This may be the reason that macrophages were found to be p24 positive
only very rarely in the immunohistochemistry trial. For further evidence supporting
this supposition that macrophage-lineage and subspecies are the major cause of
systemic spread, it is important to identify the infected cells, whether productively or
latently infected. Clearly, immunostaining to identify viral protein was insufficient,
even the sensitivity has been significantly improved (refer to chapter 3). For further
understanding of HIV pathogenesis, reconciliation of both clinical and pathological
observations with virological studies is indispensable. In the future, in-situ PCR
based on HIV proviral sequences combined with immunostaining for cell surface
markers might be employed to investigate the cell types which are latently or non-
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productively infected and therefore provide a more complete description of the
cellular targets of HIV-1 in vivo. Phenotypic characterisation of HIV-1 variants
infecting different cell types would also be of value in understanding the mechanism
of the observed genetic compartmentalisation between tissues, and the extent to
which sequence differences represent adaptation for replication in different cell types.
Also, for the large organs, such as brain, lung and gastrointestinal tract, multiple
sampling is required for more accurate characterisation of the viral species involved.
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APPENDIX I. Initials for DNA, RNA and Amino acid.











D Aspartic acid Asp



















a: Risk Groups: PDM — pre-AIDS Drug Misuser; ADM — AIDS Drug Misuser
P-Hetero — pre-AIDS heterosexual; AH — AIDS Homosexual
b: CD4/CD8: The ratio of last CD4 counts and CD8 counts
c: Rx: drug therapy
d: MAI: Mycobacteria avium-intracellulare
c: Macro: Macroscopy examination
f: Micro: Microscopical examination
g: OI: Opportunistic Infection
h: N: Necrosis
': IHC results: 0: p24 negative; 1: p24 weakly positive; 2: p24 intermediate positivity; 3: p24
strongly positive. The number of tissue blocks examined from each organ is
indicated in brackets.
PCP: Pneumocystis carinii pneumonia
k: KS: Kaposi's Sarcoma
APPENDIX II. General information and pathological findings for study subjects
No. NA97021 NA97020
Age/Gender 49/F 49/M
Risk Group" ADM AH
CD4 / CD8b 137/ 1620 8 / 388 f
Date of first HIV+test 18/Nov/1984 Ol/Jan/1991
Rxc during Pre-AIDS
25/Sep/90 ~ 1 l/Jun/91 — AZT
11 /Jun/91 ~ 24/Sep/91 — No Rx
24/Sep/91 ~ 23/Jan/92 — AZT
23/Jan/92 ~ Ol/Jan/93 — No Rx
No Rx





01 /Jan/93 ~ 09/Jan/96 - No Rx
09/Jan/96 ~ 27/Feb/96 -- AZT+ddC
27/Feb/96 ~ 27/Jan/97 — No Rx
17/Dec/96 ~ 27/Jan/97 — d4T
Date of Death 28/Jan/1997 28/Jan/1997
Clinical Summary
1. Drug and alcohol use







1. Two weeks history of persistent
diarrhoea (due to Clostridium
difficile which was treated)
2. Past history of severe weight loss,
low white cell and platelet counts
3. Infection with atypical
mycobacteria (MAI)





• Terminal chest infection in the
context of severe immune
depression due to AIDS.















APPENDIX II. Genera] information and pathological findings for study subjects (continued)
No. NA97021 (continued) NA97020 (continued)
Pathological
Findings in Spleen
Macroe — Weight 187g, appeared
reactive.
Microf— Slight lymphocyte depletion.
No OIg or Nh
IHC — p24:3+ (xl)
Macro — Weight 130g, appeared
congested.
Micro — Moderate lymphocyte depletion.
No 01 or N




Macro — Appeared reactive and
largest in the para-aortic
region.
Micro — Slight lymphocyte depletion
No 01 or N
IHC— p24:3+ (xl)
Macro — Appeared reactive





Macro — RL 392g, LL 386g. Right
lower lobe was consolidated
and showed pleural adhesions




IHC— p24:2+ (xl); 0 (xl)
Macro — RL 782g, LL 695g.
Micro — Severe bronchopneumonia with







Micro— No abnormalities within
limits of slight autolysis
No 01 orN
IHC— p24: lie 0 (xl); Colon 0(xl)
Macro — Normal
Micro — No abnormalities within limits of
slight autolysis
No 01 or N
IHC— p24: lie 0 (x2); Colon: 0 (x2)
Pathological
Findings in Brain
Macro — Fixed weight 985g.
Atrophy, no focal lesions
Micro — HIVE with unusual degree of
lymphocytic infiltration.
No 01 or N
IHC— p24: 3+ (xl)
Macro — Fixed weight 1471 g.
Slight atrophy, no focal lesions
Micro — HIVE with neurodegenerative
changes (Beta amyloid
precursor protein and ubiquitin
present in white matter)
No 01 or N
IHC— p24: 1+ (xl)
3
APPENDIX II. General information and pathological findings for study subjects (continued).
No. NA97017 NA96371
Age/Gender 32/M 34/M
Risk Group" ADM AH
CD4 / CD8b 16/120 3 / 100
Date of first HIV+
test
28/Oct/1985 12/Aug/1992
Rxd during Pre-AIDS No Rx No Rx





16/Apr/96 ~ 24/Dec/96 - AZT + ddC
24/Dec/96 ~ 24/Jan/97 - 3TC + d4T
AZT until close to death (no details)
Date of Death 25/Jan/1997 Ol/Nov/1996
Clinical Summary
1. Maintained on methadone but
has been anaemic and
pancytopenic





2. Chest infections and very
troublesome peripheral oedema due
to a combination of anaemia and
hypoalbuminaemia
3. Consistently negative for PCP
Interim Findings at
autopsy
• Florid pulmonary oedema
accompanied by serous effusions




• Renal and hepatic failure due to





1. Pulmonary oedema and
haemorrhage
2. Serous cavity effusions
3. Cardiomyopathy
4. AIDS
1. Extensive cutaneous, pulmonary,
retroperitoneal and pelvic KS which
also involves the bladder wall, liver
and LNs




APPENDIX II. General information and pathological findings for study subjects (continued)




Macro — Weight 330g, appeared
congested.
Micro — Lymphocyte depletion.
No 01 orN
IHC— p24:0 (xl)
Macro — Weight 235g, congested
Micro — Lymphocyte depletion





Macro — Appeared inconspicuous
Micro — Lymphocyte depletion
No 01 or N
IHC— p24:0 (xl)





Macro — RL 950, LL 800.
Oedema and haemorrhage
Micro — Gross oedema and focal
emphysema with pigmented
macrophages
No 01 or N
IHC— p24:0(x3)
Macro — RL 62 lg, LL 654g. RL
compressed by the large right
pleural effusion, LL haemorrhage
and bronchopenumonia







Micro — No abnormalities within limits
of slight autolysis
No 01 or N
IHC— p24: lle:0 (xl); ColornO (x2)
Macro — Oedema, otherwise normal
Micro — No other abnormalities within
limits of autolysis
No 01 or N
IHC— p24: lle:0 (xl); ColornO (x2)
Pathological
Findings in Brain
Macro — Fixed weight 1392g,
Mild atrophy, no focal lesions
Micro — Slight Alzheimer type II
astrocytosis.
No HIVE, 01 orN
IHC— p24: 0 (xl)
Macro — Fixed weight 1387g,
No atrophy or focal lesions
Micro —CMV micronodular encephalitis
No HIVE, 01 orN
IHC— p24:0 (xl)
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APPENDIX II. Genera] information and pathological findings for study subjects (continued)
No. NA96425 NA96272
Age/Gender 32 /M 32/M
Risk Group" ADM ADM






No Rx No Rx
Date of AIDSC
No AIDS-related illness (AIDS was diagnosed
on the CD4 count alone)
No AIDS-related illness (AIDS was







No Rx No Rx
Date of Death 1 l/Dec/1996 13/Augl996
Clinical
Summary
1. Heavy alcohol user in the past
2. Drug habit is maintained on Dihydrocodine
and Temazepam
3. Chest infections
4. CD4 zero for more than one year
5. CMV antibody positive
6. With jaundice and mild confusion but
apyrexial
7. Had diarrhoea and chest signs and developed
low output cardiac failure?cardiomyopathy
and probable sepsis
1.Ten years HIV with hepatitis B &C
positive
2. Episode of abdominal pain
3. Emergency complaining of chest pain





• Bronchopneumonia, heart and liver failure
• Cardiomyopathy
• Cirrhosis
• AIDS (on CD4 count alone)
• Bronchopneumonia
• Cirrhosis







5. Old cerebellar infarct
6.AIDS
1. Bronchopneumonia and right pleurisy
2. Jaundice & cirrhosis
3. Portal hypertension, ascites and





APPENDIX II. General information and pathological findings for study subjects (continued)




Macro — Weight 672g, very congested
Micro — Congested in keeping with cirrhosis.
Lymphocyte depletion
No 01 or N
IHC— p24:3+(xl)
Macro — Weight 619g, very congested
Micro — Grossly congested in keeping
with cirrhosis







Micro — Sinus hyperplasia
No 01 or N
IHC— p24:l+ (xl)
Macro —Normal











IHC— p24: 1+ (xl); 0 (x2)
Macro— RL 1209g, LL 818g.
Congestion, haemorrhage and
right bronchopneumonia








Macro —Oedema, otherwise normal
Micro — No other abnormalities within limits
of autolysis
No 01 orN
IHC— p24; lle:0 (xl); Colon: 0 (xl)
Macro — Oedema, melaena, otherwise
normal
Micro — Sparse acute inflammatory
infiltrate is noted in the
oedematous serosa of the bowel
No 01 or N




Macro — Fixed weight 1476g,
No atrophy, old right cerebellar
infarct
Micro — Old cerebellar infarct confirmed
No HIVE, 01 orN
IHC— p24: 0 (xl)
Macro — Fixed weight 1701 g,
No atrophy or focal lesions
Micro — No HIVE, 01 orN
IHC— p24: 0 (xl)
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APPENDIX II. General information and pathological findings for study subjects (continued)
No. NA98025 NA98028
Age/Gender 43/M 48/F
Risk Group" P-Hetero PDM
CD4 / CD8b 297/232 703 /4091
Date of first HIV+ test 01 /Jan/1992 07/Apr/1984
Rxd during Pre-AIDS No Rx No Rx
AIDS Presenting
Illness
Clinically in Pre-AIDS Clinically in Pre-AIDS
Date of Death 20/Jan/1998 27/Jan/1998
Rx during AIDS 1. heavy drinking and poor diet
2. shortness of breath and pain in the
chest and was found to have










Stemetil - 5mg 3 times a day
Vitamins B12 complex strong
Clinical Summary • Bronchopneumonia, cirrhosis, and
acute renal failure.
• HIV positive at Pre-AIDS stage.
• Sudden death by illicit drug
overdose.
• Old hemiplegia.




2. Hepatic cirrhosis and necrosis
3. Renal tubular necrosis
4. Pancreatic fibrosis
5. HIV positive man with probable
incipient HIV encephalitis
1. Extensive old right cerebral
infarct
2. No evidence ofHIV encephalitis
3. HIV positive woman
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APPENDIX II. General information and pathological findings for study subjects (continued)
No. NA98025 (continued) NA98028 (continued)
Pathological
Findings in Spleen
Macro — Weight 260g, septicaemia
appearance
Micro — No lymphocyte depletion,
No 01 or N
IHC— p24:3+ (xl); l+(xl)
Macro — Weight 195g, appeared normal





Macro — Reactive lymphadenopathy




IHC— p24:3+(x8); 1+ (xl); 0 (xl)
Macro — Reactive lympadenopathy
Micro — Acute lymphadenitis
No 01 orN
IHC— p24:3+(x4); 1+ (xl)
Pathological
Findings in Lung
Macro — RL 2406g, LL 1670g.
Consolidation
Micro — Bronchopneumonia and
haemorrhage
No Ol or N
IHC— p24:l+ (xl); 0 (xl)








Macro — Oedema, melaena, otherwise
normal
Micro — No other abnormalities
within limits of autolysis
No 01 or N
IHC— p24 Int :2+ (x2); 0 (x5)
Macro — Normal
Micro — Persisting mucosal lymphoid






Macro — Fixed weight 1393g
No atrophy or focal lesions
Micro — Widespread but subtle
microglial infiltrate in the
white matter; lymphocytic
infiltrate is noted; one giant
cell is identified
IHC— p24:0 (xl)
Macro — Fixed weight 802g
Large right cerebral infarct
Micro — Old cerebral infarct
No HIVE, Ol orN
IHC— p24:0 (xl)
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CD4 / CD8" Not available (not regular medical care)
Date of first HIV+test reportedly April/1986
Rxd during Pre-AIDS No information
AIDS Presenting Illness Clinically in Pre-AIDS
Date of Death 08/Apr/1997
Clinical Summary 1. User of street drugs
2. Chronic alcohol use
3.No Medical care
4. Reportedly (family) HIV positive in April 1986
Clinical cause of Death • Suspected illicit drug and alcohol overdose.
• HIV positive at Pre-AIDS stage.
Final Autopsy Diagnosis 1. Cerebral oedema
2. Slight focal chronic leptomeningitis
3.No evidence ofHIV encephalitis
4. HIV positive man
Pathological Findings in
Spleen
Macro — Weight 280g, normal









Macro — RL 1190g, LL 790g. Right bronchopneumonia









Macro — Fixed weight 1303g; No atrophy or focal lesions
Micro — Slight lymphocytic infiltrate of leptomeninges.
No HIVE, 01 orN
IHC — p24: 1+ (only in lymphocytic infiltrate of leptomeninges, and
within CD8 positive cell group)
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